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ABSTRACT

The Behavioral and Neurochemical Effects of Prenatal Stress on
Stress Responsive Systems in Rats
David Albert White

Research points to a combination of genetic, physiological, and environmental factors in
the origin of anxiety and depressive disorders. These factors are adversely impacted by stress
and can be influenced by both the prenatal and postnatal environments. Our research shows that
offspring of mothers stressed during the last week of gestation appear to be normal in basal
behavioral states. However, upon the presentation of stressful stimuli in the forms of anxiogenic
drugs (e.g. yohimbine and idazoxan), prenatally stressed offspring respond differentially in
comparison with control (normal) offspring. Doses of yohimbine and idazoxan that increased
acoustic startle in control animals were ineffective at increasing acoustic startle responses in
prenatally stressed animals. These findings suggested physiological alterations in the stress
responsive systems of the body and their associated neurotransmitter systems.
This hypothesis is supported by the observation that prenatally stressed animals had
significantly elevated levels of basal plasma corticosterone, suggesting a state of chronic stress.
This contention is further supported by alterations in the content of the neurotransmitter
corticotropin releasing factor (CRF), a key mediator of the hypothalamic and extra-hypothalamic
responses to stress. In prenatally stressed offspring, there were age-dependent increases in CRF
content in several nuclei (e.g. amygdala, PVN, and LC/PBN) critically involved in eliciting,
coordinating, and producing the body’s response to stress. From these studies it can be
concluded that the prenatal stress syndrome produces functional changes in rats in the form of
physiological, neurochemical, and behavioral differences. These changes persist well into
adulthood, suggesting their permanence.
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INTRODUCTION
It is estimated by the National Institute of Mental Health that more than 16 million adults
ages 18 to 54 in the United States suffer from anxiety disorders (e.g. panic disorder,
obsessive-compulsive disorder, post-traumatic stress disorder, social phobia, and generalized
anxiety disorder), while more than 19 million adult Americans suffer from depressive illnesses
(e.g. major depression, bipolar disorder, or dysthymia). Taken together, the estimated combined
cost of such disorders is in excess of 70 billion dollars annually (for epidemiological data see
http://www.nimh.nih.gov/publicat/stats.cfm). Anxiety and depressive disorders are frequently
complicated by other factors, including eating disorders and substance abuse. Moreover, many
people suffer more than one disorder at the same time. Research points to a combination of
genetic, physiological, and environmental factors in the origin of anxiety and depressive
disorders . Stress adversely impacts all of these factors and has been implicated etiologically .
Understanding the processes by which stress elicits its effects would clearly give insight into the
neurobiological mechanisms that mediate pathological anxiety and depression.

Stress and the stress response
Stress is not an easily defined term even though it exists in almost every language of the
civilized world. The concept of the term always addresses a basic principle of Nature, which is
to maintain equilibrium or harmony when presented with disruptive forces and to counteract
those disturbing forces to re-establish a state of harmonious balance (Chrousos et al., 1986). The
term “stress” is analogous to the word “strain,” which is rooted in the Greek verb “strangaluein”
(to strangle), and the Latin verb “stringere” to draw tight or press. Thus, the root of “stress” has
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always meant the exertion of adverse forces (Chrousos et al., 1986).
In 1936, Hans Selye, borrowing from physics, first used the term “stress” in a modern
biological sense. Based on his observations of severely ill patients, he specifically defined stress
as “the nonspecific result of any demand upon the body (Selye 1946).” He had noticed that his
patients often developed common symptoms and signs, which he was able to reproduce
experimentally in the rat using different noxious stimuli (Selye 1936). From this, he suggested
that the body has nonspecific mechanisms to adapt to adverse conditions. He called his theory
the “General Adaption Syndrome” or “Stress Syndrome” and attempted to define the syndrome
physiologically via a number of common symptoms, including enlargement of the adrenal
cortices, shrinkage of the thymus and lymph nodes, and peptic ulceration (Selye 1936; Selye
1980).
By definition any agent capable of producing a stress response is a stressful stimulus or
“stressor ” (Selye 1936; Selye 1980). This applies to any kind of physical or psychological
stressor, although in the case of the later, it must be appreciated as such. The potency of
cognitive and psychological stimuli to induce a stress response is indicated by the fact that even
common physiological stressors such as exercise and hunger do not activate the hypothalamicpituitary-adrenal (HPA) axis if they are present in a way that eliminates the fear or anxiety
(Mason 1971; Burchfield 1979). Additionally, in states of fear, typically non-aversive stimuli
elicit heightened stress responses, such as the case with the fear-potentiated startle paradigm
(Davis et al., 1993). Pairing an aversive stimulus (e.g. footshock) with a nonaversive stimulus
(e.g. light) produces increased fear in response to the light, as demonstrated by increased acoustic
startle responding, and activation of the stress system, as shown by increased secretion of
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corticosterone, and increased c-fos expression in several components of the limbic system and
various nuclei of the hypothalamus (Campeau et al., 1997). Clearly, the stress response is
associated with the arousal of fear and anxiety.
Stressors that are particularly effective involve both physical and psychological
components. One such stressor is restraint. The effects of restraint have been extensively
reviewed (Glavin et al., 1994), and a number of stress-related effects have been demonstrated in
response to restraint, including increased gastric and duodenal ulceration with chronic stress, and
increased norepinephrine (NE), serum corticosterone, and adrenocorticotropin hormone (ACTH)
(Glavin et al., 1994). The psychological component of restraint stress has also been
demonstrated by increases in fearful behavior in a number of behavioral tests. In 1989, Berridge
and Dunn demonstrated that prior restraint decreased exploration of novel objects in open field
tests in both rats and mice (Berridge and Dunn 1989a; Berridge and Dunn 1989b), while Casada
and Dafny (1991) showed that prior restraint increased stereotypic behavior in rats . Finally,
Smagin and colleagues (1996) showed that prior restraint produced fearful behavior in rats tested
in the defensive withdrawal test (Smagin et al., 1996), which is considered an ethological
measure of fear (see below) (Takahashi et al., 1989).
Under normal conditions, mild to moderate levels of stress in an organism elicit adaptive
responses that function to maintain homeostasis in the peripheral and central nervous system
(CNS) (Selye 1936). However, it is thought that severe, prolonged, or uncontrollable stress can
result in a sustained dysregulation (hyperactivity or hypoactivity) of one or more of the central
components of the stress response (e.g. the locus coeruleus-norepinephrine system, the
amygdala-corticotropin releasing factor system (CRF), and the HPA axis), leading to an
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increased susceptibility to stressful stimuli and/or the precipitation of a broad range of
psychiatric, neuroendocrine, and inflammatory disorders (Ward 1991; Brady 1994).

Components of the stress response
There are several brain regions important to the stress response with three principle
components: the amygdala- CRF system, the hypothalamic paraventricular nucleus (PVN)median eminence (ME)-CRF system (HPA axis), and the locus coeruleus (LC)- NE system. The
amygdala is an integral part of the limbic system and contains large clusters of CRF-containing
cells, with an equivalent density to that found in the PVN (Swanson et al., 1983; Cummings et
al., 1983). It serves as a crucial relay point for the coordination of behavioral, endocrine, and
autonomic responses to stress. The HPA axis is a major hormonal pathway mediating the stress
response and subtle changes in the components of the axis can have long-term effects on
behavior and development (King 1996). The axis is initiated when parvocellular neurons in the
PVN of the hypothalamus release CRF into the ME. CRF traverses the portal system to the
anterior pituitary gland, where it stimulates the release of ACTH. ACTH then stimulates the
adrenal gland to release glucocorticoids. Glucocorticoids act as major regulators of carbohydrate
and lipid metabolism, cardiovascular tone, and muscle contraction. Finally the LC is a small,
compact noradrenergic nucleus (A6 cell group) located in the pons that sends extensive
projections to the cortex, thalamus, limbic system, hypothalamus, other brain stem nuclei, and
spinal cord (Dahlstrom and Fuxe 1964; Moore and Bloom 1979). Specific behavioral and
sensory stimuli have been shown to evoke concerted activity of LC neurons and consequently
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influence the functional activity of its many target areas (Moore and Bloom 1979; Brady 1994).
The LC has been the focus of intense interest because of its involvement in vigilance, arousal,
and mediation of the stress response. The three major components interact with each other via
CRF and NE. NE directly from the LC affects the amygdala and hypothalamus, while CRF from
the amygdala affects the LC directly and the PVN indirectly, via the bed nucleus of the stria
terminalis (Moore and Bloom 1979; Brady 1994; Weiss et al., 1994; Curtis and Valentino 1994;
Feldman et al., 1995; Herman and Cullinan 1997).

Corticotropin releasing factor
History of CRF
Over four decades of research were needed to characterize CRF. In 1936, Selye proposed
the “General Adaption Syndrome” or “Stress Syndrome” and attempted to define this syndrome
physiologically by a number of common symptoms, including enlargement of the adrenal
cortices, shrinkage of the thymus and lymph nodes, and peptic ulceration (Selye 1946; Selye
1980). In that same year, he found that removal of the hypothalamus from experimental animals
abolished the ability of stress to cause adrenocortical enlargement, suggesting a link between the
hypothalamus and adrenal gland.
By 1948, Harris had described the presence of capillary loops in the ME and their
drainage to the anterior pituitary. Based on these experimental findings he proposed a
“chemotransmitter-portal vessel hypothesis,” where hypothalamic neurohormonal transmitters
were released by neurons into the portal vessel system, which subsequently stimulated the
anterior pituitary to cause the release of hormones into the general circulation (Harris 1948). His
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theory implicated the clinical importance of the HPA axis. It subsequently led to the search for a
substance synthesized in the hypothalamus that stimulated ACTH release (i.e. CRF) prior to the
attempted characterization of other putative hypothalamic releasing factors, since bioassays to
measure ACTH were available.
Characterization of the structure of CRF proved difficult for several reasons. First,
inability to appropriately control for HPA axis activation in direct response to mild stressors such
as novelty confounded many studies (Saffran and Schally 1977). Second, in tissue extracts there
were numerous substances present other than authentic CRF that possessed CRF-like activity and
were ACTH secretagogues. Third, because the sizes of CRF (41 amino acids) and ACTH (39
amino acids) are similar, the two peptides are not easily separable by liquid chromatography
(Owens and Nemeroff 1991). Finally, even though the sensitivities of the radioimmunoassays
for ACTH were remarkable (Owens and Nemeroff 1991), the assays had poor specificity, making
them vulnerable to various components found in tissue extracts, such as myelin basic protein,
histones, potassium, and the components of a variety of buffers and solvents (Vale et al., 1983).
One of the first substances thought to be CRF was arginine vasopressin (AVP) (Owens
and Nemeroff 1991). It had been shown to cause ACTH release by a number of investigators
(Saffran and Schally 1977). However, in 1966 Hedge and his colleagues disproved this theory
with their findings that intra-pituitary injection of AVP had little effect on ACTH release, which
was contrary to their findings that systemic administration of AVP caused a substantial increase
in ACTH release (Hedge et al., 1966). Furthermore, in 1971, Yates and his colleagues found that
intravenous AVP potentiated ACTH release when given immediately after a hypothalamic
extract (Yates et al., 1971). It is now known that AVP is a less potent and efficacious
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secretagogue of ACTH that potentiates the effect of CRF (Dunn and Berridge 1990b).
In 1955, the systematic search for CRF in hypothalamic tissue began with the first
convincing evidence of a hypothalamic factor that stimulated ACTH release from the pituitary
(Guillemin and Rosenberg 1955; Saffran et al., 1955). In 1957, Guillemin and colleagues used
hypothalamic tissue to isolate a peptide distinct from AVP that effectively stimulated ACTH
release in vitro (Guillemin et al., 1957). In 1958, Schally and his group isolated a peptide from
the posterior pituitary tissue extract that was distinct from AVP and caused a potent stimulation
of ACTH release (Schally et al., 1958). During this period, Schally and Guillemin began
working together at McGill University. They used extracts of neurohypophysial tissue and gel
filtration chromatography to identify three fractions with CRF-like activity. The first two, which
they labeled 1 and 2, were similar to -melanocyte-stimulating hormone, while the third, which
was labeled , was similar to vasopressin (Guillemin et al., 1962; Saffran and Schally 1977).
They called the  peptide ‘corticotropin releasing factor,’ because of its potent releasing activity
for ACTH (Schally et al., 1958). No advances were made in the characterization of the structure
of CRF until its discovery by Vale (Vale et al., 1981). During the systematic characterization of
luteinizing hormone-releasing hormone (LHRH) from nearly half a million extracts of ovine
hypothalamus, Vale and his colleagues isolated and described CRF’s amino acid sequence (Vale
et al., 1981). It was found to be a 41 amino acid peptide with the following sequence: H-SerGln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-Met-ThrLys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Leu-Asp-Ile-Ala-NH2 (Vale
et al., 1981). This peptide was subsequently synthesized by Jean Rivier and found to be as
biologically active as the endogenous peptide (Rivier et al., 1981). The primary structure of the
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CRF peptides was found to be similar in man, sheep, rats, goats, pigs, and cows with rat and
human CRF peptides being of identical size and amino acid composition (Dunn and Berridge
1990b).
At the nucleotide level, Numa and his colleagues were the first to clone the DNA
sequences complementary to the human and ovine messenger ribonucleic acid (mRNA) encoding
the CRF precursor (Furutani et al., 1983; Shibahara et al., 1983). The rat CRF gene was isolated
and sequenced in 1987 (Thompson et al., 1987). The rat and human gene coding regions and 5'
flanking region were found to be 94% homologous (Thompson et al., 1990), which may signify
DNA regulatory elements of CRF gene expression in the 5' region (Thompson et al., 1990).

Distribution and localization of CRF
In 1983, Vale’s lab made another major contribution to CRF research with the
characterization of an antibody against CRF. This led to the development and use of
immunocytochemistry and a radioimmunoassay (RIA) for CRF. CRF immunoreactive (CRFir)
neurons and fibers are found distributed throughout the CNS (Merchenthaler et al., 1982;
Swanson et al., 1983; Cummings et al., 1983; Joseph and Knigge 1983; Sawchenko and
Swanson 1985; Sakanaka et al., 1987). Centrally, the highest density of CRFir is found in the
hypothalamus, with the PVN having a very dense distribution of cell bodies and the ME of the
hypothalamus containing the densest accumulation of CRFir terminals and fibers (Swanson et
al., 1983; Cummings et al., 1983).
Other brain regions contain CRFir, including the limbic system. This system is composed
of a number of interconnected anatomically circumscribed units including, the hypothalamus,
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septum, hippocampus, ventral striatum, and amygdala (Huether 1996). Aside from its
involvement in the processing of olfactory information and control of autonomic function, the
limbic system is responsible for the emotional aspects of behavior, learning, and memory and is
closely concerned with the arousal of fear and anxiety. In the limbic system, several brain
regions have CRFir neurons and fibers, including the bed nucleus of the stria terminalis (BNST)
and the amygdala, which has the greatest number of CRFir somata (Swanson et al., 1983;
Cummings et al., 1983). All the nuclei of the amygdala have at least a few CRFir neurons
(Merchenthaler et al., 1982; Swanson et al., 1983; Cummings et al., 1983; Joseph and Knigge
1983; Sakanaka et al., 1987) with dense plexuses of CRF-stained fibers present in the central and
basolateral nuclei (Swanson et al., 1983). In fact, in the rat the central nucleus of the amygdala
(CeA) has a number of CRFir positive cells nearly equivalent to that of the PVN (Gray 1992).
There are substantial amounts of CRFir present in the perikarya, fiber plexuses, and fibers
coursing through the brainstem (Swanson et al., 1983). The highest amounts of CRFir are found
in the LC, parabrachial nucleus (PBN), and dorsal raphe (Swanson et al., 1983; Cummings et al.,
1983; Sakanaka et al., 1987). CRF is also found in the periaqueductal gray and raphe magus
(Merchenthaler et al., 1982; Swanson et al., 1983; Merchenthaler et al., 1983). Additionally, two
CRFir cell groups in the brainstem appear to send fibers down the spinal cord to the
intermediolateral column (Cummings et al., 1983). The spinal cord has CRFir neurons at all
levels of the intermediolateral column from T2 to L3 (Merchenthaler et al., 1983).
In the cerebral cortex, CRF-positive cells are morphologically similar to interneurons
(Swanson et al., 1983). Perikarya containing CRFir are present primarily in layers II-III
(Swanson et al., 1983; Sakanaka et al., 1987). However, deeper layers have neural processes that
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arise primarily from the intrinsic CRFir neurons (Sakanaka et al., 1987). Some thalamic nuclei
have a relatively high concentrations of CRFir, including the posterior complex of the thalamus.
All divisions of the inferior olive contain CRFir somata (Palkovits et al., 1987).
Additionally, climbing fiber pathways from the inferior olive to the Purkinje cell dendrites show
CRFir (Palkovits et al., 1987). Finally, the hippocampus, cranial nerve nuclei of the brainstem,
and septal regions have low levels of CRFir (Sakanaka et al., 1987).
In addition to immunocytochemical studies, micropunch studies measuring CRF
concentrations in several brain regions have been done (Palkovits et al., 1985; Skofitsch and
Jacobowitz 1985; Chappell et al., 1986). These studies show similar results in terms of
correlation between the micropunch data and the immunocytochemical data. The ME has the
highest concentration of CRF (Palkovits et al., 1985; Chappell et al., 1986). The PVN of the
hypothalamus and the CeA also have high levels of CRF. Moderate to high levels are found in
the dorsal vagal complex (DVC), LC, dorsal raphe, BNST, inferior olive, ventral tegmental area,
other hypothalami nuclei and amygdaloid nuclei (Palkovits et al., 1985; Skofitsch and
Jacobowitz 1985; Chappell et al., 1986). Low levels of CRF are present in the cerebral cortex,
hippocampus, striatum and septal nuclei (Chappell et al., 1986) with undetectable levels in the
cerebellar cortex (Palkovits et al., 1985; Skofitsch and Jacobowitz 1985).

CRF receptor distribution and transduction
The distribution, tissue specificity, and biochemical and pharmacological characteristics
of CRF receptors have been extensively reviewed (Dunn and Berridge 1990b; Owens and
Nemeroff 1991; Grigoriadis et al., 1996b; Dieterich et al., 1997). In short, there are two major
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subtypes of CRF receptors (CRF1 and CRF2), which are distributed throughout the CNS and in
the periphery (Vita et al., 1993; Perrin et al., 1993; Chang et al., 1993; Lovenberg et al., 1995a;
Perrin et al., 1995; Lovenberg et al., 1995b; Kishimoto et al., 1995). CRF1 receptors are present
in the pituitary, cerebral cortex, olfactory bulb, the amygdala, hippocampus, cerebellum, and
several nuclei of the brainstem. CRF1 receptors have also been found in the adrenal medulla,
sympathetic ganglia, prostate, spleen, liver, kidneys, and testis (Dunn and Berridge 1990b;
Owens and Nemeroff 1991; Chalmers et al., 1996). CRF2 receptors consist of two
pharmacologically distinct isoforms, CRF2 and CRF2 (Perrin et al., 1995; Lacroix and Rivest
1996; Chalmers et al., 1996; Grigoriadis et al., 1996a; Grigoriadis et al., 1996b; Dieterich et al.,
1997). CRF2 is found primarily in the lateral septal nucleus, entorhinal cortex, amygdala,
olfactory bulbs, and hypothalamus (Lovenberg et al., 1995a; Lacroix and Rivest 1996; Primus et
al., 1997). CRF2, which thus far has not been detected in humans, is found in rats in the choroid
plexus and cerebral blood vessels as well as in the periphery in heart, skeletal muscle, lung and
intestines (Perrin et al., 1995; Kishimoto et al., 1995; Chalmers et al., 1996).
Several studies demonstrate that CRF receptors are linked to adenlylate cyclase and cyclic
adenosine monophosphate (cAMP) generation (Chen et al., 1986; Battaglia et al., 1987; Olianas
and Onali 1990; Olianas et al., 1993; Olianas and Onali 1995; Kapcala and Aguilera 1995). CRF
receptor activation in the anterior pituitary (Chen et al., 1986), throughout the brain (Chen et al.,
1986; Battaglia et al., 1987) and in the retina (Olianas and Onali 1990; Olianas and Onali 1995)
leads to cAMP generation. However, receptor density in the brain does not correlate with CRFinduced cAMP generation (Owens and Nemeroff 1991). This may be due to poor coupling, CRF
activating other second messengers, or binding to receptors not functionally coupled to adenyl
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cyclase (Owens and Nemeroff 1991). CRF-induced cAMP generation and CRF stimulated
ACTH release can be potentiated by several protein kinase C activators, indicating a potential for
a synergism with other transmitters (Lutz-Bucher et al., 1991). In the hypothalamus, CRF
increases phosphoinostitide turnover (Owens and Nemeroff 1991). CRF may also activate the
calcium-calmodulin system to cause ACTH release (Murakami et al., 1985).
A CRF binding protein (CRF-bp) has been discovered in the brain and binds human/rat
CRF with higher affinity than the CRF1 receptor (Potter et al., 1992). CRF-bp is found
predominantly in the cerebral cortex, olfactory bulb, lateral septum, BNST, the CeA, and anterior
pituitary corticotrophs (Potter et al., 1992). Dual labeling indicates some co-localization of the
binding protein and CRF in the olfactory bulb, BNST and CeA (Potter et al., 1992). Also, nerve
terminals containing the CRF-bp are found in close association with several CRFir cell groups in
the forebrain, BNST, CeA, and suprachiasmatic nucleus (Potter et al., 1992). The exact role of
this protein in the CNS is not known, but it would appear to regulate or modulate CRF’s activity.

CRF processing, storage and degradation
CRF is synthesized as preproCRF (Furutani et al., 1983) and through post-translational
endoproteolytic processing active CRF is produced (Castro et al., 1991). The storage of CRF is
similar to that of the other neuropeptides as processed CRF is stored in presynaptic terminals in
many small clear vesicles aggregated near the synaptic specializations and in large dense core
vesicles in central regions of the terminal or distant from the synaptic junction (Milner et al.,
1993). The population of small, clear vesicles associated with the active zone of the synapses are
thought to represent the releasable pool of CRF, while a smaller number of large, dense granular,
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vesicles located distant to the active zone of the synapse are thought to be a mechanism of
storage and transport (Maley 1990). In a synaptosomal preparation of the whole brain, the
gradient fraction containing synapsin, a marker of protein for synaptic vesicles, also contained
CRFir, further demonstrating a localization of CRF to presynaptic terminals (Cain et al., 1991).
Soluble endopeptidases appear to inactivate CRF by degradation to two smaller fragments
(Owens and Nemeroff 1991).

Neuroanatomical pathways for CRF
High amounts of CRFir in the amygdala have led to much interest in the role of the
CRFergic system within the amygdala. The amygdala is centrally responsible for coordinating
and eliciting the behavioral, autonomic and endocrine response to stress, suggesting CRF may
serve as key neurotransmitter in the body’s response to stress. This hypothesis is supported by
the findings of Uyru and his colleagues (1992) that showed a significant number of CRF nerve
endings and dendrites from the lateral hypothalamus, dorsal raphe, BNST, and PBN and from
adjacent nuclei in the amygdala forming synapses on non-immunoreactive dendrites and axons in
the CeA (Uryu et al., 1992). Furthermore, CRFergic innervation from the CeA to PBN (Moga
and Gray 1985), DVC (Gray and Magnuson 1987), midbrain central gray (Gray 1990),
ventromedial hypothalamus, mesencephalic nucleus of the trigeminal nerve, and BNST
(Sakanaka et al., 1986) has also been demonstrated. The evidence for CRF’s role as a
neurotransmitter in the LC continues to mount as well. Electrolytic lesions of the CeA cause a
three-fold decrease in CRF concentrations in the LC, suggesting that a CRF pathway from the
CeA to the LC is present (Koegler-Muly et al., 1993). CRF is an afferent or efferent transmitter
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at all of the brain regions that are important in regulating cardiovascular, respiratory, and
behavioral responses to stress (Moga et al., 1989; Moga et al., 1990; Davis 1992), suggesting
that CRF innervation to various sites in the brainstem may be important in the expression of
behavioral and/or autonomic components of stress and anxiety.
As mentioned above the posterior complex of the thalamus contains CRFir. Sensory
fibers for pain terminate in the posterior complex, and physiological studies suggest that this
region may be involved in the central pain mechanism (Merchenthaler et al., 1984). Therefore,
CRF may be playing a role in central pain mechanisms. This is supported as CRF is also found
in other regions involved in pain, including the periaqueductal gray, raphe magus, and spinal
cord (Merchenthaler et al., 1982; Swanson et al., 1983; Merchenthaler et al., 1983).

Physiological effects of CRF
In 1985, Koob and Bloom proposed that CRF, despite its differential expression in
different brain regions and targeting, may function in a unified manner to achieve multi-system
response to stress. This hypothesis was based on CRF’s ability to cause numerous centrallymediated physiological and behavioral changes as well as its neuroendocrine role in an animals’s
adaptation to stress (Koob and Bloom 1985; Koob et al., 1992). Neurochemical studies provide
further evidence that CRF is important in the stress response. Numerous investigators have
shown a stress-induced increase in CRF and CRF mRNA in several brain regions (e.g. the
amygdala and PVN) (Harbuz et al., 1993; Rivest and Rivier 1994; Itoi et al., 1994; Imaki et al.,
1996; Barbazanges et al., 1996; Albeck et al., 1997). Also, acute stress has been shown to
increase CRF content in the LC, and to decrease CRF content in ME (Chappell et al., 1986).
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Intracerebroventricular (i.c.v.) CRF produces several autonomic and endocrine effects
that are similar to those observed in stress. For example, i.c.v. CRF increases ACTH and
corticosteroid levels as a result of activation of the HPA axis (Rivier et al., 1982). Other
endocrine effects induced by i.c.v. CRF include an inhibition of luteinizing hormone and growth
hormone release and a slight increase in glucagon release (Owens and Nemeroff 1991). As
mentioned, i.c.v. CRF has centrally mediated autonomic effects as well, which include increases
in sympathetic outflow from the CNS, resulting in increases in both plasma epinephrine and NE
(Brown et al., 1982). An increase in arterial pressure, heart rate and circulating glucose levels
may also be due to increased sympathetic outflow (Brown et al., 1982a; Fisher et al., 1982;
Brown et al., 1982b). The idea that CRF’s effects are centrally mediated is supported by the fact
that no CRF is detected in the plasma after i.c.v. injection (Dunn and Berridge 1990b) and that
the CRF antagonist (alpha helical CRF) and CRF antisera administered peripherally do not affect
sympathetic activation following i.c.v. CRF (Dunn and Berridge 1990b). Additionally,
adrenalectomy and hypophysectomy have little impact on the effects of i.c.v. CRF (Owens and
Nemeroff 1991).
CRF possesses an analgesic effect which is supported by i.c.v. CRF’s ability to attenuate
the pain of noxious stimuli (Tian and Wei 1989). Some evidence suggests that CRF stimulates
-endorphin release to produce antinociception (Hargreaves et al., 1990). However, in another
study, CRF’s analgesic effects were not modified by naloxone treatment, suggesting a non-opioid
mechanism (Ayesta and Nikolarakis 1989; Owens and Nemeroff 1991).
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Behavioral effects of CRF
The importance of CRF in eliciting fearful behavior is demonstrated by experiments
using CRF receptor antagonists. These studies show that the release of endogenous CRF
mediates the aversive effects of several noxious stimuli, including morphine withdrawal
(Heinrichs et al., 1995), shock-induced defensive burying (Korte et al., 1994), and social defeat
(Heinrichs et al., 1992). Most of the behavioral effects of stress and anxiety are blocked by CRF
antagonists, and can be produced by i.c.v. or intra-amygdala injections of CRF. Effects of
exogenous CRF are reversed by CRF antagonists and anxiolytic benzodiazepines (BZ) (Dunn
and Berridge 1990a; Dunn and Berridge 1990b). For example, in open field experiments
designed to address the stress of the animal when presented with a novel environment, i.c.v. CRF
increased grooming and freezing, and decreased locomotion and rearing (Dunn and Berridge
1990b). These changes were thought to be associated with CRF-induced increases in sensitivity
to the stressful aspects of the test and were blocked by the CRF antagonist -helical-CRF (Owens
and Nemeroff 1991).
In behavioral models of anxiety, such as the Geller-Seifter conflict test (punished
responding), social interaction, and fear-potentiated acoustic startle, CRF causes anxiogenic
effects, which are antagonized by the BZ, chlordiazepoxide (Britton et al., 1985; Swerdlow et al.,
1986; Dunn and Berridge 1990a; Davis 1992). In the elevated-plus maze, i.c.v. CRF is
anxiogenic and suppresses exploratory behavior (Koob et al., 1992).
The amygdala is a major target of CRF’s actions on behavior. CRF antagonists, injected
bilaterally into the amygdala, reverse stress-induced suppression of exploratory behavior (Koob
et al., 1992) and reduce stress-induced freezing (Swiergiel et al., 1993). Injection of the CRF
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antagonist into the CeA reverses the anxiogenic effects of alcohol withdrawal as determined in
the elevated-plus maze (Rassnick et al., 1993). Lesions of the CeA or bilateral injections of the
BZ, diazepam, into the amygdala decrease conditioned fear (Davis 1992) and defensive freezing
(Helmstetter 1993). These data suggest that endogenous CRF acting in the amygdala is
important in the anxiety response and further suggest an interaction between BZs and the CRF
system in the amygdala.

The noradrenergic system
Central distribution and localization and neuroanatomical pathways of NE
Vogt (1954) first suggested that there were noradrenergic neurons in the brain (Vogt,
1954). He showed that NE was present in the brain and was unevenly distributed in that its
distribution did not follow the distribution of blood vessels. Therefore, it did not represent the
sympathetic innervation of blood vessels. The development of the fluorescence histochemical
method for NE allowed direct demonstration of noradrenaline in nerve cells in the brain, and in
1964, Dahlstrom and Fuxe used this technique to map the distribution of noradrenergic neurons
(Dahlstrom and Fuxe, 1964). They showed that noradrenergic cell bodies were confined to the
brainstem, where they occurred in a number of separate groups or clusters that were named A1A7 (Fillenz, 1990). Of these nuclei, the LC complex comprised of nuclei A4 and A6 and
scattered neurons that overlap with the nucleus subcoeruleus (A7), has attracted the greatest
interest as it supplies most of noradrenergic innervation to the forebrain and consists of about
45% of all noradrenergic neurons in the brain (Stanford, 1995).
In 1979, Moore and Bloom, in their review, grouped all the non-coerulear brainstem
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noradrenergic neurons into a single system, which they called the lateral tegmental system. This
included the A1 and A3 groups of cells in the medulla associated with the nucleus of the tractus
solitarius and dorsal nucleus of the vagus and the lateral medullary tegmentum as well as the A5
and A7 cell groups of the pons (Moore and Bloom, 1979). The A2 nucleus, originally considered
to be a separate “dorsal medullary system” (Lindvall and Bjorkland, 1978) is now included in the
is group (Holets, 1990).
Ascending and descending efferent projections from noradrenergic brainstem nuclei have
been extensively reviewed (Lindvall and Bjorkland, 1978; Moore and Bloom, 1979; Holets,
1990). Noradrenergic fibers project in four main pathways: the dorsal noradrenergic bundle in
the central tegmental tract, which carries most of the fibers of from the LC and merges with the
median forebrain bundle in the caudal hypothalamus; the median forebrain bundle, which
extends from the central tegmental tract, carries fibers from non-coerulear nuclei, as well as the
LC; the dorsal longitudinal fasciculus in the periaqueductal gray, which carries fibers passing
from the central gray; and finally, the medullary catecholamine bundle, which passes from the
central tegmental tract to the caudal medulla. Projections are ipsilateral, although there is a
contralateral component, which is generally small (Jones and Moore, 1977) in most brain areas
but can be considerable in others (Fernandez-Galaz et al., 1994). Finally, there is extensive
overlap in the brain regions innervated by the LC and lateral tegmental systems. However,
terminal fibers of neurons from these two systems have distinctive morphology and differ
functionally (Fritschy and Grzanna, 1989).
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Adrenoceptors: distribution and transduction
Actions of the adrenergic and noradrenergic neurotransmitter systems are mediated by
adrenoceptors. Historically, adrenoceptors were divided into two major subtypes: - and adrenoceptors based on epinephrine’s ability to cause vasoconstriction or vasodilation of vascular
smooth muscle from different species (Ahlquist, 1948). Subsequent subclassifications of
adrenoceptors were based on their physiological actions and second messenger systems in
addition to their differential affinities for various ligands (Bylund et al., 1994; Ford et al., 1994).
With the advancement of pharmacological and molecular cloning techniques, the number of
receptors types and subtypes in general has vastly increased. It is now clear that there are three
major subtypes of adrenergic receptors: 1, 2, and  (Bylund et al., 1994; Ford et al., 1994).
Each can be divided into three subtypes. Of the nine adrenoceptors that have been cloned to
date, eight are found in the rat CNS: 1A, 1B, 1D, 2A, 2B, 2C, 1, and 2 (Nicholas et al., 1996).
Alpha1- and 2-adrenoceptors have similar structural components (Shreeve et al., 1985).
Alpha2- adrenoceptors are localized both pre- and postsynaptically, whereas 1-adrenoceptors
appear to be exclusively located postsynaptically (Janowsky and Fridolin, 1998). Alpha2adrenoceptors localized at presynaptic nerve endings function as autoreceptors, controlling the
release of NE via coupling to the Gi-protein and subsequent inhibition of adenylate cyclase (Fain
and Garcia-Sainz, 1980; Limbird, 1983). These are predominantly of the 2A-adrenoceptor
subtype (Aantaa et al., 1995). Alpha2-adrenoceptors have also been shown to increase
potassium conductance, decrease calcium conductance, and to increase the phospholipase C and
A2 cycles via the Gi and Go second messenger systems (Aantaa et al., 1995). As the result, the
each physiological role of postsynaptic 2-adrenoceptors remains to be clearly elucidated.
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However, most evidence suggests that postsynaptic 2-adrenoceptors are inhibitory (Fink et al.,
1995).
All three presently identified rat 2-adrenoceptor mRNAs have a widespread distribution
in the rat CNS (Nicholas et al., 1996). Using in situ hybridization analyses (McCune et al.,
1993; Nicholas et al., 1993; Scheinin et al., 1994) 2A-adrenoceptor mRNA labeling has been
localized primarily in layer VI of the cerebral cortex, the LC, amygdala, PVN, pontine nuclei,
BNST, ventrolateral medullary reticular formation, and the dorsal horn and intermediolateral cell
column (IML) of the thoracic spinal cord and dorsal root ganglia, while 2B-adrenoceptor mRNA
has been found exclusively in the thalamus (McCune et al., 1993; Nicholas et al., 1993; Scheinin
et al., 1994). Finally, 2C-adrenoceptor mRNA has been found in the olfactory bulb, islands of
Calleja, cerebellar cortex, cerebral cortex, hippocampal formation, striatum and dorsal root
ganglia (McCune et al., 1993; Nicholas et al., 1993; Scheinin et al., 1994). These findings are in
accordance with studies using northern blot analysis (McCune et al., 1993; Nicholas et al., 1993;
Scheinin et al., 1994).

Physiological and behavioral effects of norepinephrine
Evidence implicating the importance of norepinephrine’s role in mediating the stress
response has been clearly demonstrated. Both the amygdala and parvocellular division of
paraventricular nucleus receive extensive noradrenergic inputs from neurons in the lower
brainstem, which have direct synaptic contacts with CRFergic neurons (Sawchenko and
Swanson, 1981; Sawchenko and Swanson, 1982; Cunningham and Sawchenko, 1988; Itoi et al.,
1994; Gray and Bingaman, 1996). This strongly suggests that NE input plays a role in the activity

20

of CRF neurons. Norepinephrine’s role as stress mediator is suggested by evidence that
footshock stimulates NE release in the amygdala (Galvez et al., 1996), while i.c.v. CRF and
hemodynamic shock stimulate NE release in LC (Curtis et al., 1993; Curtis et al., 1997).
Additionally, bilateral micro-injection of NE into the PVN leads to dose dependent increases in
CRF gene expression and plasma levels of ACTH (Itoi et al., 1994). Pharmacological and
behavioral evidence also suggest that NE modulates CRF activity in vitro. For example, NE and
several sympathomimetics (e.g. phenylephrine and methoxymine) have been shown to increase
secretion of CRF in rat hypothalamic perfusion systems (Buckingham and Hodges, 1979; Fehm
et al., 1980).
In vivo, pharmacological agents that increase noradrenergic neurotransmission are
associated with increases in fearful behavior. For example, phenylephrine, an 1-adrenoceptor
agonist, elicits increased defensive withdrawal and decreased exploration of the open field in the
defensive withdrawal test (Berridge and Dunn, 1989b; Yang et al., 1990), while yohimbine, a
known 2-adrenoceptor antagonist, has been shown to be anxiogenic in number of behavioral
tests, including the elevated plus mazed, social interaction test, feeding tests, and defensive
burying (Pellow et al., 1985; López-Rubalcava and Fernández-Guasti, 1994; Bhattacharya et al.,
1997). Additionally, drugs that decrease or inhibit noradrenergic neurotransmission are
anxiolytic. For example, the noradrenergic-selective neurotoxin, DSP-4, the 2-adrenoceptor
agonist, clonidine, and the 1-adrenoceptor antagonist, prazosin, and the non-selective adrenoceptor antagonist, propranolol, have all been shown to reverse restraint-induced or CRFinduced increases in defensive withdrawal (Berridge and Dunn, 1989b; Yang et al., 1990), while
propranolol has also been shown to be anxiolytic open field tests of emotionality (Angrini et al.,
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1998). Such behavioral effects are similar to those of the anxiolytic benzodiazepine,
chlordiazepoxide (Yang et al., 1990; Angrini et al., 1998). Finally, phenylephrine-induced
increases in defensive withdrawal are blocked by centrally administered CRF antagonist, helical CRF9-41 (Yang et al., 1990). Taken together, these findings not only demonstrate the
interactions between the noradrenergic and CRFergic systems, but also suggest the importance of
NE in eliciting anxiety and fearful behavior.

The effects of prenatal stress in humans
Prenatal stress is a state in which alterations in offspring are produced by changes in the
mother that occur as a response to stress during the pregnancy. The earliest studies investigating
the influences of prenatal stress were conducted in humans, assessing various types of maternal
stress on neonatal activity (Ottinger and Simmons 1963; Ottinger and Simmons 1964) and the
development of mental disorders (Pasamanick and Lilienfeld 1955; Pasamanick et al., 1956;
Stott 1959). Since that time, numerous studies have addressed the assorted effects of prenatal
stress, investigating birth characteristics (Wadhwa et al., 1993; Lobel 1994), health and
development (Stott 1973; Stott and Latchford 1976), sinistrality (Schwartz 1988), and even
sexual orientation of offspring (Dorner et al., 1980; Dorner et al., 1983; Bailey et al., 1991).
In 1973, Stott (Stott 1973) looked at the effects of prenatal stress in children during their
first four years of life by assessing the environment (e.g. employment, events, circumstances,
operations, accidents, etc.) and health of mothers during pregnancy. He found a significant
overall increase in offspring morbidity associated with prenatal psychological stress. This effect
was most profound in mothers who experienced situations of inescapable and continuous stress,
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usually in the form of interpersonal tension. This psychological form of prenatal stress produced
significant increases in physical illnesses (e.g. eczema, bronchitis, respiratory trouble, middle-ear
disease), physical (e.g. fat, small, pale) and developmental abnormalities (e.g. late onset in
walking ability), neurological dysfunction (e.g. speech impediment), and behavioral disturbances
(hyperactivity, restlessness, fretful whimpering, clinging, impersonality). These findings are
supported by other studies (Joffe 1969; Lipsitt and Field 1982) showing associations between
maternal stress and the delivery of offspring who are smaller, have slower developmental rates,
and behave abnormally.
The relationship between prenatal maternal anxiety and childhood psychopathlogy was
later confirmed by Ward (Ward 1991). In retrospective studies on children with early childhood
autism and populations of emotionally disturbed, developmentally disabled, or neurotic children
and adolescents, Ward found that psychological stress or emotional disturbances during
pregnancy occurred in 73 and 72% of the cases. Significant correlations were found between the
occurrence of developmentally disabled and emotionally disturbed children and familial discord,
maternal apathy, and excessive physical problems during pregnancy (Ward 1976; Ward 1991).
These findings are supported by an epidemiological study conducted by Stott and Latchford
(1976) on a non-psychiatric population of 1300 children. They found that children, born after
their mothers had been subjected to exteroceptive stresses during pregnancy, such as personal
tension due to marital discord and other stressful social relationships, suffered more behavioral
disturbances, physical illness and defects, and developmental lags than the remainder of the
sample. Based on the studies discussed above, prenatal stress has clearly had profound physical
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and behavioral effects on human offspring. Understanding the mechanisms of such a
phenomenon necessitated the development of animal models.

Prenatal stress in rats
As a result of early investigations into the effects of prenatal stress on humans, studies
with animals quickly ensued. The goals of this research were (and still are) to provide precise
information about the behavioral changes produced by prenatal stress and to test hypotheses
regarding the mechanisms of its effects. Several species of animals have been used, including
guinea pigs (Dauprat et al., 1985; Cadet et al., 1986), mice (Politch and Herrenkohl 1984;
Kinsley and Svare 1986; Kinsley and Svare 1987; Kinsley and Svare 1988), primates (Schneider
1992; Clarke and Schneider 1993; Coe et al., 1993; Clarke et al., 1994; Reyes and Coe 1997),
and even cattle (Lay et al., 1997a; Lay et al., 1997b). However, the majority of this research has
been conducted using rats. The work of Thompson (1957) used the first animal model of
prenatal stress used. Thompson trained female rats in shuttle-box avoidance, mated them, and
presented them with daily trials of inescapable shock during pregnancy, which induced
behavioral and physiological signs of anxiety (Hockman 1961). Thompson found that the
offspring of the stressed mothers were more fearful, as demonstrated by decreased ambulation
and increased latencies to ambulation when tested in an open field at 30-40 and 130-140 days of
age. The prenatally stressed offspring also defecated more, suggesting heightened emotionality.
In a final experiment, Thompson showed that prenatally stressed offspring took longer to
complete food reward tasks following 24-hours of food deprivation (Thompson 1957). From
these findings and subsequent research, Thompson postulated that fetal organisms could not
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perceive discrete cues and had no capacity for memory (Thompson 1965). Therefore, prenatal
treatments affected the general responsiveness (“emotionality,” “fearfulness,” and
“temperament”) of the organism as opposed to specific responses.
Since the early research of Thompson, numerous environmental, physical, and
psychological stressors have been applied to pregnant rats at various times during gestation
(Chapman and Stern 1979; Fride and Weinstock 1984; Glavin 1984; Fride et al., 1986; Peters
1989; Sanchez et al., 1992; Alvarez-Ordas et al., 1992; Sanchez et al., 1993; Smythe et al.,
1994). Stressors include radiation (Mintz et al., 1998), chronic hypoxia (Hermans et al., 1993),
noise stress (Siegel and Doyle 1975; Weinstock et al., 1998), malnutrition (Menendez-Patterson
et al., 1982; Anderson et al., 1985; Weinberg 1987), disease (Archer and Blackman 1971), drugs
or hormones (Thompson and Goldenberg 1962; DeFries et al., 1967; Chapman and Stern 1979;
Ward et al., 1996; Shelat et al., 1997; Zimmerberg and Blaskey 1998), physical stress (e.g.
restraint, heat, shock, handling, crowding, forced swimming) (Keeley 1962; Ader and Conklin
1963; Siegel et al., 1977; Chapman and Stern 1979; Zimmerberg and Blaskey 1998; Stohr et al.,
1998; Takahashi et al., 1998; Keeley 1962) and psychological stress (Thompson 1957). Various
effects have been studied, including survival rate, phenotypic (Williams et al., 1995) and
morphological changes (Anderson et al., 1985), alterations in hormonal system (Peters 1982;
Wakshlak and Weinstock 1990; Weinstock et al., 1992; McCormick et al., 1995) and
neurotransmitters (Huttunen 1971; Peters 1982; McDowell and Kitchen 1987; Shemer et al.,
1988; Peters 1989; Takahashi et al., 1992b; Henry et al., 1995; Wang et al., 1995), and
behavioral abnormalities (Chapman and Stern 1979; Fride et al., 1986; Wakshlak and Weinstock
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1990; Suchecki and Palermo 1991; Takahashi et al., 1992a). Much of the earlier work in this
field has been extensively reviewed by Montagu (1962) and Joffe (1969).

The neurochemical, morphological, and phenotypical effects of prenatal stress in rats
Prenatal stress is characterized by widespread changes on all functional levels of the
organism. An effect common to most of the models of prenatal stress is an up-regulation of the
HPA axis, as shown by increased adrenal weight (Birkle and Salm, unpublished results),
increased ACTH and corticosterone levels under basal conditions (Peters 1982; Takahashi and
Kalin 1991; Weinstock et al., 1992; Weinstock et al., 1998) and in response to anxiogenic
stimuli (Takahashi and Kalin 1991; McCormick et al., 1995; Bakker et al., 1998; Weinstock et
al., 1998), and a down-regulation of hippocampal type I and II glucocorticoid receptors (i.e.
decreased negative feedback) (Weinstock et al., 1992; Maccari et al., 1995). These changes are
likely due, in part, to an up-regulation of the CRFergic system (Cratty et al., 1995).
Neurochemically, prenatal stress has been shown to generate both transient and long term
changes in receptor levels in a number of transmitter systems including the noradrenergic
(Huttunen 1971; Moyer et al., 1978; Peters 1982; Peters 1984), serotonergic (Peters 1982; Peters
1989), opioidergic (McDowell and Kitchen 1987; Sanchez et al., 1992; Sanchez et al., 1993;
Keshet and Weinstock 1995), and dopaminergic systems (Fride and Weinstock 1988; Fride and
Weinstock 1989; Takahashi et al., 1992b; Alonso et al., 1994; Henry et al., 1995). Associated
changes in turnover rate and/or neurotransmitter levels are observed as well (Peters 1982; Peters
1986b; Takahashi et al., 1992b; Wang et al., 1995). Not surprisingly, these changes have
morphologic ramifications as several neurotransmitter systems play pivotal roles in growth and
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proliferation (Whitaker-Azmitia and Azmitia 1989; Borgundvaag et al., 1992; Dirami et al.,
1996), the development and elaboration of neuronal processes (Lovell 1982; Bardo et al., 1985),
the formation of synapses (Hauser et al., 1987; Zhu et al., 1994), and normal rate of cell attrition
(Meriney et al., 1985). For example, prenatal stress has been shown to reduce both the area
(Anderson et al., 1985; Anderson et al., 1986) and volume (Kerchner and Ward 1992) of the
preoptic area of the hypothalamus and to reduce the number of neurons in the bulbocavernosus
and dorsolateral nuclei of the spinal cord (Grisham et al., 1991) and nitric oxide producing
neurons in the hippocampus (Vaid et al., 1997) in male offspring. Jones et al. (1997) showed
that male offspring of pregnant rats exposed to heat, light, and restraint stress during days 15-22
of pregnancy had a significantly larger anterior division of the anterior commissure compared to
controls, while Salm et al. (1999) have shown an increased volume of amygdaloid nuclei in
response to prenatal handling and saline injection.
Prenatal stress has been shown to alter other aspects of development as well. Fride and
Weinstock (1984) found that stressing pregnant dams with randomly presented light and noise
significantly altered both physical and behavioral development of offspring, with delays in
acoustic startle responding, eye-opening, and motor development. They and others have also
shown that severe or unpredictable prenatal stress affects both litter size and birth weight (Fride
and Weinstock 1984; Menendez-Patterson et al., 1985; Pfister and Muir 1992; Williams et al.,
1998) and other phenotypic characteristics such as the formation and symmetry of bone
structures (Siegel and Doyle 1975; Siegel et al., 1977; Mooney et al., 1985), laterality of tail
position and amphetamine-induced directional bias (Fride and Weinstock 1989), anogenital
distance (Kashon et al., 1992; Secoli and Teixeira 1998), and organ (e.g. brain, spleen, testicles)
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or structure (e.g. cerebral cortex, hippocampus) size, symmetry, and sexual dimorphism
(Menendez-Patterson et al., 1985; Fleming et al., 1986; Stewart and Kolb 1988; Szuran et al.,
1994; Cela et al., 1995; Williams et al., 1998). Both the timing and the severity of the maternal
stressor influences the outcome of the offspring. For example, mild prenatal stress such as
handling, does not alter litter size, but does cause an increase in HPA axis activity. Peters
(1984,1986b,1988), demonstrated that the third trimester of gestation (days 14 to 21) was the
critical period for eliciting changes in the serotonergic and noradrenergic neurotransmitter
systems, the HPA axis, and the behavior of offspring. Stress, especially if begun on the first day
of gestation, has more severe effects (Fride and Weinstock 1984; Mooney et al., 1985;
Menendez-Patterson et al., 1985; Fride et al., 1986). This “dose-response” effect of prenatal
stress supports the hypothesis that the maternal stress response impacts the development of the
offspring.

The behavioral effects of prenatal stress in rats
Contemporary animal research over the past 40 years has shown that prenatal stress
adversely affects various aspects of behavior. Many studies have focused on the effects of
prenatal stress on reproductive behavior and are reviewed by Herrenkohl (1986). In short,
prenatal stress feminizes male sexual behavior, as manifested by increasing lordosis (Ward 1972;
Ward 1977) and the increasing likelihood of engaging in maternal behavior when presented with
rat pups (Kinsley and Bridges 1988). It also demasculinizes the sexual behavior of males by
decreasing spontaneous copulation (Ward 1972; Masterpasqua et al., 1976; Ward 1977; Hermans
et al., 1993) and ejaculation (Ward 1972; Hermans et al., 1993) when presented with estrous
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females. In female rats, prenatal stress reduces receptivity, fertility and fecundity (Herrenkohl
1986; Reznikov and Nosenko 1996). It also produces estrous cycle disorders (Herrenkohl and
Politch 1978; Menendez-Patterson et al., 1982; Herrenkohl and Scott 1984), spontaneous
abortions or vaginal hemorrhaging (Herrenkohl 1979), and high neonatal infanticide (Herrenkohl
1979; Miley et al., 1982) and mortality (Cela et al., 1995), in addition to reducing maternal
behavior (Kinsley and Bridges 1988).
There is a growing body of research investigating other behavioral effects of prenatal
stress. Prenatal stress has been demonstrated to cause significant increases in emotionality,
fearfulness, and timidity as measured by increased defecation (Thompson 1957; Joffe 1965), and
decreased ambulation in an open field (Thompson 1957), increased latency to emerge from their
home cage (Thompson 1957), and less time spent in the open arms of the elevated plus maze
(Chapman and Stern 1979; Pellow et al., 1985; Fride et al., 1986; Poltyrev et al., 1996). It has
also been suggested that prenatally stressed animals have an altered responsiveness and increased
vulnerability to severe stress (Fride et al., 1985; Fride et al., 1986). Takahashi et al. (1992) and
others showed prenatal stress causes an inability to adapt, indicated by a decreased propensity to
play in a novel environment (Ward and Stehm 1991; Takahashi et al., 1992a), persistently
increased ultrasonic vocalization during isolation stress (Takahashi et al.,1992a), increased
shock-induced freezing (Takahashi et al.,1992a), and persistently elevated corticosteroid levels in
open field tests (Weinstock et al., 1992; Henry et al., 1994). Increased activation of the HPA
axis (Takahashi and Kalin 1991; McCormick et al., 1995; Bakker et al., 1998; Weinstock et al.,
1998), decreased negative feedback via down-regulation of glucocorticoid receptors (Weinstock
et al., 1992; Maccari et al., 1995), and shifts in the rhythm of corticosterone secretion of
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prenatally stressed offspring (Koehl et al., 1997) support such behavioral findings and further
suggest an increased susceptibility to stress.
With regard to learning, Thompson and colleagues (1963) found that it took longer for
prenatally stressed animals to learn a Hebb-Williams open field maze than controls, and that it
took prenatally stressed rats significantly longer to perform a water maze task and significantly
longer to re-attain performance criterion following previous training (Thompson et al., 1963).
Similarly, Fride et al. (1986) showed acquisition of active avoidance in a shuttle box was reduced
in male prenatally stressed offspring, while Weller and colleagues found deficits during the
reversal stage of an operant discrimination task (Weller et al., 1988). These findings suggest that
learning and acquisition of tasks are impaired by prenatal stress, which could have implications
for the survival of prenatally stressed animals. Furthermore, decreased performances in pup
retrieval tasks and decreased maintenance of previously learned appetitive tasks under mildly
aversive conditions (Fride and Weinstock 1984; Fride et al., 1986; Wakshlak and Weinstock
1990) suggests an inability of prenatally stressed animals to cope under conflicting situations.
Prenatal stress generates a propensity for depression, as demonstrated in the Porsolt swim test
(Alonso et al., 1991; Alonso et al., 1994; Secoli and Teixeira 1998). Lastly, prenatal stress has
been reported to cause an altered sensitivity to morphine (Kinsley et al., 1988; Insel et al., 1990),
caffeine (Pohorecky et al., 1989), and ethanol (DeTurck and Pohorecky 1987) treatment, an
increased susceptibility to amphetamine self administration (Deminiere et al., 1992; Henry et al.,
1995), and an increased sensitivity to pentylenetetrazol-induced clonic seizures (Suchecki and
Palermo 1991).
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Acoustic startle as a method of studying fearful behavior.
One of the ultimate goals of neuroscience is to determine how the brain causes behavior
in man. There are numerous behavioral models designed to assess fearful behavior and its
underlying mechanisms. Many such models are extremely complex, making analysis and
interpretation of data difficult. Fortunately, there are a number of relatively simple behaviors that
can be used to address changes in fearful behavior, including the mammalian acoustic startle
reflex.
The mammalian startle reflex has been extensively reviewed by Davis (1984). The
acoustic startle reflex is a characteristic sequence of flexor and extensor muscular movements
down the neural axis, which occurs in response to a sudden, intense stimulus (Landis and Hunt
1939; Davis 1984). The amplitude of the response is directly proportional to the level of fear of
the test subject and can be readily seen in direct muscle recordings or in the output of cages
equipped to detect whole body movements. In both rats and humans, auditory and air puff
stimuli are effective in eliciting startle (Meier-Ewert et al., 1974; Davis 1984). However,
acoustic startle eliciting stimuli are frequency, intensity, and time dependent as demonstrated by
Fleshler (1965). He reported that in the cat, an acoustic stimulus has to reach an intensity of
about 90 dB within 12 msec of its onset in order to elicit a measurable response and reported that
the threshold to elicit startle in adult cats decreased monotonically as the frequency of the
eliciting tones increased from 720 to 13,250 Hz (Fleshler 1965). Subsequent research showed
similar findings in rats (Davis 1970; Davis 1972).
In the rat the latency of the acoustic startle is 8 msec when recorded
electromyographically in the hindleg and 6 msec recorded in the foreleg (Ison et al., 1973). This
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very short latency indicates that only a few synapses could be involved in mediating the acoustic
startle response. Using a variety of techniques (Davis et al., 1982; Cassella and Davis 1986), it
has been proposed that the acoustic startle reflex is mediated by the ventral cochlear nucleus, the
paralemniscal zone or the central nucleus of the acoustic tract (medial to the ventral nucleus of
the lateral lemniscus), the nucleus reticularis pontis caudalis (dorsal to the superior olives), and
motor neurons in the spinal cord (Davis et al., 1993). Bilateral electrolytic lesions in each of
these nuclei eliminate startle, whereas lesions in a variety of other auditory or motor areas do not
(Davis et al., 1993). Startle-like responses can be elicited electrically from each of these nuclei,
with progressively shorter latencies as the electrode is moved down the pathway (Davis 1984).

There are a number of advantages to using acoustic startle to study fear. It is sensitive to
a variety of experimental treatments. Also, since changes in startle amplitude are highly graded,
it is ideally suited for quantitative analysis (Davis 1984). Acoustic startle can be measured at
early ages in many different species, making it appropriate for developmental and comparative
studies. And it is sensitive to different types of plasticity such as habituation, sensitization,
prepulse inhibition, and modification by prior associative learning (Brown et al., 1951; Groves et
al., 1974; Davis and Gendelman 1977; Davis 1984; Grillon et al., 1996; Grillon et al., 1999),
making it an invaluable tool for the investigation of brain mechanisms involved in behavioral
plasticity.
There have been numerous studies assessing the effects of various neurotransmitters, as
well as agents that show anxiogenic and anxiolytic effects in people or in other behavioral tests,
on acoustic startle responding (see Davis, 1984; Davis, 1993; Walker et al., 1997 for reviews).
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The model is validated by the observations that anxiogenic drugs increase startle and anxiolytic
drugs decrease startle. Acoustic startle is additionally modified by a number of aversive (i.e.
anxiogenic) conditions. For example, startle responses are increased when elicited shortly after a
series of inescapable tail or footshocks (Prosser and Hunter 1936; Moyer and Bunnell 1960;
Korn and Moyer 1965). Additionally, startle responses increase following either 24 or 48 hours
of water deprivation, or in the presence of a condition that had previously been paired with the
absence of water in water-deprived rats (Mellgren 1969). Finally, CRF has been shown to
potentiate the acoustic startle reflex and to be involved in facilitation of fear potentiated startle
(Swerdlow et al., 1986; Swerdlow et al., 1989; Liang et al., 1992a; Lee et al., 1994; Lee and
Davis 1997; Pelton et al., 1997; Birnbaum and Davis 1998). Such effects are blocked by CRF
antagonists (Swerdlow et al., 1989; Fendt et al., 1997).

The defensive withdrawal test as a method for studying fearful behavior
An adaptive behavioral trait shown by animals in response to both real and potential
sources of danger is to withdraw or increase the distance between themselves and the source of
danger. First developed by Takahashi and colleagues, the defensive withdrawal test is a conflict
test that takes advantage of this behavioral trait (Takahashi et al., 1989). The test is designed to
emulate a naturally occurring situation and is based on the rat’s predisposition to exhibit strong
initial defensive-withdrawal patterns in response to unfamiliar situations, coupled with their
subsequent tendency to explore the unfamiliar environment (Takahashi et al., 1989). The test is
accomplished by presenting an aversive and novel stimulus to the rat, in the form of a well lit
open field. The open field has an accompanying small, dark enclosed chamber, which may be
adjoined to or contained within the open field. In theory, the rat will explore a new environment
33

(i.e. the open field) in the absence of a perceived threat and will retreat to the safety of the
defensive withdrawal chamber when fearful. Generally speaking, increasing amounts of time
spent in the defensive withdrawal chamber are associated with increased fearfulness (Takahashi
et al., 1989; Yang et al., 1990; De Fonseca et al., 1996) Hence, anxious behavior can be
quantified by comparing the relative amount of time spent in the withdrawal chamber vs. the
open field or by determining the average amount of time spent during each visit to the chamber.
Another behavior specific to the test that can be used to assess fearfulness is the amount of time
it takes the animals to initially exit from the defensive withdrawal chamber, termed latency.
Again, increasing latency times before exiting are thought to reflect an increased fearfulness.
One of the main advantages of this assay is that it can be used to examine other behaviors
measured in more traditional open field tests (e.g. rearing rates and ambulatory activity). This
not only gives a more complete behavioral profile of the drugs tested but also allows comparison
to studies assessing these specific behaviors. Rearing behavior is thought to be indicative of
exploration (Dunn and Berridge 1990b; Yang et al., 1990; Yang and Dunn 1990) and is inversely
proportional to the level of fearfulness, while decreases in ambulatory behavior in some form of
open field apparatus have traditionally been thought to be indicative of increases in “timidity”
and fearful behavior (Thompson 1957; Joffe 1965; Chapman and Stern 1979; Weinstock et al.,
1988; Weinstock et al., 1992; Henry et al., 1994). Hence, decreased exploration (i.e. decreased
rearing and ambulation) suggests increased fearfulness.
The defensive withdrawal test induces a characteristic and reliable pattern of behavior in
response to a number of stressors (e.g. restraint stress, airpuff-startle, swim stress) and
anxiogenic agents (e.g. CRF, isoproterenol, cocaine, phenylephrine) (Yang et al., 1990; Yang et
al., 1992; Gorman and Dunn 1993; De Fonseca et al., 1996; Smagin et al., 1996; Engelmann et
al., 1996). This pattern consists of decreased rearing, increased latency, and increased average
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time per visit ATPV to the chamber (ATPV). Previous work has demonstrated that centrally
administered CRF is anxiogenic in the defensive withdrawal test, an effect that is prevented by
pretreatment with the CRF antagonist, -helical CRF(9-41), and anxiolytics such as the BZ
chlordiazepoxide and the -adrenergic antagonist propranolol (Takahashi et al., 1989; Yang et
al., 1990). These findings not only support reports of CRF-induced increases in fearful behavior
(Dunn and Berridge 1987; Takahashi et al., 1989; Dunn and Berridge 1990b; Owens and
Nemeroff 1991; Cratty et al., 1995) but also implicate potential interactions between CRFergic
and other stress responsive neurotransmitter systems. Furthermore, these findings demonstrate
that behaviors exhibited in the defensive withdrawal test are, at least partially, mediated by the
CRFergic and noradrenergic systems. The findings support the rationale for the use of the
defensive withdrawal test to validate anxiety-provoking effects of agents that produce such
effects in other behavioral tests (e.g. acoustic startle).
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DISSERTATION OBJECTIVES

There is a continually growing body of evidence linking long term physical and
psychological maladies in offspring with exposure of mothers to stressful and/or fear-provoking
stimuli during critical stages of gestation (Weinstock 1997). A working model of prenatal stress
has been developed using pregnant rats stressed using a combination of mild handling and saline
injection during the last week of gestation (Peters 1982). The resultant prenatal stress syndrome
induced in the offspring generates characteristically exaggerated behavioral and physiological
responses to stressful stimuli and anxiogenic agents (Peters 1982; Peters 1988; Peters 1989;
Suchecki and Palermo 1991; Cratty et al., 1995).
There are a number of neurotransmitter systems involved in coordinating and eliciting the
body’s response to stress, including the CRFergic and noradrenergic systems (Glavin et al., 1994;
Coupland et al., 1996; Lehnert et al., 1998; Arborelius et al., 1999). Previous investigations in
our lab have shown that the content of CRF is increased in the amygdala of prenatally stressed
rats (Cratty et al., 1995). However, there has been little investigation with regard to brain region
specificity or age dependence. Additionally, on the functional level, prenatal stress has been
shown to produce exaggerated fearful behavior in response to anxiogenic stimuli in a number of
behavioral tests. However, little has been done to assess the effects of prenatal stress on the
underlying mediators of fearful behavior.
My research has studied the effects of prenatal stress on CRF levels in brain regions
relevant to producing the response to stress: the amygdala, the PVN of hypothalamus, and the
LC/PBN in adult rats. Also, the behavioral effects of prenatal stress were characterized by the
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acoustic startle reflex test. To determine the possible role of alterations in noradrenergic control
of fearful behavior and stress responsiveness, the effects of yohimbine, idazoxan, and RS 79948
were assessed in control and prenatally stressed offspring using both the acoustic startle and tail
cuff blood pressure tests. Additionally, to validate and confirm acoustic startle test results, the
anxiogenic effect of these drugs, restraint and several other anxiogenic agents were assessed in
the defensive withdrawal test, as was the anxiolytic drug, diazepam.
The first hypothesis was that prenatally stressed offspring would have an up-regulation of
the CRFergic system, resulting in increased CRF content in the afore mentioned brain regions.
The second hypothesis was that prenatally stressed offspring would be more fearful in the
acoustic startle test under basal conditions. Furthermore, I hypothesized that prenatally stressed
offspring would be more fearful than control offspring in response to anxiogenic agents such as
yohimbine, idazoxan and RS 79948. Therefore, the following objectives were pursued:
1. To characterize of differences in total CRF content between prenatally stressed and control
rats.
a. Brain regions: the amygdala, the paraventricular nucleus of the hypothalamus, the locus
coeruleus/parabrachial nucleus
b. Age time-course in adult animals (age range: 90-150 days)
2. To develop of behavioral techniques to evaluate differences in prenatally stressed and control
offspring.
a. To characterize and develop of the acoustic startle test
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3. Assessment of fearful behavior in control and prenatally stressed offspring using the acoustic
startle test.
a. Under basal conditions
b. In response to anxiogenic agents (i.e. yohimbine, idazoxan, RS 79948)
4. Assessment of stress responsiveness (i.e. changes in blood pressure and heart rate) in control
and prenatally stressed offspring using tail cuff blood pressure measurements.
a. Under basal conditions
b. In response to anxiogenic agents (i.e. yohimbine, idazoxan, RS 79948)
5. Validation and confirmation of anxiety-provoking effects of agents in the acoustic startle test
using the defensive withdrawal test.
a. In response to anxiogenic agents (i.e. yohimbine, idazoxan, RS 79948, caffeine, DMCM,
and FG7142)
b. In response to anxiogenic stimuli (i.e. restraint)
c. In response to anxiolytic agents (i.e. diazepam)
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METHODS

Induction of prenatal stress
Adult, virgin, female, Sprague-Dawley rats (225-250 g, Hilltop Labs, Hilltop, PA) were
bred with adult males (250-275 g) in the WVU Animal Care Facility. The appearance of vaginal
plugs was counted as day 0 of pregnancy. Male and female rats were paired for five days (one
complete estrous cycle), regardless of plug day. After such time, the males were removed from
the cages, and the pregnant females were transferred to plastic cages (one rat per cage) for the
rest of their term. Starting on gestational day 14, pregnant females were exposed daily to a mild
stressing paradigm of handling and saline (0.9%) injection (0.1 mL, subcutaneously, s.c.). To
prevent habituation, the stressing paradigm was administered randomly between 8 AM and 7 PM
until day 21. Control (unstressed) dams were not handled except for normal animal care
consisting of a 12 hour light:dark cycle with feeding and changing of cages three times per week.
The offspring of unstressed dams served as the control group. At birth, the litters were randomly
culled to 12 pups within 24 hours post-delivery. Litters were left undisturbed with their birth
mothers until weaning at postnatal days 21-25. At that time, all female offspring were removed.
Male pups were separated and maintained in groups of 2-3 according to litter and treatment
group. Peters (1982) and Cratty et al. (1995) have shown this stress protocol does not affect litter
size, gestational period, or birth weight. However, these parameters were continually monitored
throughout the studies. To avoid artificially reducing variability by taking all subjects from one
litter (Chapman and Stern 1979), the N value (5-12) was derived from the number of independent
litters tested.
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Tissue preparation and microdissection
Microdissection was performed following the methods of Palkovits et al. (for summary
see Cuello, 1983). Animals were sacrificed by decapitation, and their brains were rapidly
removed. The tissue was then placed in 20 mL plastic scintillation vials, quickly frozen in liquid
nitrogen and stored in a deep freeze (-70C) until processed. At the time of dissection, the brains
were placed ventral side up into a Plexiglas template corresponding to the shape of the brain and
cut perpendicular to the long axis of the brain approximately half way through the cerebellum to
“block” the tissue. Serial 100- 300 µm frozen sections were cut in the coronal plane in a Microm
cryostat at -10 to -6C (model HM 505 E, Microm Laborgeräte GmbH, Waldorf, Germany).
Sections were placed on gelatin coated Superfrost slides (VWR Scientific, Bridgeport, NJ)
maintained at room temperature. The tissue was thawed briefly to promote adherence and
quickly refrozen and maintained in the cryostat. For microdissection, slides were placed on a
cold plate under a stereomicroscope, and micropellets of brain nuclei and other areas were
removed from the frozen sections with stainless steel curettes (0.5-2 mm diameter) .
For dissection of the amygdala, punching began approximately 1.8 mm caudal to Bregma
at the level where the CA3 region of the dorsal hippocampus first appears (Plate 25 in Paxinos
and Watson, 1982). As shown in Figure 1, bilateral punches were taken just ventral and slightly
medial to the lateral tips of the external capsule. Tissue punches were taken caudally
approximately 2 mm until the appearance of the ventral hippocampus and the ventral extension
of the lateral ventricles (Plate 33).
Punches for the PVN (Figure 1) began approximately 1.30 mm posterior to Bregma at the
level of the ventral hip commissure and optic chiasm. Additionally, there is a separation of the
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dorsal third ventricle and the lateral ventricles at this level (Plate 23). Bilateral punches were
taken just medial to the fornix and lateral to the ventral third ventricle caudally approximately 1
mm. Beginning on Plate 27, bilateral punches were then taken dorsal to the fornix, ventral to the
mammillothalamic tract, and medial to the lateral hypothalamus. Punching was concluded 2.56
mm posterior to Bregma, where a small triangular opening appears in the ventral third ventricle
just dorsal to the ME (Plate 28).
Punching for the PBN/LC began approximately 8.72 mm posterior to Bregma (Plate 52),
where the second cerebellar lobule protrudes through the cerebral aqueduct (Figure 2). The
central gray and pyramidal tracts are also clearly visible. Bilateral punches for the lateral PBN
were taken from the lateral edge of the superior cerebellar peduncle and medial to the A7
noradrenergic cell group. Punches were taken approximately 0.44 mm posterior to this area. At
Plate 54, the second cerebellar lobule has a rhomboid-like shape, and the fourth ventricle has a
flat, horizontal shape. Bilateral punches for the LC and PBN were taken from the areas just
ventral and lateral to the lateral extremities of the fourth ventricle. Tissue samples were collected
caudally from the same areas approximately 1.36 mm to a level 10.52 mm posterior of Bregma
(Plate 59).
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Figure 1: Microdissection of the amygdala and PVN. Representations of rat brain slices were
taken from Paxinos and Watson’s (1982) stereotaxic guide to the rat brain. a: Plates 23-26; b:
Plates 27-30; c: Plates 31-33. Plates should be read from left to right. qdenotes punches taken
for amygdala.

L

denotes punches taken for PVN. For demonstration purposes, punched areas are

represented unilaterally. For dissection of the amygdala, punching began approximately 1.8 mm
caudal to Bregma at the level where the CA3 region of the dorsal hippocampus first appears on
Plate 25. Bilateral punches were taken just ventral and slightly medial to the lateral tips of the
external capsule. Tissue punches were taken caudally approximately 2 mm until the appearance
of the ventral hippocampus and the ventral extension of the lateral ventricles (Plate 33). Punches
for the PVN began approximately 1.30 mm posterior to Bregma at the level of the ventral hip
commissure and optic chiasm (Plate 23). Additionally, there was a separation of the dorsal third
ventricle and the lateral ventricles at this level. Bilateral punches were taken just medial to the
fornix and lateral to the ventral third ventricle caudally approximately 1 mm. Beginning on Plate
27, bilateral punches were then taken dorsal to the fornix, ventral to the mammillothalamic tract,
and medial to the lateral hypothalamus. Punching was concluded 2.56 mm posterior to Bregma,
where a small triangular opening appears in the ventral third ventricle just dorsal to the ME
(Plate 28). For abbreviations see pp. xi-xiii.

42

23

24

25

26

Figure 1a. Plates 23-26
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Figure 1b. Plates 27-30
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Figure 1c. Plates 31-33
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Figure 2: Microdissection of the LC/PBN. Representations of rat brain slices were taken from
Paxinos and Watson’s (1982) stereotaxic guide to the rat brain. a: Plates 52-55; b: Plates 56-59.
Plates should be read from left to right. qdenotes punches taken for LC/PBN. For demonstration
purposes, punched areas are represented unilaterally. Punching for the LC/PBN began
approximately 8.72 mm posterior to Bregma (Plate 52), where the second cerebellar lobule
protrudes through the cerebral aqueduct. The central gray and pyramidal tracts are also clearly
visible. Bilateral punches for the lateral PBN were taken from the lateral edge of the superior
cerebellar peduncle and medial to the A7 noradrenergic cell group, continuing caudally
approximately 0.44 mm. At Plate 54, the second cerebellar lobule has a rhomboid-like shape,
and the fourth ventricle has a flat, horizontal shape. Bilateral punches for the LC and PBN were
taken from the areas just ventral and lateral to the lateral extremities of the fourth ventricle.
Tissue samples were collected caudally from the same areas approximately 1.36 mm to a level
10.52 mm posterior of Bregma (Plate 59). For abbreviations see pp. xi-xiii.
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Figure 2a. Plates 52-55
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Figure 2b. Plates 56-59
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CRF extraction
For biochemical analysis of total CRF content, regions were microdissected as described
above. Collected micropunches were extracted into 1 mL of 0.05 N HCl (containing 1 mg/mL
ascorbic acid and 0.1 % Triton X-100), heated in a water bath at 70C for 10 minutes, and
sonicated (setting of 3, Branson, Sonic Power, Branson Instruments Inc. Melville, L.I., NY)
(Smith et al., 1986; Clarke et al., 1987). Fifty µL of the sonicated extract was removed and
resuspended in 450 µL of 1 N NaOH for protein determination. Total protein was determined
using the Lowry assay (Lowry et al., 1951). The remaining homogenate was centrifuged at
16,000 g for 15 minutes. The supernatant was lyophilized in a Sorvall Speed-Vac evaporator
(Forma Scientific, Inc., Marietta, OH) and resuspended in 1-3 mL RIA buffer (30 mM phosphate
buffer with 25 mM ethylene-diamine-tetracetic acid; EDTA, 0.1% Triton X-100, and 0.02
mg/mL aprotonin). Samples were assayed for CRF using the quantitative RIA. Appropriate
blanks were also prepared for use in the generation of standard curves for quantitative RIA.

Radioimmunoassay
Samples were divided into duplicates or triplicates equal to 300 µL (40-60% of total
sample) aliquots. Sample dilutions were calculated to yield 10-100 pg CRF per aliquot, which
were well within the linear portion of the CRF standard curve. A 20 µL aliquot of RIA buffer
equaling the volume of the CRF standard solutions (see below) and 100 µL of cocktail
containing a C-terminal directed rabbit anti-human/rat CRF primary antisera (rC70, donated by
Dr. Wylie Vale, The Salk Institute for Biological Studies, La Jolla, CA), rabbit serum (1:33,
Sigma Chemical Co., St. Louis, MO) in RIA buffer, were added for a 24 hour incubation at 4C.
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The RIA used primary antibody at a dilution of 1:600,000. 125I-iodo-histidyl-CRF (Amersham,
Arlington Heights, IL) was diluted to a concentration of 10,000-12,000 c.p.m/100 µL of RIA
buffer. 100 µL of radioisotope was added to each sample. The samples were again incubated for
24 hours at 4C. Sheep anti-rabbit IgG (H+L) precipitating secondary antibody (1:5, 100 µL,
Serotec, Harlan Bioproducts, Indianapolis, IN) was added to each assay tube immediately
followed by the precipitating agent, polyethylene glycol (PEG, mw 7000, 0.14g/mL, 100 µL).
The antibody-CRF complexes precipitated in 20 minutes at room temperature. Samples were
centrifuged for 20 minutes at 4000 g. The supernatant containing the unbound radioligand was
aspirated, and the radioactivity of the pellet was counted using a Wallac gamma counter
(Pharmacia, Gaithersburg, MD).
Individual standard curves for the RIA were prepared in 300 µL aliquots of the matrix
solution used in the extraction experiments (0.05 N HCl containing 1 mg/mL ascorbic acid and
0.1 % Triton X-100 per mL). The 0.5 to 500 pg of synthetic CRF standard (Bachem Inc.,
Torrance, CA) were added in a 20 µL volume of RIA buffer, making the total volume 320 µL.
Each point of the standard curve was done in triplicate or quintuplicate. The amount of CRF in
each sample was calculated by interpolation of the standard curve after linearization by a logit
transformation. The limit of detection (pg CRF/tube) for the RIA was calculated from the mean
counts per minute (cpm) at zero CRF minus one standard deviation of that mean (n=5) and
ranged from 0.5 to 1.5 pg CRF. The upper limit of detection was >500 pg. The intra- and interassay coefficients of variation for the standard curve were 1.51 and 6.09 in the micropunch
dissection studies, respectively.

50

Data analysis for the RIA
Total CRF content was calculated for each sample as pg/brain region. CRF content was
also normalized on a pg CRF/ mg protein basis. The normalized CRF content (pg CRF/mg
protein) values of prenatally stressed offspring were also expressed as percent of control values.
CRF values are expressed as mean ± SEM. The CRF data expressed as total pg or on a pg/mg
protein basis were analyzed for each brain region independently using a two factor (age x breed
group: prenatal stress versus control) analysis of variance (ANOVA) with a post-hoc comparison
by Tukey’s protected t-test (GB-STAT). Data expressed as a percent of control were analyzed
using a modified Student’s t-test comparing the sample mean to a fixed value of 100 percent. A
p-value of less than 0.05 was accepted as statistically significant.

Corticosterone assay
Trunk blood samples (1-1.5 mL) were collected into chilled microcentrifuge tubes
containing four units of heparin sulfate (160 units/mg; 67 mg heparin sulfate/mL diH2O) and
immediately centrifuged (3000 rpm, 30 min at 4C) to obtain plasma. Plasma corticosterone
levels were determined using an ImmuchemTM double antibody corticosterone 125I RIA kit for rats
and mice (ICN Biomedicals, Costa Mesa, CA). Assay sensitivity was 0.1 ng/mL, with reported
intra-assay coefficient of variation of 5.27.

The acoustic startle test
Each of two startle test stations (Figure 3; SR-LAB, San Diego Instruments, San Diego,
CA) was housed in a ventilated isolation cabinet with a 75 dB ambient noise level. Test stations
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were composed of an animal enclosure resting on an enclosure base. Animal enclosures
consisting of a clear Plexiglas cylinder (8.2 cm diameter by 20 cm length) resting on a 12.5 x
25.5 cm opaque Plexiglas frame mounted on 4- 2 cm metal pins. The four pins rested in fitted
moldings on top of the 30.5 x 30.5 cm opaque Plexiglas enclosure base. Acoustic noise bursts
were presented via a speaker mounted 24 cm above the animal enclosure. A piezoelectric
accelerometer mounted below the Plexiglas frame detected and transduced motion within the
cylinder, which was subsequently amplified by specialized circuitry in the enclosure base. The
delivery of the acoustic stimuli was controlled by the SR-LAB microcomputer and interface
assembly, which also digitized, rectified, and recorded stabilimeter readings with 250 x 1 ms
reading collected beginning at stimulus onset. Startle amplitude was defined as the average of
250 readings. Background noise and all acoustic stimuli were delivered through one Radio
Shack Realistic speaker (8 Ohm; frequencies predominantly between 60 Hz and 18 kHz) in each
chamber. Stimulus intensities were calibrated to be nearly identical in each of the startle cabinets
(maximum variability 2 dB). Response sensitivities were calibrated using the SR-Lab Calibration
system (maximum variability <3.33%). Chambers were also balanced across all experiment
groups.
For the age-response time course studies, a repeated measures design was implemented.
A predesignated group of control and prenatally stressed offspring representing each litter were
repeatedly tested at five different ages (75, 85, 125, 155, 185 days old). Each animal was
presented with 60 acoustic startle stimuli trials (95 dB, 50 ms noise burst) at a variable inter-trial
interval (ITI) average of 28 seconds after a five minute acclimation period. The effects of
prenatal stress on acoustic startle responding, habituation to the acoustic startle test over time
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(minutes and days), correlations between weight and acoustic startle responding, between age
and acoustic startle responding, and acoustic startle responding and time of day were assessed
following the same protocol. A subsequent series of habituation experiments using a fixed ITI of
30 seconds were conducted to assess changes on acoustic startle responding acutely (minutes)
and over a three-day period. Each testing session consisted of 60 acoustic startle stimuli trials
(95 dB, 50 ms noise burst) with a five minute acclimation period.
For drug studies, a three-day repeated measures design was implemented. On the first
day of experimentation, animals were presented with 60 acoustic startle stimuli trials (95 dB, 50
ms noise burst) with an ITI of 30 seconds after a five minute acclimation period. This first
exposure served to establish a baseline acoustic startle response. It also served to habituate the
animal to the testing procedure. On the second and third days of experimentation, rats were give
vehicle or drug (intraperitoneally, i.p.; in random order) and presented with 120 acoustic startle
trials with a fixed ITI of 30 seconds.
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Figure 3: The acoustic startle testing apparatus. The startle test station (SR-LAB, San Diego
Instruments, San Diego, CA) was housed in a ventilated isolation cabinet with a 75 dB ambient
noise level. Test stations were composed of an animal enclosure resting on an enclosure base.
Animal enclosures consisted of a clear Plexiglas cylinder (8.2 cm diameter by 20 cm length)
resting on a 12.5 x 25.5 cm opaque Plexiglas frame mounted on 4- 2 cm metal pins. The four
pins rested in fitted moldings on top of the 30.5 x 30.5 cm opaque Plexiglas enclosure base.
Background noise and all acoustic stimuli were delivered through a Radio Shack Realistic
speaker (8 Ohm; frequencies predominantly between 60 Hz and 18 kHz) mounted 24 cm above
the animal enclosure. A piezoelectric accelerometer mounted below the Plexiglas frame detected
and transduced motion within the cylinder, which was subsequently amplified by specialized
circuitry in the enclosure base. The delivery of the acoustic stimuli was controlled by the SRLAB microcomputer and interface assembly, which also digitized, rectified, and recorded
acoustic startle reflex readings. The microcomputer and interface assembly were housed in a
Dell computer. The acoustic startle cabinet and computer were linked via a control chassis,
which transmitted all information between the two units.
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Figure 3. The acoustic startle testing apparatus
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Drugs for acoustic startle
Yohimbine hydrochloride was obtained from Sigma Chemical Company (St. Louis, MO),
and idazoxan hydrochloride was obtained from Research Biochemicals International (RBI;
Natick, MA). RS 79948 hydrochloride was obtained from Tocris Cookson, Inc. (Ballwin, MO).
Yohimbine (0.025-2.5 mg/mL) was dissolved in phosphate buffered saline (PBS, pH 3.0).
Yohimbine (10 mg/mL) was prepared in 2-Hydroxylpropyl- - cyclodextrin (HBCD; Sigma
Chemical Company, St. Louis, MO) . Idazoxan (0.08-20 mg/mL) and RS 79948 (0.01-10
mg/mL) were dissolved in normal saline. All drugs and the appropriate vehicles were
administered i.p. in male, Sprague-Dawley control or prenatally stressed offspring, 60-200 days
of age. All rats were tested in the acoustic startle test for 60 minutes after a five minute
acclimation following injection of the respective drugs or vehicle. Acoustic startle data for
yohimbine collected 30-50 minutes post-injection were analyzed, while idazoxan and RS 79948
were collected 20-65 minutes post-injection and analyzed. Analysis times were based on pilot
studies to determine the peak effects of each drug.

Data analysis for acoustic startle
Results for all studies involving repetitive exposure to the acoustic startle test are
expressed as mean ± SEM. The data were analyzed using a repeated measures, two-factor
ANOVA (breed group x day) with a post-hoc comparison by Tukey’s protected t-test (GBSTAT). Comparisons of paired groups were analyzed using Student’s t-test (GB-STAT). A pvalue of less than 0.05 was accepted as statistically significant.
Results for the drug studies are expressed as percent vehicle. Values are mean ± SEM.
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Data were analyzed using a modified Student’s t-test comparing the sample mean to a fixed value
of 100 percent. The data were also analyzed using Student’s t-test to determine the effects of
prenatal stress. A p-value of less than 0.05 was accepted as statistically significant.

Blood pressure and heart rate studies
Blood pressure and heart rate studies were performed using a computerized blood
pressure monitor (IITC Model 31; IITC Inc./Life Science Instruments, Woodland Hills, CA).
The system is comprised of test stations (up to six), a pump, a sensing (tail) cuff, an amplifier,
and an automatic scanner. All stations are housed in a large, multi-tiered cabinet (60 cm wide by
85 cm high by 42 cm deep) maintained at an ambient temperature of 28-29C. Each station
consists of a clear Plexiglas cylinder (7.5 cm diameter by 23 cm length or 9 cm diameter by 30
cm length, depending on the size of the animal) closed off by an adjustable Teflon stopper at one
end and a Plexiglas plate (9.5 cm diameter by 9.5 cm or 12 cm diameter by 12) at the other. The
Plexiglas end plate has an opening where a tail cuff equipped with a photoelectric sensor is
mounted. The test subject’s tail extends through both the opening and the tail cuff. Test
information collected from the equipment comes in two forms: plots of analog waveforms (two
kinds) and digital values. One of the analog tracings shows the pressure applied to the sensing
cuff, and the other shows the pulses detected by the sensor. The digital values are calculated
automatically from the analog data and displayed along with the waveforms.
For drug studies, animals were trained for three days prior to testing to allow habituation
to the apparatus and testing procedure. Training consisted of a 30 minute acclimation period
followed by seven to ten blood pressure/heart rate pressure measurements. The animals were
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then administered a mock injection while in the cylinder enclosure and subjected to another 20 or
30 minute holding period to simulate drug/vehicle injection and the subsequent waiting period
allotted for the drug to elicit its effects. This was followed by an additional seven to ten blood
pressure/heart rate measurements. For testing, a repeated measures design was implemented.
Each day of testing consisted of a 30 minute acclimation period followed by seven to ten blood
pressure measurements. These readings were averaged together and used to establish basal levels
of blood pressure and heart rate for each animal. Animals were then administered either drug or
vehicle, and seven to ten blood pressure readings were recorded beginning 20 minutes postinjection for idazoxan and 30 minutes post injection for yohimbine. Each testing session lasted
10-15 minutes. These values were averaged together to determine the effects of vehicle or drug
on basal systolic blood pressure and heart rate. This procedure was repeated on the subsequent
test day with animals receiving the alternative treatment. Testing times were based on those used
in the acoustic startle test for idazoxan (20-65 minutes post-injection) and yohimbine (30-50
minutes post-injection), respectively.

Drugs for blood pressure studies
Yohimbine hydrochloride was obtained from Sigma Chemical Company (St. Louis, MO),
while idazoxan hydrochloride was obtained from Research Biochemicals International (RBI;
Natick, MA). Yohimbine (5.0 mg/mL) hydrochloride was dissolved in 2-hydroxypropyl-cyclodextrin. Idazoxan hydrochloride (8 mg/mL) was dissolved in normal saline. All drugs and
the appropriate vehicles were administered i.p. in male, Sprague-Dawley control or prenatally
stressed offspring 110-130 days of age. The doses of yohimbine and idazoxan were based on
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findings using the acoustic startle test, which demonstrated significant differences in acoustic
startle responding between control and prenatally stressed offspring.

Data analysis for blood pressure studies
Values for basal systolic blood pressure are expressed as mean ± SEM. Comparisons
between control and prenatally stressed offspring values were analyzed using Student’s t-test
(GB-STAT). A p-value of less than 0.05 was accepted as statistically significant.
Data for the drug studies are expressed as percent baseline. Values are mean ± SEM.
Data were analyzed using a modified Student’s t-test comparing the sample mean to baseline (i.e.
100 %). The data were also analyzed using a Student’s t-test to determine the effects of prenatal
stress. A p-value of less than 0.05 was accepted as statistically significant.

The defensive withdrawal test
Fearful behavior or pharmacologically-induced anxiety was measured using a
modification of the defensive withdrawal test (Takahashi et al., 1989). Testing was conducted in
an open field (100 cm x 100 cm x 40 cm) with an adjoining side compartment (15 cm x 15 cm x
20 cm) (Figure 4). The two areas were separated by a removable, opaque Plexiglas door. The
entire apparatus was constructed of wood and lined with opaque Plexiglas. The open field was
illuminated by direct fluorescent lighting at 2300 lux. The side compartment (defensive
withdrawal chamber) received indirect light measured at less than 1 lux. Before testing, the
animal was placed into the defensive withdrawal chamber via a back door. After closing the
back door, a 5 second test delay was implemented to standardize the beginning of the test. After
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such time, the door to the open field was removed starting the test. Testing was 10 minutes in
duration. Activity was video-recorded using a Videomex-V Image Motion Computer (Model
0120-005L, Columbus Instruments, Columbus, OH) to allow for repeated viewing and
quantitative analysis of each behavioral parameter. Activity was later scored by an observer.
Behaviors measured were: latency, defined as the time spent in the defensive withdrawal
chamber before the first exit into the open field; exits, defined as the number of passages (all four
paws) into the open field from the chamber; total time spent in the defensive withdrawal
chamber; rearing behavior (rears per minute in the open field) defined as raising the front paws
from the floor; and locomotor activity defined as the number of lines crossed (all four paws) per
minute in the open field. After testing, the open field and chamber were cleaned with dilute
acetic acid (0.1%) between subjects to eliminate olfactory cues. All behavioral tests using the
defensive withdrawal apparatus are conducted between 8 AM and 12 PM. Animals not exiting
from the defensive withdrawal chamber or spending greater than 85% (i.e. 510 seconds) of the
total testing time in the open field were excluded from the study.
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Figure 4: The defensive withdrawal testing apparatus. The apparatus consisted of an open field
(100 cm x 100 cm x 40 cm) with an adjoining side compartment (15 cm x 15 cm x 20 cm). The
two areas were separated by a removable, opaque Plexiglas door. The entire apparatus was
constructed of wood and lined with an opaque Plexiglas. The open field was illuminated by
direct fluorescent lighting at 2300 lux. The side compartment (defensive withdrawal chamber)
received indirect light measured at less than 1 lux. Before testing, the animal were placed into
the defensive withdrawal chamber via a back door. After closing the back door, a 5 second test
delay is implemented to standardize the beginning of the test. After such time, the door to the
open field was removed, starting the test. Activity was video-recorded using a Videomex-V
Image Motion Computer (Model 0120-005L, Columbus Instruments, Columbus, OH). The
monitor camera was mounted approximately 150 centimeters above the open field floor. Video
recording allowed repeated viewing and quantitative analysis of the test.
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Figure 4. The defensive withdrawal testing apparatus
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15 cm

Drugs for defensive withdrawal
Caffeine hydrochlorate, diazepam, and yohimbine hydrochloride were obtained from
Sigma Chemical Company (St. Louis, MO). N-methyl--carboline-Carboxamide (FG7142),
idazoxan hydrochloride, and methyl-6,7,-dimethoxy-4-ethyl--carboline-3-carboxylate (DMCM)
were obtained from Research Biochemicals International (RBI; Natick, MA). RS 79948
hydrochloride was obtained from Tocris Cookson, Inc. (Ballwin, MO). Caffeine hydrochlorate
(10, 20, and 40 mg/mL), idazoxan hydrochloride (0.08 and 0.8 mg/mL), and RS 79948
hydrochloride (0.1 mg/mL) were dissolved in normal saline. Diazepam (1 and 2 mg/mL) was
dissolved in a vehicle of 45 g of 2-Hydroxylpropyl- - cyclodextrin (HBCD; Sigma Chemical
Company, St. Louis, MO) per 100 mL deionized water (DiH2O). Yohimbine (1.25 mg/2 mL)
hydrochloride was dissolved in phosphate buffered saline (PBS, pH 3.0). FG7142 (5 and 15
mg/2 mL) was dissolved in a vehicle of 1 mL of DiH2O water with 1 drop of Tween 20 (Sigma
Chemical Company, St. Louis, MO). DMCM (0.5 mg/mL) was dissolved in a vehicle of 2 mL of
0.025 N HCl brought up to a total volume of 8 mL upon the addition of 6 mL of PBS. All drugs
and the appropriate vehicles were administered i.p. in male, Sprague-Dawley control or
prenatally stressed offspring 60-120 days of age. After injection, animals were kept in individual
holding cages until testing. All rats were tested in the defensive withdrawal test 15 minutes
(DMCM), 20 minutes (FG7142, Idazoxan hydrochloride, and RS 79948 hydrochloride), or 30
minutes (caffeine hydrochlorate, diazepam, and yohimbine hydrocloride) minutes after injection
of the respective drugs. Doses and drug onset times for Caffeine, FG7142, and DMCM were
based on previous studies demonstrating anxiogenic effects of these drugs (Knorr et al., 1989;
Pohorecky et al., 1989; Cole et al., 1995; Bhattacharya et al., 1997). Doses of yohimbine,
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idazoxan and RS 79948 were chosen based on findings using the acoustic startle test
demonstrating an anxiogenic effect of these drugs. The times allotted for yohimbine, idazoxan,
and RS 79948 to elicit their effects prior to testing were based on pilot studies using the acoustic
startle test, where the peak effects of each drug were determined.

Acute restraint stress for defensive withdrawal
Restraint stress was accomplished by placing rats (males, 75-100 days of age) in a plastic
restraining tube (2.5" x 7", length adjustable) for 60 and 120 minutes at 25C in normal room
light. The rat’s head was exposed but forward and backward movement was prevented and there
was limited side-to-side mobility. Rats were tested immediately after the end of the designated
restraining period or were tested without prior restraint.

Data analysis for defensive withdrawal
Results are expressed as mean ± SEM. The data were analyzed using Student’s t-test
(GB-STAT). The data were also expressed as percent vehicle and analyzed using a modified
Student’s t-test, comparing the sample mean to a fixed value of 100 percent. A p-value of less
than 0.05 was accepted as statistically significant.

64

RESULTS

Effects of prenatal stress on plasma corticosterone
Chronic stress is characterized by a number of physiological characteristics, including
stimulation of the HPA axis (Selye 1936). The effects of the prenatal stress syndrome on the
HPA axis were assessed by measuring plasma corticosterone levels in control and prenatally
stressed male offspring (60 to 90 days old). Plasma corticosterone was significantly higher in
prenatally stressed offspring (212 ± 22 ng/mL) in comparison with controls (136 ± 31 ng/mL;
Figure 5), suggesting prenatal stress generated a state of chronic stress.

The effects of prenatal stress on CRF content in the amygdala, PVN, and LC/PBN of the
brainstem
The neurochemical effects of the prenatal stress syndrome were assessed in adult animals
ranging from approximately 90 to 150 days of age. CRF levels, as an index of the stress response
system, were measured in the amygdala, PVN, and LC/PBN. When expressed as total pg CRF
per region (Table 1), there was a significant effect of age in the prenatally stressed offspring in
PVN (F(2,49)= 7.576; p=0.0015) and LC/PBN (F(2,50)= 3.259; p=0.0476). Levels of CRF in the
PVN and LC/PBN at 120 days and 150 days of age were higher than at 90 days of age. There
were no age- related effects in the amygdala and no age-related changes in any control brain
region. Additionally, there was a significant difference between control and prenatally stressed
in the amygdala (F(1,46)= 6.177; p=0.0166), PVN (F(1,49)= 6.781; p=0.0125), and LC/PBN (F(2,49)=
7.576; p=0.0015) albeit at different ages for each region. CRF values for prenatally stressed
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offspring were significantly higher than those of control offspring in the PVN at 120 days (496.7
± 56.8 pg vs. 1058.5 ± 123.6 pg; Table 1) and in amygdala and LC/PBN at 150 days (793.2 ±
60.9 pg vs. 1039.2 ± 53.8 pg and 773.2 ± 52.9 pg vs. 1047.0 ± 82.9 pg, respectively; Table 1).
Expressing CRF by normalizing to pg CRF/mg protein (Table 2) demonstrated a
significant effect of age in control offspring in the amygdala (F(2,54)= 5.693; p=0.006) and PVN
(F(2,55)= 6.111; p=0.0042), but only in the PVN of prenatally stressed offspring at 150 days of age
compared to 90 days. There were no age-related changes in LC/PBN or amygdala of prenatally
stressed offspring. Additionally, there was a significant overall effect of prenatal stress in the
amygdala (F(2,55)= 6.111; p=0.0042). CRF content for prenatally stressed offspring was
significantly higher than in control offspring in the PVN at 150 days (496.7 ± 56.8 pg/mg protein
vs. 1085.5 ± 123.6 pg/mg protein; Table 2). There were no significant effects of prenatal stress
in the LC/PBN. Finally, expressing the normalized CRF data (pg CRF/mg protein) for prenatally
stressed offspring as percent control values (Figure 6) revealed significantly more CRF in
prenatally stressed offspring in all three brain regions at 150 days of age. These data taken
together suggest that there are differences in stress responsive systems of control and prenatally
stressed offspring. There is an up regulation of the CRFergic system in all three brain regions of
the prenatally stressed animals, which is age-dependent.
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Figure 5: The stimulatory effects of prenatal stress on stress responsive systems were assessed in
rats by measuring plasma corticosterone levels in control and prenatally stressed male offspring
(60 to 90 days old) using a RIA. Values are mean ± std. err (N= 6-10). #significantly different
from control offspring, p<0.05, Student’s t-test. Plasma corticosterone levels were significantly
higher in prenatally stressed offspring compared to control offspring.
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Figure 5. The stimulatory effects of PNS on stress responsive systems
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Table 1: The effects prenatal stress on CRF content (total pg CRF) in the amygdala, PVN, and
LC/PBN. Frozen tissue samples were collected using the micropunch technique from control
and prenatally stressed animals 90, 120, and 150 (or greater) days of age. CRF levels expressed
as total pg CRF were determined using a RIA. Values are mean ± std. err (90 days N= 5-8; 120
days N= 5-8; 150 days N= 10-15). Lsignificantly different from 90 days of age, p<0.05,
ANOVA, Tukey’s protected t-test. #significantly different from control offspring, p<0.05,
ANOVA, Tukey’s protected t-test. There was an age dependent increase in CRF levels of
prenatally stressed offspring in the PVN and LC/PBN at both 120 and 150 days of age.
However, there were no age related effects in control animals. Additionally, CRF values for
prenatally stressed offspring were significantly higher than control offspring in the PVN and
LC/PBN at 120 days and in the amygdala and LC/PBN at 150 days.
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Table 1: The effects prenatal stress on CRF content (total pg CRF) in the amygdala, PVN
of the hypothalamus, and LC and PBN of the brainstem.

Brain region

Group

Amygdala

Control

651.5 ± 105.3

878.1 ± 117.2

793.2 ± 60.9

Prenatal
Stress

828.3 ± 51.5

1038.7 ± 114.8

1039.2 ± 53.8#

PVN of
Control
hypothalamus
Prenatal
Stress

505.6 ± 72.7

496.7 ± 56.8

747.8 ± 63.0

452.1 ± 92.2

1058.5 ±
123.6¼#

Control

791.8 ± 109.7

812.6 ± 148.9

Prenatal
Stress

578.5 ± 87.7

LC/PBN of
brainstem

90 days
120 days
>150 days
(Total pg CRF) (Total pg CRF) (Total pg CRF)
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802.5 ± 54.0¼

773.2 ± 52.9

1135.6 ± 148.1¼ 1047.0 ± 82.9¼#

Table 2: The effect of prenatal stress on CRF (pg CRF/mg protein) in the amygdala, PVN, and
LC/PBN. Frozen tissue samples were collected using the micropunch technique from control
and prenatally stressed animals 90, 120, and 150 (or greater) days of age. CRF levels expressed
as total pg CRF per mg protein were determined using a RIA. Values are mean ± std. err (90
days N= 5-8; 120 days N= 5-8; 150 days N= 10-15). Lsignificantly different from 90 days of age,
p<0.05, ANOVA, Tukey’s protected t-test. #significantly different from control offspring,
p<0.05, ANOVA, Tukey’s protected t-test. There was an age dependent increase in CRF levels
of control offspring in the amygdala and in prenatally stressed offspring in the PVN at 150 days
of age. Additionally, CRF values for prenatally stressed offspring were significantly higher than
control offspring in the PVN at 150 days of age.
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Table 2: The effects prenatal stress on CRF (pg CRF/mg protein) in the amygdala, PVN of
the hypothalamus, and LC and PBN of the brainstem.

Brain region

Group

Amygdala

Control

191.1 ± 15.5

260.7 ± 38.9

359.3 ± 19.8¼

Prenatal
Stress

296.2 ± 53.3

380.7 ± 98.9

414.1 ± 19.7

Control

294.0 ± 51.9

254.0 ± 58.8

418.7 ± 40.4¼

Prenatal
Stress

269.8 ± 34.9

368.5 ± 64.4

562.9 ± 48.3¼#

Control

390.1 ± 56.2

274.5 ± 66.3

258.1 ± 18.3

Prenatal
Stress

306.9 ± 80.1

356.7 ± 82.7

317.8 ± 17.4

PVN of
hypothalamus

LC/PBN of
brainstem

90 days
120 days
>150 days
(pg CRF per mg protein)
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Figure 6: Effects of the prenatal stress syndrome on CRF content in the amygdala, PVN, and
LC/PBN. Frozen tissue samples were collected using the micropunch technique from control
and prenatally stressed animals 90, 120, and 150 (or greater) days of age. CRF levels (pg
CRF/mg protein) were determined using a RIA. Prenatal stress data are expressed as percent of
control values. Values are mean ± std. err (90 days N= 5-8; 120 days N= 5-8; 150 days N= 1015). #significantly different from control offspring, p<0.05, Student’s t-test. At 150 days of age,
CRF content was higher in prenatally stressed offspring in all three brain regions.
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Results from behavioral studies using the acoustic startle test
Effects of prenatal stress on characteristics of the acoustic startle reflex
Random and repetitive presentations of an acoustic startle stimulus were used to elicit
acoustic startle reflexive responses in control and prenatally stressed rats. Figure 7 shows
baseline acoustic startle responding in one control and one prenatally stressed rat following
randomly presented acoustic startle stimuli (95 dB, 50 ms) over a 30 minute testing period. The
average acoustic startle responses for control and prenatally stressed were 33.7 ± 2.4 and 33.8 ±
2.6, respectively (Figure 8).

Acute habituation
The possible effects of acute habituation to repetitive acoustic startle stimuli were
assessed by comparing the average acoustic startle responses for the first 5 and last 5 minutes of
a 30 minute testing period in both control and prenatally stressed rats. There were no habituative
effects of acutely repetitive stimuli following either random or fixed interval (30 seconds) stimuli
presentation patterns in either group (Figure 9). The fixed ITI produced much less variable
results. Based on these findings, all drug studies used a fixed ITI of 30 seconds for acoustic
startle stimuli.
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Figure 7: Acoustic startle responding in control and prenatally stressed offspring. Fear-related
responses in the form of reflexive jumps were recorded from control and prenatally stressed
offspring following randomly presented acoustic startle stimuli (95 dB, 50 ms) trials. The
average inter-trial interval was 28 seconds for the 30 minute testing period. One control and one
prenatally stressed rat are presented.

76

100
Control
PNS

Acoustic Startle Response (mV)

90
80
70
60
50
40
30
20
10
0

1

3

5

7

9

11 13 15 17 19 21 23 25 27 29

Time (minutes)

77

Figure 7. Acoustic startle in control and PNS offspring

Figure 8: Basal acoustic startle responding in control and prenatally stressed offspring. Fearrelated responses in the form of reflexive jumps were recorded from control and prenatally
stressed offspring following randomly presented acoustic startle stimuli (95 dB, 50 ms) trials.
The average inter-trial interval was 28 seconds for the 30 minute testing period. Each bar
represents the average acoustic startle response for its respective group, mean ± std. err (N= 1525). There was no significant difference in basal acoustic startle responding between control and
prenatally stressed offspring.
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Figure 8. Basal ASR in control and PNS offspring
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Figure 9: The potentially habituative effects of acute repetitive acoustic startle stimuli on
acoustic startle responding. The effects of repetitive acoustic startle stimuli following two
different presentation patterns on the acoustic startle reflex were assessed by comparing the
average startle responses for the first 5 and last 5 minutes of the testing period in both control and
prenatally stressed rats. All animals were naive to the testing procedure. Baseline acoustic
startle responding was recorded from control and prenatally stressed offspring following acoustic
startle stimuli trials (95 dB, 50 ms) presented randomly (average inter-trial interval (ITI) was 28
seconds) or with a ITI of 30 seconds. Each bar represents the average acoustic startle response
for its respective group and time period, mean ± std. err (N= 9-40). There was no acute
habituation of the acoustic startle reflex in either control or prenatally stressed offspring in
response to acoustic startle stimuli presented randomly or at a fixed ITI of 30 seconds.
Additionally, there were no significant differences between control or prenatally stressed
offspring for either presentation pattern.
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Figure 9. Acute repetitive acoustic startle stimuli
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The effects of time of day on acoustic startle responding
Physiological circadian cycles have been shown to influence behavioral responses, and
prenatal stress has been shown to alter circadian cycles (Koehl et al., 1997). Therefore, the
effects of the time of day (i.e. morning vs. afternoon) at which testing was conducted were
assessed. There was no effect of the time of testing for either control or prenatally stressed
offspring (Figure 10). Additionally, there were no significant differences between control or
prenatally stressed offspring (Figure 10). Based on these results, all treatment groups in future
studies contained individuals tested throughout the day.

Repetitive exposure to the acoustic startle test
The effects of short-term daily exposure and chronic episodic exposure to the acoustic
startle apparatus were assessed in control and prenatally stressed offspring. Possible short-term
habituation of the acoustic startle reflex was tested by comparing the daily average acoustic
startle responses for control and prenatally stressed animals over three consecutive days of testing
(Figure 11). The experiment used a repeated measures design. There was no habituative effect
of the repeated daily exposure on acoustic startle responding for either the control or prenatally
stressed offspring. Additionally there was no effect of prenatal stress. In Figure 12, the data are
expressed as a percentage of each animal’s first day average acoustic startle response. Again,
there was no habituative effect of repeated exposure and no effect of prenatal stress. These
findings suggest that a three day repeated measures design could be used to assess drug effects
for both control and prenatally stressed offspring in subsequent studies.
The effects of habituation due to five exposures over a 110 day period on acoustic startle
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responding were assessed by comparing the average acoustic startle responses for control and
prenatally stressed animals tested at 75, 85, 125, 155, and 185 days of age (Figure 13). There
was a significant decrease in acoustic startle responding in both control (P75: 45.1± 5.9 versus
P185: 26.1 ± 4.1) and prenatally stressed offspring (P75: 53.8 ± 7.7 versus P185: 31.7 ± 4.1) by
the last time point (F(4,99)= 12.31; p<0.001; Figure 13). There was no effect of prenatal stress
(F(1,94)= 2.16; p=0.1452). Decreased acoustic startle responding could not be clearly attributed to
effects of repetitive exposure to the acoustic startle apparatus and test (i.e. habituation) versus
repetitive handling versus increasing age. Based on these findings, treatment groups were
matched in terms of age and prior exposure for each drug study.
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Figure 10: The effect of time of testing on acoustic startle responding. The effects of time
during the day (i.e. morning vs. afternoon) at which testing was conducted on the acoustic startle
reflex was assessed in control and prenatally stressed offspring by comparing the average
acoustic startle response for animals tested in the morning (AM) and the afternoon (PM).
Acoustic startle responding was recorded following the presentation of acoustic startle stimuli
(95 dB, 50 ms) with an inter-trial interval of 30 seconds. The testing period was 30 minutes.
Values are mean ± std. err (N= 10-20). There were no significant effects of time of testing on
acoustic startle responding for either the control or prenatally stressed offspring.
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Figure 11: The effects of short term daily exposure to the acoustic test on acoustic startle
responding in control and prenatally stressed offspring. Possible habituation of the acoustic
startle reflex following three consecutive days of testing was assessed by comparing the daily
average acoustic startle responses for control and prenatally stressed animals in a repeated
measures design. Acoustic startle responding was recorded following the presentation of
acoustic startle stimuli (95 dB, 50 ms). The inter-trial interval for the 30 minute testing period
was 30 seconds. Values are mean ± std. err (N= 7-8). There was no habituative effect of the
repeated daily exposure on acoustic startle responding for either the control or prenatally stressed
offspring.
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Day 3

Figure 12: The effects of short term daily exposure to the acoustic test on acoustic startle
responding in control and prenatally stressed offspring expressed as a percentage of day 1 values.
Acoustic startle responding was recorded following the presentation of acoustic startle stimuli
(95 dB, 50 ms). The inter-trial interval for the 30 minute testing period was 30 seconds. Values
are mean ± std. err (N= 7-8). There was no habituative effect of the repeated daily exposure to
the acoustic startle test on acoustic startle responding for either the control or prenatally stressed
offspring.
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Figure 13: The effect of chronic repetitive exposure to the acoustic test on acoustic startle
responding in control and prenatally stressed offspring. The effects of habituation due to
repetitive exposure over a 110 day period on acoustic startle responding were assessed by
comparing the average acoustic startle responses for control and prenatally stressed animals
tested at 75, 85, 125, 155, and 185 days of age. Baseline acoustic startle responding was
recorded from animals following randomly presented acoustic startle stimuli (95 dB, 50 ms)
trials. The average inter-trial interval during the 30 minute test was 28 seconds. Values are mean
± std. err (N= 9-10). *significantly different from P75 (naive animals), p<0.05, ANOVA,
Tukey’s protected t-test. Jsignificantly different from P75 (naive animals), p<0.05, Student’s ttest. Acoustic startle responding for control and prenatally stressed offspring was significantly
lower at 185 days of age.
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Figure 13. Chronic repetitive exposure to the ASR test
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Weight influences on acoustic startle responding
Behavioral testing conducted in the labs of others using a different acoustic startle
apparatus has shown that acoustic startle responding can be positively correlated with the weight
of the test subject (Davis 1984). To determine if acoustic startle responding in our test system
was weight dependent, weights and the corresponding acoustic startle responses for naive control
and prenatally stressed animals 75 days of age were analyzed (Figure 14). There was no
significant correlation between weight and acoustic startle responding for either control (r2=
0.077) or prenatally stressed (r2= 0.0447) rats.

Effects of prenatal stress on yohimbine-induced alterations of acoustic startle responding
The acoustic startle responses of a representative control rat treated with the anxiogenic
agent yohimbine (5 mg/kg, i.p.) during a three day repeated measure experiment are presented in
Figure 15. Yohimbine increased acoustic startle responding over minutes 25-45 of the test (3050 minutes post-injection).
Increased basal corticosterone levels (Figure 5) and up-regulation of the CRFergic system
of prenatally stressed rats (Tables 1 and 2; Figure 6) suggests that prenatally stressed offspring
may have alterations in stress responsive systems, leading to changes in behavioral responses to
stressful stimuli. To further pursue these findings, the effects of the anxiogenic agent yohimbine
(0.05-10 mg/kg, i.p.) were assessed in control and prenatally stressed rats using the acoustic
startle test (Figure 16). Yohimbine was found to produced peak effects 30-50 minutes postinjection in control rats (Figure 15). Therefore, all comparisons made between vehicle and drug
treatment were made from data collected during that time period. The data are expressed as
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percent vehicle. Yohimbine caused a significant increase in acoustic startle responding in control
(0.5, 1.25, and 5 mg/kg) and prenatally stressed (1.25 and 5 mg/kg) offspring. Yohimbine
produced similar effects in control and prenatally stressed rats at 0.5 and 1.25 mg/kg. However,
at the 5 mg/kg dose, the prenatally stressed rats had significantly lower acoustic startle
responding compared to control animals. Acoustic startle levels for control and prenatally
stressed offspring returned to vehicle control levels (i.e. 100%) at the 10 mg/kg dose,
demonstrating a bi-phasic effect of yohimbine. These data show that yohimbine is anxiogenic
and that prenatally stressed rats respond differently than control, suggesting possible alterations
in neurotransmitter systems impacted by yohimbine.
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Figure 14: The effect of weight on acoustic startle responding in control and prenatally stressed
offspring. The effects of weight on acoustic startle responding were assessed in naive control
and prenatally stressed animals at 75 days of age to determine if a positive correlation exists
between the two parameters. Weights were recorded from animals on the day of testing.
Acoustic startle responding was recorded from animals following randomly presented acoustic
startle stimuli (95 dB, 50 ms) trials. The average inter-trial interval during the 30 minute test was
28 seconds. There was no positive correlation between weight and acoustic startle responding
for either the control or prenatally stressed group.
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Figure 15: Changes in the acoustic startle reflex in response to yohimbine (5.0 mg/kg, i.p.). The
effects of yohimbine on acoustic startle responding were assessed by using a three-day repeated
measures design. Naive animals were tested the first day to establish a baseline level of
responding. Test subjects were then randomly given either vehicle or drug on the second day and
the alternative treatment on the third day. Acoustic startle responding was recorded from animals
presented with acoustic startle stimuli (95 dB, 50 ms) having an inter-trial interval of 30 seconds
for 30 (baseline) or 60 (test) minutes. Values are minute to minute means for baseline acoustic
startle responding or acoustic startle responding following vehicle or yohimbine administration.
The acoustic startle responses for one control animal subjected to the three-day experimental
design are presented.
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Figure 16: Changes in fear-related behavior in response to yohimbine (0.05-10.0 mg/kg)
administered intraperitoneally 30-50 minutes prior to testing. Changes in acoustic startle
responding following yohimbine administration were assessed in control and prenatally stressed
offspring. The data are expressed as percent vehicle. Values are means ± std. err (N= 5-8).
*significantly different from vehicle (i.e. 100%), p<0.05, modified Student’s t-test. #
significantly different from control group, p<0.05, modified Student’s t-test. Yohimbine caused
a significant increase in acoustic startle responding in control (0.5, 1.25, and 5 mg/kg) and
prenatally stressed (1.25 and 5 mg/kg) offspring. Additionally, there was a significant difference
between the control and prenatal stressed groups at the 5 mg/kg dose.
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Effects of prenatal stress on idazoxan-induced alterations of acoustic startle responding
Yohimbine is a known anxiogenic agent (Handley and Mithani 1984; Morgan, III et al.,
1993; Davis et al., 1993; Venault et al., 1993) that produces fearful behavior as measured in the
acoustic startle test (Figures 15 and 16). However, yohimbine produced a lower acoustic startle
response in prenatally stressed offspring compared to control offspring at a dose of 5 mg/kg
(Figure 16). Yohimbine alters several neurotransmitter systems and has affinity for a number of
receptors, including 2-adrenoceptors (Winter and Rabin 1992). In order to determine if 2adrenoceptor blockade was causing the discrepancy in effects between control and prenatally
stressed offspring, the anxiogenic effects of idazoxan (0.08-20 mg/kg, i.p.), a more selective 2adrenoceptor antagonist (Winter and Rabin 1992), were assessed in the acoustic startle test.
The acoustic startle responding of a representative control rat treated with the anxiogenic
agent idazoxan (8 mg/kg, i.p.) during a three day repeated measure experiment is presented in
Figure 17. Idazoxan increased acoustic startle responding over 15-60 minutes of the test (20-65
minutes post-injection). Therefore all comparisons made between vehicle and drug treatment
were made from data collected and averaged during that time period.
As shown in Figure 18, idazoxan had a multi-phasic effect on acoustic startle responding.
At lower doses, idazoxan significantly increased acoustic startle responding to a similar degree in
both control and prenatally stressed animals (0.8 mg/kg). At higher doses, idazoxan significantly
decreased acoustic startle responding in control (20 mg/kg) and prenatally stressed offspring (16
and 20 mg/kg). Additionally, at the 8 mg/kg dose acoustic startle responding in prenatally
stressed offspring was significantly lower than in control. These data show that idazoxan is
anxiogenic at low doses and may have non-specific effects that interfere with acoustic startle
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responding at high doses. The data further suggest alterations in idazoxan-sensitive
neurotransmission in prenatally stressed rats.
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Figure 17: Differences in fear-related behavior expressed as changes in the acoustic startle reflex
in response to idazoxan (8 mg/kg, i.p.). The effects of idazoxan on acoustic startle responding
were assessed by using a three-day repeated measures design. Naive animals were tested the first
day to establish a baseline level of responding. Test subjects were then randomly given either
vehicle or drug on the second day and the alternative treatment on the third day. Acoustic startle
responding was recorded from animals presented with acoustic startle stimuli (95 dB, 50 ms)
having an inter-trial interval of 30 seconds for 30 (baseline) or 60 (test) minutes. Values are
minute to minute means for baseline acoustic startle responding or acoustic startle responding
following vehicle or idazoxan administration. The acoustic startle responses for one control
animal subjected to the three-day experimental design are presented.
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Figure 18: Changes in fear-related behavior in response to idazoxan (0.08-20 mg/kg, i.p.) 20-65
minutes post injection. Changes in acoustic startle responding following idazoxan administration
were assessed in control and prenatally stressed offspring. The data are expressed as percent
vehicle. Values are means ± std. err (N= 5-8). *significantly different from vehicle (i.e. 100%),
p<0.05, modified Student’s t-test. # significantly different from control group, p<0.05, modified
Student’s t-test. Idazoxan caused a significant increase in acoustic startle responding in control
and prenatally stressed offspring at the 0.8 mg/kg dose. Idazoxan significantly decreased
acoustic startle responding in control (20 mg/kg) and prenatally stressed offspring (16 and 20
mg/kg). Additionally, there was a significant difference between the control and prenatal stressed
groups at the 8 mg/kg dose.
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Effects of prenatal stress on RS 79948-induced alterations of acoustic startle responding
In order to confirm if 2-adrenoceptor blockade was causing the difference in behavior
between control and prenatally stressed offspring, the anxiogenic effects of RS 79948 (0.01-10
mg/kg, i.p.), a highly selective 2-adrenoceptor antagonist (Hume et al., 1996; Milligan et al.,
1997), were measured in control and prenatally stressed offspring using the acoustic startle test.
The acoustic startle responding of a representative control rat treated with the anxiogenic
agent RS 79948 (0.1 mg/kg, i.p.) during a three day repeated measure experiment is presented in
Figure 19. RS 79948 increased acoustic startle responding over 15-60 minutes of the test (20-65
minutes post-injection). Therefore all comparisons made between vehicle and drug treatment
were made from data collected during that time period.
As demonstrated in Figure 20, RS 79948 significantly increased acoustic startle
responding in control (0.1, and 1 mg/kg) and prenatally stressed offspring (0.01, 0.1, and 1
mg/kg), suggesting that the increased acoustic startle responding elicited by both yohimbine and
idazoxan may be mediated by actions at 2-adrenoceptors. Alterations in acoustic startle
responding in response to RS 79948 showed a bi-phasic nature similar to that observed for
yohimbine and idazoxan, again suggesting a common mechanism mediated by 2-adrenoceptor
blockade. However, there were no significant differences between control and prenatally
stressed offspring, suggesting that the difference in acoustic startle responding in response to
yohimbine (5 mg/kg) and idazoxan (8 mg/kg) is a property not shown by RS 79948. This is
likely related to the fact that RS 79948 is highly selective for 2-adrenoceptors, while yohimbine
and idazoxan interact with other receptors.
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Figure 19: Differences in fear-related behavior expressed as changes in the acoustic startle reflex
in response to RS 79948 (0.1 mg/kg, i.p.). The effects of RS 79948 on acoustic startle
responding were assessed by using a three-day repeated measures design. Naive animals were
tested the first day to establish a baseline level of responding. Test subjects were then randomly
given either vehicle or drug on the second day and the alternative treatment on the third day.
Acoustic startle responding was recorded from animals presented with acoustic startle stimuli (95
dB, 50 ms) having an inter-trial interval of 30 seconds for 30 (baseline) or 60 (test) minutes.
Values are minute to minute means for baseline acoustic startle responding or acoustic startle
responding following vehicle or RS 79948 administration. The acoustic startle responses for one
control animal subjected to the three-day experimental design are presented.
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Figure 20: Changes in fear-related behavior in response to RS 79948 (0.01-10 mg/kg, i.p.)
administered 20-65 minutes prior to testing. Changes in acoustic startle responding following RS
79948 administration were assessed in control and prenatally stressed offspring. The data are
expressed as percent vehicle. Values are means ± std. err (N= 5-8). *significantly different from
vehicle (i.e. 100%), p<0.05, modified Student’s t-test. RS 79948 significantly increased acoustic
startle responding in control (0.1, and 1 mg/kg) and prenatally stressed offspring (0.01, 0.1, and 1
mg/kg). There were no significant differences between control and prenatally stressed offspring.
These data suggest that RS 79948 is anxiogenic in the acoustic startle test.
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Results from blood pressure and heart rate studies
The effects of yohimbine and idazoxan on blood pressure and heart rate in control and
prenatally stressed rats
One explanation for differences in acoustic startle responding between control and
prenatally stressed offspring after the administration of yohimbine and idazoxan is that these
drugs are acting via the noradrenergic system, which has been altered by prenatal stress. In
addition to serving as a key mediator of the behavioral responses to stress, norepinephrine also
mediates other aspects of the body’s response to stress, including autonomic responses via the
sympathetic nervous system. Consequently, cardiovascular parameters (e.g. blood pressure and
heart rate), which are under control of the sympathetic nervous system, may be altered under
basal conditions or in response to drugs (e.g. yohimbine and idazoxzan). Therefore, the effects
of yohimbine and idazoxan on systolic blood pressure and heart rate were determined in control
and prenatally stressed offspring using a tail cuff blood pressure and heart rate monitoring
system. Doses that produced significant differences in acoustic startle responding between
control and prenatally stressed offspring were used for the study (e.g. 5 mg/kg and 8 mg/kg;
Figures 16 and 21, respectively). There was no significant difference in basal systolic blood
pressure between control and prenatally stressed offspring (Figure 21). However, basal heart rate
in prenatally stressed rats was significantly higher than in controls (Figures 24-26), suggesting
increased activation of the sympathetic nervous system or decreased parasympathetic activation.
Yohimbine did not alter basal systolic blood pressure (Figure 22) but significantly
increased heart rate (Figure 25) in all rats. Idazoxan significantly increased both blood pressure
and heart rate (Figures 23 and 26). The differences between idazoxan and yohimbine in their
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ability to affect systolic blood pressure suggests that the drugs are acting via different
mechanisms. There were no significant effects of prenatal stress in the response to either drug
(Figures 22, 23, 25 and 26). These data suggest that activation of the sympathetic nervous
system and particularly increased heart rate are common to both idazoxan and yohimbine.
Furthermore, the data suggest that differences in effects of these drugs on control and prenatally
stressed rats are probably not due to differential effects on cardiovascular parameters controlled
by the sympathetic nervous system.
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Figure 21: The effects of prenatal stress on basal systolic blood pressure were assessed in
control and prenatally stressed offspring using a tail cuff blood pressure and heart rate monitoring
system. Animals were trained for three consecutive days prior to testing to allow habituation to
the apparatus and testing procedure. Training for each animal consisted of a 30 minute
acclimation period followed by seven to ten blood pressure measurements. Testing occurred on
the fourth day following the same procedure as the previous training sessions. The seven to ten
readings were averaged together to determine the mean basal blood pressure for each animal.
Values are means ± std. err (N= 8). There were no significant differences in basal systolic blood
pressure between control and prenatally stressed offspring.

113

150
Control

Systolic blood pressure (mm Hg)

140

PNS

130
120
110
100
90
80
70
60
50
Figure 21. The effects of PNS on basal systolic blood pressure
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Figure 22: The effects of yohimbine (5 mg/kg, i.p.) on systolic blood pressure were assessed in
control and prenatally stressed offspring 30-45 minutes post-injection. The data are expressed as
percent baseline systolic blood pressure. Values are means ± std. err (N= 6). There was no effect
of vehicle or yohimbine on systolic blood pressure for either control or prenatally stressed
animals. There were no significant differences between control or prenatally stressed offspring.
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Figure 23: The effects of idazoxan (8 mg/kg, i.p.) on systolic blood pressure were assessed in
control and prenatally stressed offspring 20-35 minutes post-injection. The data are expressed as
percent baseline systolic blood pressure. Values are means ± std. err (N= 6). *significantly
different from baseline (i.e. 100%), p<0.05, modified Student’s t-test. There was no effect of
vehicle on systolic blood pressure for either control or prenatally stressed animals. Idazoxan
significantly increased systolic blood pressure in both control and prenatally stressed groups.
There were no significant differences between control or prenatally stressed offspring.
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Figure 23. The effects of idazoxan on systolic blood pressure in control and PNS offspring
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Figure 24: The effects of prenatal stress on basal heart rate were assessed in control and
prenatally stressed offspring using a tail cuff blood pressure and heart rate monitoring system.
Animals were trained for three consecutive days prior to testing to allow habituation to the
apparatus and testing procedure. Training for each animal consisted of a 30 minute acclimation
period followed by seven to ten heart rate measurements. Testing occurred on the fourth day
following the same procedure as the previous training sessions. The seven to ten readings were
averaged together to determine the mean basal heart rate for each animal. Values are means ±
std. err (N= 6). # significantly different from control group, p<0.05, Student’s t-test. Prenatally
stressed offspring had a significantly higher basal heart rate compared to control offspring.
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Figure 25: The effects of yohimbine (5 mg/kg, i.p.) on heart rate were assessed in control and
prenatally stressed offspring 30-45 minutes post-injection. Values are means ± std. err (N= 612). Inset: the data are expressed as percent baseline heart rate. Values are means ± std. err (N=
6-12). *significantly different from baseline (i.e. 100%), p<0.05, modified Student’s t-test.
#

significantly different from control group, p<0.05, Student’s t-test. Basal heart rates for

prenatally stressed animals were significantly higher than those of control animals. However,
there were no significant differences between control or prenatally stressed offspring following
vehicle or yohimbine administration. There was no effect of vehicle on heart rate for either
control or prenatally stressed animals. Yohimbine significantly increased heart rate in both
control and prenatally stressed groups.
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Figure 25. The effects of yohimbine on heart rate in control and PNS offspring
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Figure 26: The effects of idazoxan (8 mg/kg, i.p.) on heart rate were assessed in control and
prenatally stressed offspring 20-35 minutes post-injection. Values are means ± std. err (N= 612). Inset: the data are expressed as percent baseline heart rate. Values are means ± std. err (N=
6-12). *significantly different from baseline (i.e. 100%), p<0.05, modified Student’s t-test.
#

significantly different from control group, p<0.05, Student’s t-test. Basal heart rates for

prenatally stressed animals were significantly higher than those of control animals. However,
there were no significant differences between control or prenatally stressed offspring following
vehicle or idazoxan administration. There was no effect of vehicle on heart rate for either control
or prenatally stressed animals. Idazoxan significantly increased heart rate in both control and
prenatally stressed groups.
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Figure 26. The effects of idazoxan on heart rate in control and PNS offspring
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Results from behavioral studies using the defensive withdrawal test
Effects of anxiogenic agents in the defensive withdrawal test
In an attempt to support the acoustic startle findings that yohimbine, idazoxan, and RS
79948 are anxiogenic agents, the effects of these drugs were compared to the anxiogenic effects
of caffeine, FG7142, DMCM, and restraint stress, in the defensive withdrawal test. Behaviors
associated with increased fear and anxiogenic drug effects are increased latency, decreased
rearing, decreased line crossing, and increased ATPV. The data collected for each behavioral
parameter are presented in their original form (Table 3) and as percent vehicle (Figures 27-30).
Caffeine produced anxious behavior at the 20 mg/kg dose reflected by a significant
increase in latency (Figure 28) and significant decrease in rearing (Table 3 and Figure 29). The
partial inverse BZ receptor agonist FG7142 produced a significant decrease in line crossing rates
at the 15 mg/kg dose (Figure 30) indicative of fear-related decreases in exploration. The full
inverse BZ receptor agonist DMCM generated anxious behavior at 0.5 mg/kg by eliciting
significant decreases in rearing rate and line crossing rate and significant increases in ATPV
(Table 3; Figures 27, 29 and 30). Idazoxan was anxiogenic as demonstrated by the significant
increase in the initial latency to exit at the 0.8 mg/kg dose (Figure 28), the increase ATPV at the
0.08 mg/kg dose (Table 3; Figure 27), and the significant decreases in line crossing rates at both
0.08 and 0.8 mg/kg (Table 3, Figure 30). Yohimbine produced fear behavior as demonstrated by
decreased rearing rates at both 1.25 and 5 mg/kg doses (Table 3, Figure 29) and increased ATPV
at 1.25 mg/kg (Table 3, Figure 27). Furthermore, yohimbine significantly decreased line crossing
rates (Table 3, Figure 30). The 2-adrenergic antagonist, RS 79948, significantly decreased line
crossing rates, suggesting a mild anxiogenic effect of the drug at the dose tested (Figure 30).
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Finally, restraint was anxiogenic in the defensive withdrawal test as demonstrated by the
significant increases in latency (Figure 28) and the significant increase in ATPV (Figure 27).
Similar to the acoustic startle test, both yohimbine and idazoxan had bi-phasic effects on ATPV
(Figure 27). Also, decreased line crossing rates were common to idazoxan, yohimbine, and RS
79948 (Figure 30), implying 2-adrenoceptor blockade as the underlying mechanism of the
behavior. Taken together, these data suggest that all the drugs and restraint are anxiogenic in the
defensive withdrawal test. However, these effects are dependent on the behavioral parameter
being measured.
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Table 3: Normal, Sprague-Dawley rats were injected (i.p.) with caffeine (10, and 20 mg/kg), Nmethyl--carboline-3-Carboxamide (FG7142; 5 and 15 mg/kg), methyl-6,7-dimethoxy-4-ethyl-carboline-carboxylate (DMCM; 0.5 mg/kg), idazoxan (0.08 and 0.8 mg/kg), yohimbine (1.25 and
5 mg/kg), RS 79948 (0.1 mg/kg), or restrained for 60 or 120 minutes and tested for 10 minutes
immediately after restraint or 15 (DMCM), 20 (FG7142, idazoxan, and RS 79948), or 30
(caffeine and yohimbine) minutes after drug injection to allow onset of drug action. Values are
means ± std. err (N= 3- 12). *significantly different from vehicle, p<0.05, modified Student’s ttest. 1Latency is the number of seconds it takes the animal to make its initial exit from the
chamber. 2Rears per minute in the open field calculated as (total number of rears)/(total time
spent in the open field)* 60. 3Average time per visit (ATPV; sec) to the chamber calculated as
[(total time in chamber)- (latency to first exit)]/(total exits-1). 4Lines crossed per minute in the
open field (total number of lines crossed)/(total time spent in the open field)* 60. Caffeine was
able to generate anxious behavior at the 20 mg/kg dose reflected by a significant decrease in
rearing. The partial inverse benzodiazepine (BZ) receptor agonist FG7142 was unable to
produce any significant changes in behavior. However, the full inverse BZ receptor agonist
DMCM generated anxious behavior at 0.5 mg/kg by eliciting significant decreases in rearing rate
and line crossing rate and significant increases in ATPV. Idazoxan was anxiogenic as
demonstrated by the significant increase in the initial latency to exit at the 0.8 mg/kg dose, the
increase in ATPV at the 0.08 mg/kg dose, and the significant decreases in line crossing rates at
both 0.08 and 0.8 mg/kg. Yohimbine produced fear behavior as demonstrated by decreased
rearing rates at both 1.25 and 5 mg/kg doses and increasing ATPV at 1.25 mg/kg. Furthermore,
yohimbine significantly decreased line crossing rates. The 2-adrenergic antagonist, RS 79948,
significantly decreased line crossing rates, suggesting only a mild anxiogenic effect of the drug.
Finally, restraint was anxiogenic in the defensive withdrawal test as demonstrated by the
significant increases in latency following 120 minutes restraint and the significant increase in
ATPV following 60 minutes restraint.
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Table 3: The behavioral effects of anxiogenic agents in the defensive withdrawal test.
Drug

Dose
(mg/kg)

Latency to
initial
exit (sec)1

Rears per
time
in field2

Average time
per visit
(sec)3

Lines crossed
per time in
field4

Caffeine

0
10
20

2.4 ± 0.3
2.7 ± 0.7
3.7 ± 0.6

9.0 ± 0.5
8.4 ± 0.6
4.9 ± 0.3¼

16.6 ± 2.6
12.7 ± 1.1
12.4 ± 1.2

15.7 ± 0.9
19.2 ± 2.2
15.4 ± 1.0

FG7142

0
5
15

10.0 ± 4.9
6.3 ± 2.0
7.0 ± 2.6

7.5 ± 1.1
6.3 ± 1.1
8.0 ± 1.4

26.3 ± 4.9
32.3 ± 10.2
286.8 ± 89.5

15.6 ± 2.3
17.2 ± 4.2
10.3 ±1.2

DMCM

0
0.5

7.6 ± 2.1
12.3 ± 2.5

4.6 ± 0.5
0.7 ± 0.3¼

28.1 ± 3.6
289.6 ± 77.6¼

12.8 ± 0.9
7.1 ± 1.6¼

Idazoxan

0
0.08
0.8

8.3 ± 1.2
20.1 ± 5.6
14.5 ± 1.5¼

3.9 ± 0.6
5.32 ± 1.9
3.7 ± 0.9

51.3 ± 8.9
280.5 ± 86.4¼
80.6 ± 23.4

31.1 ± 1.6
20.5 ± 2.5¼
20.7 ± 3.6¼

Yohimbine

0
1.25
5

6.5 ± 1.1
13.8 ± 3.1
7.3 ± 0.9

7.3 ± 0.8
3.3 ± 0.5¼
1.3 ± 0.3¼

27.7 ± 2.0
45.5 ± 5.2¼
19.2 ± 4.1

18.2 ± 1.5
11.5 ± 0.8¼
11.8 ± 3.7

RS79948

0
0.1

8.0 ± 1.7
11.8 ± 3.5

6.8 ± 1.2
4.7 ± 0.3

73.8 ± 15.9
225.9 ± 96.7

34.0 ± 1.9
26.3 ± 1.2¼

Restraint

0
1 hr

4.0 ± 0.2
5.6 ± 1.1

2.5 ± 0.2
4.4 ± 0.6¼

24.1 ± 2.9
59.9 ± 11.1¼

12.0 ± 1.0
15.1 ± 1.7

2.1 ± 0.7

62.0 ± 17.8

9.4 ± 1.8

2 hr

153.6 ± 39.0¼
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Figure 27: Changes in fearful behavior expressed as differences in ATPV in response to
anxiogenic agents. Normal, Sprague-Dawley rats were injected (i.p.) with caffeine (CAF; 0, 10,
and 20 mg/kg), N-methyl--carboline-3-Carboxamide (FG7142; 0, 5, and 15 mg/kg), methyl-6,7dimethoxy-4-ethyl--carboline-carboxylate (DMCM; 0 and 0.5 mg/kg), idazoxan (IDA; 0, 0.08,
and 0.8 mg/kg), yohimbine (YOH; 0, 1.25 and 5 mg/kg), RS 79948 (0.1 mg/kg), or restrained
(RSTR) for 60 or 120 minutes and tested for 10 minutes immediately after restraint or 15
(DMCM), 20 (FG7142, IDA, and RS 79948), or 30 (CAF and YOH) minutes after drug injection
to allow onset of drug action. Defensive withdrawal expressed as the average time per visit to the
chamber (ATPV) was measured using the defensive withdrawal test. ATPV is calculated as
(Total time in chamber- latency)/(total number of exits -1). The data are expressed as percent
control (i.e. vehicle or no restraint). Values are means ± std. err (N= 3-12). *significantly
different from vehicle (i.e. 100%), p<0.05, modified Student’s t-test. DMCM (0.5 mg/kg), IDA
(0.08 mg/kg), YOH (1.25 mg/kg), and RSTR (60 and 120 min.) significantly increased ATPV,
suggesting the drugs at these doses are anxiogenic. CAF (10 and 20 mg/kg) significantly
decreased ATPV, an effect that is associated with decreased fear. There were no effects of
FG7142 or RS 79948.
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Figure 27: Changes in ATPV following the administration of anxiogenic agents
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Figure 28: Changes in fear-related behavior expressed as differences in the latency to the initial
exit from the chamber in response to anxiogenic drugs. Normal, Sprague-Dawley rats were
injected (i.p.) with caffeine (CAF; 0, 10, and 20 mg/kg), N-methyl--carboline-3-Carboxamide
(FG7142; 0, 5, and 15 mg/kg), methyl-6,7-dimethoxy-4-ethyl--carboline-carboxylate (DMCM;
0 and 0.5 mg/kg), idazoxan (IDA; 0, 0.08, and 0.8 mg/kg), yohimbine (YOH; 0, 1.25 and 5
mg/kg), RS 79948 (0.1 mg/kg), or restrained (RSTR) for 60 or 120 minutes and tested for 10
minutes immediately after restraint or 15 (DMCM), 20 (FG7142, IDA, and RS 79948), or 30
(CAF and YOH) minutes after drug injection to allow onset of drug action. The data are
expressed as percent control (i.e. vehicle or no restraint). Values are means ± std. err (N= 3-12).
*significantly different from vehicle (i.e. 100%), p<0.05, modified Student’s t-test. CAF (20
mg/kg), IDA (0.8 mg/kg), and RSTR (120 min.) significantly increased the initial latency,
suggesting the drugs at these doses are anxiogenic. There were no significant effects of FG7142,
DMCM, YOH, or RS 79948.
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Figure 28: Changes in latency following the administration of anxiogenic agents
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Figure 29: Changes in exploratory behavior expressed as alterations in rearing rates in response
to anxiogenic drugs. Normal, Sprague-Dawley rats were injected (i.p.) with caffeine (CAF; 0,
10, and 20 mg/kg), N-methyl--carboline-3-Carboxamide (FG7142; 0, 5, and 15 mg/kg), methyl6,7-dimethoxy-4-ethyl--carboline-carboxylate (DMCM; 0 and 0.5 mg/kg), idazoxan (IDA; 0,
0.08, and 0.8 mg/kg), yohimbine (YOH; 0, 1.25 and 5 mg/kg), RS 79948 (0.1 mg/kg), or
restrained (RSTR) for 60 or 120 minutes and tested for 10 minutes immediately after restraint or
15 (DMCM), 20 (FG7142, IDA, and RS 79948), or 30 (CAF and YOH) minutes after drug
injection to allow onset of drug action. The effects of these fear-provoking agents were assessed
by measuring the average rears per minute in the open field of the defensive withdrawal test.
Rears per minute in the open field is calculated as (total number of rears)/(total time spent in the
open field)*60. The data are expressed as percent control (i.e. vehicle or no restraint). Values are
means ± std. err (N= 3-12). *significantly different from vehicle (i.e. 100%), p<0.05, modified
Student’s t-test. CAF (20 mg/kg), DMCM (0.5 mg/kg), YOH (1.25 and 5.0 mg/kg), and RS
79948 (0.1 mg/kg) significantly decreased rearing rates, suggesting an anxiogenic effect of these
drugs. However, 60 minutes RSTR significantly increased rearing rates, an effect associated
with increased exploration and decreased fear. There were no significant effects of FG7142 or
IDA.
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Figure 29: Changes in rearing rates following the administration of anxiogenic agents
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Figure 30: Changes in ambulatory/exploratory behavior expressed as alterations in line crossed
per minute in the open field in response to anxiogenic drugs. Normal, Sprague-Dawley rats were
injected (i.p.) with caffeine (CAF; 0, 10, and 20 mg/kg), N-methyl--carboline-3-Carboxamide
(FG7142; 0, 5, and 15 mg/kg), methyl-6,7-dimethoxy-4-ethyl--carboline-carboxylate (DMCM;
0 and 0.5 mg/kg), idazoxan (IDA; 0, 0.08, and 0.8 mg/kg), yohimbine (YOH; 0, 1.25 and 5
mg/kg), RS 79948 (0.1 mg/kg), or restrained (RSTR) for 60 or 120 minutes and tested for 10
minutes immediately after restraint or 15 (DMCM), 20 (FG7142, IDA, and RS 79948), or 30
(CAF and YOH) minutes after drug injection to allow onset of drug action. Lines crossed per
minute in the open field is calculated as (total number of lines crossed)/(total time spent in the
open field)*60. The data are expressed as percent control (i.e. vehicle or no restraint). Values are
means ± std. err (N= 3-12). *significantly different from vehicle (i.e. 100%), p<0.05, modified
Student’s t-test. FG7142 (15 mg/kg), DMCM (0.5 mg/kg), IDA (0.08 and 0.8 mg/kg), YOH
(1.25 mg/kg), and RS 79948 (0.1 mg/kg) significantly decreased line crossing rates, suggesting
an anxiogenic effect of these drugs. There were no significant effects of CAF or RSTR.
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Figure 30: Changes in line crossing rates following the administration of anxiogenic agents
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The effects of sedation in the defensive withdrawal test
Diazepam, a known anxiolytic and sedative compound, was assessed in the defensive
withdrawal test by measuring changes in motor activity. Male rats were injected with diazepam
(1 and 2 mg/kg, i.p.) or vehicle and were tested for sedation by measuring changes in line
crossing rates over the 10 minute test. Habituation occurred during the testing period (F(2,107)=
14.74; p<0.05) as shown by significant decreases in line crossing rates for vehicle treated animals
(20.2 ± 1.75 vs. 9.6 ± 1.8; Figure 31) and animals treated with 1 mg/kg and 2 mg/kg diazepam
(20.2 ± 1.6 vs. 6.2 ± 2.1 and 17.2 ± 4.2 vs. 1.3 ± 0.8, respectively; Figure 31). One mg/kg
produced a rapid and significant decrease in line crossing rates within 7.5 minutes (13.9 ± 1.8 vs.
7.3 ± 1.8; Figure 31). The 2 mg/kg dose of diazepam also produced rapid and significant
decreases in line crossing rates within 5 minutes (16.8 ± 2.6 vs. 3.2 ± 1.9; Figure 31). The data
show that decreased line crossing rates can occur as a result of sedative effects of drugs.
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Figure 31: The sedative effects of diazepam on line crossing rates in open field of the defensive
withdrawal test. Male Sprague-Dawley rats were injected with diazepam (1 and 2 mg/kg, i.p.) or
vehicle and tested in the defensive withdrawal test for 10 minutes after a 30 minute waiting
period. The effects of habituation to the open field and/or sedation were assessed by measuring
line crossing rates as four 2.5 minute blocks. The line crossing rate is calculated as (total number
of lines crossed)/(total time spent in the open field)*60. Values are mean ± std. err (N= 5-12).
*significant effect of time (i.e. habituation), p<0.05, ANOVA, Tukey’s protected t-test.
#

significant effect of drug, p<0.05, ANOVA, Tukey’s protected t-test. There was a significant

decrease in line crossing rates for animals treated with vehicle at 7.5 and 10 minutes, 1 mg/kg
diazepam at 5, 7.5 and 10 minutes, and 2 mg/kg diazepam at 5, 7.5, and 10 minutes of the test,
suggesting habituation to the open field. There was a significant effect of both 1 mg/kg
diazepam at 7.5 minutes and 2 mg/kg diazepam at 5, 7.5 and 10 minutes of the test.
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Figure 31: Changes in line crossing rates following the administration of diazepam
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DISCUSSION
These studies show that the prenatal stress syndrome produces functional changes in rats
in the form of physiological, neurochemical, and behavioral differences. These changes persist
well into adulthood, suggesting their permanence.
With regard to global functioning, prenatally stressed offspring appear to be normal in
basal behavioral states. However, upon the presentation of stressful stimuli in the forms of
anxiogenic drugs (e.g. yohimbine and idazoxan), these animals respond differentially in
comparison with control (normal) offspring. Doses of yohimbine and idazoxan that produced
increased acoustic startle in control animals were ineffective at increasing acoustic startle
responses in prenatally stressed animals. These findings suggested physiological alterations in the
stress responsive systems of the body and their associated neurotransmitter systems.
This hypothesis is supported by the observation that prenatally stressed animals had
significantly elevated levels of plasma corticosterone, suggesting a state of chronic stress. This
contention is further supported by alterations in the content of the neurotransmitter, CRF, a key
mediator of the hypothalamic and extra-hypothalamic responses to stress (Dunn and Berridge
1990b; Owens and Nemeroff 1991; Davis 1992; Koob et al., 1992). In prenatally stressed
offspring, there were age-dependent increases in CRF content in several brain nuclei critically
involved in eliciting, coordinating, and producing the body’s response to stress (i.e. amygdala,
PVN, and LC/PBN). Taken together, the results from this project clearly demonstrate
abnormalities in the stress response induced by prenatal stress.
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Effects of prenatal stress on stress responsive systems
The hypothesis for this particular set of experiments was that prenatal stress would
cause differences in a key stress responsive system, namely the HPA axis. The effects of prenatal
stress on the HPA axis were assessed by measuring plasma corticosterone levels in naive control
and prenatally stressed offspring. Prenatal stress significantly increased plasma corticosterone by
56% in comparison with control (Figure 5).
These findings support the hypothesis that there are measurable physiological differences
in the basal states of stress responsive systems in prenatally stressed and control rats (Peters
1982; Takahashi and Kalin 1991; Weinstock et al., 1992; Maccari et al., 1995; Weinstock et al.,
1998). Similar findings have been shown in younger prenatally stressed offspring (Takahashi
and Kalin 1991). Takahashi and Kalin (1991) found that preweanling rats (7 to 21 days of age)
of dams stressed with uncontrollable footshock throughout pregnancy had significantly elevated
basal corticosterone compared to control rats. These findings suggest that prenatal stress
generates a state of chronic stress. And when taken with our data, they demonstrate that the
effects are long lasting. Prenatal stress has also been shown to significantly affect circadian
rhythms by producing a four hour phase advance in the circadian rhythm of corticosterone during
the light phase of the light cycle (Koehl et al., 1997). This results in prenatally stressed offspring
attaining peak levels of corticosterone several hours before control offspring, where
corticosterone peaks at the beginning of the dark phase of the light cycle (Koehl et al., 1997).
These findings could potentially account for differences in corticosterone levels between control
and prenatally stressed offspring observed in our hands. However, all experiments were
conducted within the first four hours of the light phase of the light cycle, which was reportedly
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unaltered by prenatal stress (Koehl et al., 1997). A point of interest is that corticosterone level
estimates for both control and prenatally stress offspring from our lab were several fold higher
than those of Koehl. A possible explanation for such differences is that they used a different
model of prenatal stress, consisting of thrice daily restraint and heat during the last week of
gestation, which is substantially more severe than our stressing paradigm. Additionally, we
collected trunk blood following decapitation. Whereas, they collected samples by drawing blood
from a tail vein, which tends to be more indicative of true basal corticosterone levels. These
findings suggest that our animals may have been in a stressful state, which could have been due
to the adverse nature of the sample collection procedure. With changes in the HPA axis of
prenatally stressed offspring, the question is raised of additional biochemical changes caused by
prenatal stress in other aspects of the stress response.

Effects of prenatal stress on the CRFergic stress responsive system
The objective of this experimental series was to characterize biochemical differences
between prenatally stressed and control offspring by assessing changes in a neurotransmitter
system responsible for eliciting the stress response (i.e. CRFergic). Based on the previous
experiment, prenatally stressed offspring are in a state of chronic stress as suggested by elevated
basal corticosterone levels. One mechanism for this is increased release of CRF from the PVN to
the ME. Prenatally stressed offspring have also been shown to be hyper-sensitive to stressful
stimuli as measured by various behavioral tests (Peters 1982; Fride et al., 1986; Weinstock et al.,
1992; Takahashi et al.,1992a; Henry et al., 1994; Reznikov and Nosenko 1996). A possible
mechanism for such findings is increased release in extrahypothalamic regions involved in the
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emotional and behavioral response to stress (e.g. amygdala, LC/PBN). Indeed, previous
experiments in our lab have shown prenatal stress increases release of CRF from amygdala
minces in response to depolarizing concentrations of potassium (Cratty et al., 1995). Therefore,
the hypothesis for this experimental series was that prenatally stressed offspring would have
increased CRF content at adult ages in brain regions responsible for coordinating and eliciting
the stress response.
The brain regions of interest for this particular series of experiments were the amygdala,
the PVN, and LC/PBN. When CRF content was expressed as total pg CRF per region (Table 1),
there was a significant effect of age in the PVN and LC/PBN of prenatally stressed rats as
demonstrated by increased levels of CRF at 120 days and 150 days of age versus 90 days of age.
Additionally, there was a significant effect of prenatal stress in the amygdala, PVN, and LC/PBN.
CRF values for prenatally stressed offspring were significantly higher than those of control
offspring in the PVN at 120 days and in amygdala and LC/PBN at 150 days. Expressing CRF by
normalizing to pg CRF/mg protein (Table 2) demonstrated a significant effect of age in the
amygdala and PVN with increased CRF levels in the amygdala of control offspring and in the
PVN of prenatally stressed offspring at 150 days of age. Additionally, there was a significant
overall effect of prenatal stress in the amygdala. CRF content for prenatally stressed offspring
was significantly higher than in control offspring in the PVN at 150 days. There were no
significant effects of age or prenatal stress in the LC/PBN. Finally, expressing the normalized
CRF data (pg CRF/mg protein) for prenatally stressed offspring as percent control values (Figure
6) revealed significantly more CRF in prenatally stressed offspring in all three brain regions at
150 days of age. These data taken together suggest that there are differences in stress responsive
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systems of control and prenatally stressed offspring. Additionally, there is an up-regulation of
the CRFergic system in all three brain regions of the prenatally stressed animals, which is agedependent.
These findings are in agreement with our hypothesis that prenatally stressed offspring
would have increased CRF content at adult ages in brain regions responsible for coordinating and
eliciting the stress response. These data, at least with regard to the amygdala, are also consistent
with previous findings from our lab showing increased potassium-stimulated release of CRF
from amygdala minces in adult prenatally stressed animals (Cratty et al., 1995). Greater change
in CRF levels with age in prenatally stressed rats suggests there is a cumulative effect of the
chronic stress produced by prenatal stress on stress responsive systems. This idea concurs with
the research of Albeck et al. (1997) who found chronic social stress increased CRF mRNA in the
CeA of subordinate rats from a visible burrow system compared with cage-housed control rats.
Interestingly, expressing the data as total pg CRF (Table 1) revealed more significant
differences between control and prenatally stressed offspring compared to expressing the data as
pg CRF/mg protein (Table 2). The lack of differences between control and prenatally stressed
offspring following normalization of the data to pg CRF/mg protein suggests that increasing
amounts of CRF occur with an associated increase in protein levels. Several possibilities could
result in such a finding. It is possible that the size or number of CRF containing neurons is
increased in prenatally stressed offspring, causing an increase in both CRF and protein levels.
Such a finding would be consistent with data from our lab demonstrating 30 to 100% increases in
the number of CRF immunopositive neurons in the CeA of the amygdala, PVN, and BNST in
prenatally stressed animals (Gray et al., 1995). Additionally, it is possible that CRFergic neurons
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of prenatally stressed animals could produce significantly more CRF with little or no increase in
CRFergic cell number or size but rather a significant increase in total or non-CRFergic cell size
or number. This would be consistent with recent findings in our lab showing an increase in the
total number of cells found in the basolateral nucleus of the amygdala of prenatally stressed rats
(Salm et al., 1999). Moreover, analysis of CRF mRNA in our lab using in situ hybridization
revealed a three-fold increase of CRF mRNA content in the amygdala and BNST in prenatally
stressed offspring (Gray et al., 1995) These data suggest increased translation of CRF mRNA
may account for increases in peptide. Alternatively, increased CRF content could be the result of
a change in the processing of prepro-CRF or the catabolism of CRF by peptidases.
These experimental findings taken together suggest up-regulation of the CRFergic system
is a mechanism through which prenatal stress may be eliciting its deleterious and maladaptive
effects, specifically chronic activation of the HPA axis and increased fearfulness.

The effects of prenatal stress on the acoustic startle response
A number of behavioral tests have been used to study anxious and fearful behavior,
including the elevated plus maze (Pellow et al., 1985; Weinstock et al., 1988), punished
responding (Fride et al., 1985; Fride et al., 1986), and the defensive withdrawal test (Takahashi
et al., 1989; Yang et al., 1990; Yang and Dunn 1990; De Fonseca et al., 1996). In light of the
complexity involved in generating and interpreting data using these behavioral tests, a simpler
behavioral model of fear in the form of the acoustic startle test was characterized and used to
distinguish differences in behavior between prenatally stressed and control offspring. As the
acoustic startle reflex can be modified by higher cognitive centers, the level of an acoustic startle
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response is analogous to the level of fear in the test subject (Davis 1984). In other words,
increasing acoustic startle responses are associated with an increased fearfulness.
The overall objective for using this behavioral test was to address the questions of
differences between prenatally stressed and control offspring for both basal levels of fearful
behavior and changes in fearful behavior associated with anxiogenic drugs.

Characterization of the acoustic startle test
The objective of this experiment was to determine if there were differences between
control and prenatally stressed offspring in basal acoustic startle responding. Findings from the
previous studies looking at the effects of prenatal stress on corticosterone (Figure 5) and CRF
(Tables 1 and 2; Figure 6) suggest alterations in basal activity of stress responsive systems due to
prenatal stress. Numerous behavioral studies have demonstrated increased fearfulness in
prenatally stressed offspring when presented with anxiogenic stimuli (Thompson 1957; Fride and
Weinstock 1988; Takahashi et al.,1992a; Poltyrev et al., 1996; Vallée et al., 1997). Therefore
the hypothesis was that prenatally stressed offspring would be more fearful than control offspring
in the acoustic startle test, resulting in significantly elevated acoustic startle responding. In order
to test this hypothesis, random and repetitive presentations of an acoustic startle stimulus were
used to elicit acoustic startle reflexive responses in control and prenatally stressed rats. There
were no significant differences in acoustic startle responding between control and prenatally
stressed animals (Figure 8).
These results were not in agreement with our initial hypothesis. However, such results
should not come as a complete surprise as others have found not all behaviors are altered in the
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prenatal stress model particularly behaviors measured in conditions of low anxiety or stress.
Takahashi and colleagues (1990, 1992) showed that there were no significant differences in
ultrasonic vocalization and defensive freezing between juvenile control and prenatally stressed
offspring following habituation to the testing situation. Additionally, Kinsley et al. (1988)
demonstrated that there were no significant differences in basal tail-flick latency between adult
male offspring of mothers subjected to heat and restraint stress during the last week of gestation
and control offspring. Taken together, these findings suggest that prenatally stressed offspring
appear to be normal in basal behavioral states.
The lack of differences between control and prenatally stressed animals may be
interpreted in a number of ways. It is possible that measuring the acoustic startle reflex under
basal testing conditions is not fear provoking, producing the given result of no measurable
differences between the two groups of animals. Such an explanation would be consistent with
the evidence presented above. However, it is also possible that prenatal stress does not affect the
pathways directly involved in eliciting or modifying the acoustic startle reflex at the level of the
brainstem and spinal cord or higher cognitive centers. Additionally, it is possible that there are
differences in acoustic startle responding between control and prenatally stressed offspring, but
such differences are dependent on factors, such as the number of exposures to the testing
procedure or the time of day of testing. With these points in mind, further characterization of the
acoustic startle test was necessary.

The possible effects of habituation during the test
The objective of this experiment was to determine the effects, if any, of habituation to
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repetitive acoustic startle stimuli presented in two different time patterns (i.e. randomly or at a
fixed interval of 30 seconds) in both control and prenatally stressed offspring. Similar stimulus
presentation patterns have been used by other researchers (Plappert et al., 1993; Campeau et al.,
1997; Walker and Davis 1997; Blaszczyk 1997). Therefore, the hypothesis of this experiment
was that neither group would habituate to either of the stimulus presentation patterns. This
hypothesis was assessed by comparing the average acoustic startle responding for the first five
minutes and last five minutes of a 30 minute testing period in both control and prenatally stressed
rats. There was no acute habituation to repetitive stimuli following either pattern in either
control of prenatally stressed offspring (Figure 9).
These findings were in agreement with our hypothesis. This question of acute habituation
to a repetitive stimulus was of some concern as rats have been shown to habituate to an acoustic
stimulus when presented in a repetitive (Davis 1984; Plappert et al., 1993; Pilz and Schnitzler
1996; Koch and Schnitzler 1997) or continuous manner (Weinstock 1997). Additionally, the
ability to make comparisons between animals during specific time frames of the test and between
control and prenatally stressed offspring was pivotal for future experimental design. One
possible explanation of differences between our findings and those of the literature is that
habituation may have occurred within the first few stimuli with responses quickly reaching
asymptotic levels. It is also possible that the relative amount of change between initial responses
and asymptotic responses may be small, making differences indiscernible.

The effects of time of day on acoustic startle responding
Another important question to address was when testing could be conducted, as
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physiological circadian cycles have been shown to alter stress responsive systems (Chastrette et
al., 1991; Kwak et al., 1992; Fuchs et al., 1996) and behavior (Stroebel 1967; Smith and Turek
1989; Chabot and Taylor 1992; Frankland and Ralph 1995; Amir and Stewart 1998a; Mistlberger
et al., 1998; Amir and Stewart 1998b). Additionally, prenatal stress has been shown to alter
circadian rhythms for corticosterone secretion (Koehl et al., 1997). Therefore, the objective of
the next series of experiments was to determine the effects of the time of day (i.e. morning vs.
afternoon) during which testing was conducted on the acoustic startle reflex. Based on previous
observations using the defensive withdrawal test in our lab, it was hypothesized that acoustic
startle responding would be greater in the afternoon for both control and prenatally stressed
offspring, and based on the findings assessing basal acoustic startle responding (Figure 8), there
would be no effect of prenatal stress on acoustic startle responding.
There was no effect of the time of testing for either control or prenatally stressed
offspring (Figure 10). Additionally, there were no significant differences between control or
prenatally stressed offspring (Figure 10). These findings agreed with our hypothesis that there
would be no difference between control and prenatally stressed offspring and reaffirmed our
previous findings (Figure 8). However, the lack of influence of time of day on acoustic startle
responding for either group did not agree with our hypothesis. The results of several behavioral
studies have shown that acoustic startle responding is influenced by time of testing during the
light cycle and circadian rhythms in rats (Horlington 1970; Davis and Sollberger 1971; Ison et
al., 1991; Chabot and Taylor 1992a; Chabot and Taylor 1992b; Frankland and Ralph 1995). In
these studies, acoustic startle responding was invariably higher during the dark phase of the light
cycle. Additionally, Chabot and Taylor (1992a and 1992b) analyzed acoustic startle responding
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hourly during the light phase and found significant time-dependent fluctuations in acoustic startle
responding in both male and female rats during the light phase of the light cycle. In their model,
acoustic startle responding was higher during early morning hours and late afternoon versus the
middle part of the day. Differences in acoustic startle responding during the light phase for either
control or prenatally stressed offspring may not have been observed in our model because hourly
fluctuations in acoustic startle responding were masked by taking the average acoustic startle
responses for all the animals tested throughout each six hour time period (e.g. 7 AM to 1 PM and
1 PM to 7 PM). Based on our results, all treatment groups in subsequent studies contained
individuals tested throughout the day.

Repetitive exposure to the acoustic startle test and the effects of weight on acoustic startle
responding
The objective of this particular series of experiments was to assess the effects of shortterm (three consecutive days) and long-term (five times over approximately two months)
repetitive exposure to the acoustic startle test on acoustic startle responding in control and
prenatally stressed offspring. The first hypothesis for this experiment was that there would be no
effect of repetitive testing for either time period on acoustic startle responses. Based on the
findings from the previous experiments, the second hypothesis was that there would be no effect
of prenatal stress.
Regardless of expressing the data as the average acoustic startle response or as a
percentage of the first day’s average acoustic startle response for each animal (Figures 11 and
12), there was no habituation to repeated three day exposure for either the control or prenatally
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stressed offspring. Additionally, in the chronic exposure study, prenatal stress had no effect on
acoustic startle responding. These findings were in agreement with both of our hypotheses
Animals did habituate to chronic testing as shown by 42-43% decreases in acoustic startle
responding for both control and prenatally stressed offspring by the fifth exposure (Figure 13).
It was necessary to evaluate any potential differences in acoustic responding for each
animal over the three day test as others have found changes in acoustic startle responding with
repetitive testing (Davis 1972). These findings determined that a three day repeated measures
design could be used to assess drug effects for both non stressed and prenatally stressed offspring
in subsequent studies and that each animal could serve as its own control.
The data collected from the long-term exposure study were consistent with the hypothesis
that there would be no effect of prenatal stress on acoustic startle responding, but did establish
that repetitive testing would affect acoustic startle responding if extended for a long enough
period (Figure 13). The habituation that occurred in the form of decreased acoustic startle
responding could not be clearly attributed to effects of repetitive exposure to the acoustic startle
apparatus and test, repetitive handling, or increasing age.
Behavioral testing conducted in the labs of others using a different acoustic startle
apparatus has shown that the weight of the test subject can influence acoustic startle responding
(Davis 1984). Since there was an associated weight increase with increasing age over the course
of the long term exposure experiment, the objective of the next experiment was to determine if
acoustic startle responding in our test system was weight dependent in control and prenatally
stressed animals. Naive animals of the same age were used to eliminate potential effects of test
habituation, handling or age on acoustic startle responding. The hypothesis for this particular
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experiment was that there would be no positive correlation between weight and acoustic startle
responding for either the control or prenatally stressed offspring.
The data presented in Figure 14 demonstrated there was no significant correlation
between weight and acoustic startle responding for either control or prenatally stressed rats 75
days of age. These findings were in agreement with our hypothesis and not unexpected as our
testing apparatus eliminated the influences of body weight by measuring absolute changes in the
force exerted by the animal (e.g. jumping) as opposed to tonic force (e.g. weight). The force
signal produced was also rectified further eliminating the influence of weight.
A number of behaviors have been shown to be altered by prenatal stress. Additionally,
prenatally stressed offspring are more susceptible to anxiogenic or aversive stimuli. The data
presented here demonstrate that there is no effect of prenatal stress on basal acoustic startle level
responses. These findings are interesting because previous studies from our lab demonstrate a
prenatal stress induced up-regulation of the CRFergic system (Cratty et al., 1994; Cratty et al.,
1995; Ward et al., 1995; Gray et al., 1995), and CRF has been shown to potentiate the acoustic
startle reflex and to be involved in facilitation of fear potentiated startle (Swerdlow et al., 1986;
Swerdlow et al., 1989; Liang et al., 1992a; Lee et al., 1994; Lee and Davis 1997; Pelton et al.,
1997; Birnbaum and Davis 1998). It is possible that there could be adaptive changes in the
intrinsic circuitry for fear processing in prenatally stressed offspring to compensate for this upregulation of the CRFergic system, resulting in normal behavior under basal conditions and
exaggerated fearful behavior in response to stressful stimuli. Parallels of such findings can be
drawn to psychiatric disorders in humans (e.g. panic disorder, depression, post traumatic stress
disorder), where symptoms of disorders are exacerbated or revealed in response to stressful
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stimuli (Lipton 1994; Bremner et al., 1997; Mayou 1997; Zuercher-White 1997).

Yohimbine-induced alterations of acoustic startle responding
The objectives for this particular series of experiments were the further development and
characterization of the acoustic startle test using anxiogenic agents and to assess differences in
fearful behavior in control and prenatally stressed offspring in response to those anxiogenic
agents. Yohimbine, a known anxiogenic agent, has been shown to increase fear-potentiated
startle in rats (Davis et al., 1979) and acoustic startle in rat (Fendt et al., 1994) and in humans
(Morgan, III et al., 1993). Therefore, the hypothesis for this experiment was that yohimbine
would significantly increase acoustic startle responding in control and prenatally stressed rats.
No one has tested yohimbine in prenatally stressed rats. However, prenatally stressed offspring
have been shown to be hyper-responsive to a number of anxiogenic stimuli, including novelty,
footshock, and restraint (Fride et al., 1986; Wakshlak and Weinstock 1990; Takahashi et
al.,1992a; Ward et al., 1994; Ward et al., 1995; Poltyrev et al., 1996; Vallée et al., 1997). As a
result, it was also hypothesized that acoustic startle responding for prenatally stressed rats would
be significantly higher than controls in response to yohimbine.
In preliminary studies, yohimbine produced peak effects 30-50 minutes post-injection in
the acoustic startle test (Figure 15). Therefore, all comparisons made between vehicle and drug
treatment were made from data collected during that time period. Yohimbine caused a
significant increase in acoustic startle responding in control (0.5, 1.25, and 5 mg/kg) and
prenatally stressed (1.25 and 5 mg/kg) offspring (Figure 16). At the 5 mg/kg dose, the prenatally
stressed rats had significantly lower acoustic startle responding compared to control animals.

153

Acoustic startle levels for control and prenatally stressed offspring returned to vehicle control
levels (i.e. 100%) at the 10 mg/kg dose, demonstrating a bi-phasic effect of yohimbine.
The results from this experiment agreed with the hypothesis that yohimbine would
produce a significant increase in acoustic startle responding in control and prenatally stressed
offspring. On the contrary, these results disproved our hypothesis that prenatally stressed rats
would be more sensitive to the anxiogenic effects of yohimbine. Prenatally stressed rats were
equally sensitive to low doses of yohimbine and less sensitive to yohimbine at the 5 mg/kg dose.
These results suggest a potential change in neurotransmission of stress responsive systems due to
prenatal stress. Yohimbine has been proposed to elicit its anxiogenic effects by stimulation of
the noradrenergic system and subsequently the sympathetic nervous system (Cole et al., 1995),
but it has been shown to have affinity at other neurotransmitter receptors, including 5-HT1a
receptors (Goldberg and Robertson 1983; Winter and Rabin 1992; López-Rubalcava and
Fernández-Guasti 1994; Cole et al., 1995; Redfern and Williams 1995). Winter and Rabin
(1992) showed the dissociation constant of 30 nM for yohimbine at 2-adrenoceptors and 74 nM
for yohimbine at 5-HT1a receptors, where it serves as a partial agonist. Such findings suggest that
yohimbine may act on the receptors of other neurotransmitters, which may also explain its biphasic effects at higher doses (Figure 16). The literature describing the role of serotonin as a
neurotransmitter involved in modifying or mediating acoustic startle, let alone mediating anxiety,
is controversial. However, buspirone, a partial agonist at 5-HT1a receptors, has generally been
found to anxiolytic in acoustic startle test as demonstrated by decreases in fear potentiated startle
(Davis et al., 1988; Davis, 1993). In addition to buspirone, other more selective 5-HT1a agonists,
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such as 8-OH-DPAT, gepirone, and ipsapirone have been shown to reduce acoustic startle prepulse inhibition (Rigdon and Weatherspoon, 1992), but the significance of such findings with
regard to anxiety remain unclear. The effects of these compounds on acoustic startle and fearpotentiated acoustic startle are less consistent, demonstrating both significant increases and
decreases (Svensson and Ahlenius, 1983; Ahlenius et al., 1985; Svensson, 1985; Eison et al.,
1986; Mansbach et al., 1988). Without a selective 5-HT1a antagonist, the role of the 5-HT1a
receptor in acoustic startle remains to be elucidated.
In a study by Johnson and File (1989), the anxiogenic effects of yohimbine in the elevated
plus-maze at doses similar to the ones used in this study (2.5 and 4 mg/kg) were blocked by a low
dose of the D1 receptor agonist, apomorphine (0.57 mg/kg). This finding suggests that
yohimbine’s anxiogenic effects possibly could be mediated by a reduction in dopaminergic
neurotransmission. Moreover, increased dopamine transmission potentiates the acoustic startle
response (Davis 1984), while D1 antagonists, such as SCH23390, block fear potentiated startle
(Davis, 1993). Therefore, it is possible that the significant decreases in acoustic startle seen in
response to increasing doses of yohimbine are due to yohimbine-induced antagonism of
dopaminergic neurotransmission. In order to more clearly determine the underlying causes of the
paradoxical responses to yohimbine in prenatally stressed offspring, the 2-adrenoceptor
antagonist, idazoxan was tested in control and prenatally stressed offspring using the acoustic
startle test. Idazoxan is more selective for 2-adrenoceptors versus other adrenoceptor subtypes
compared to yohimbine. Similarities in the behavioral profiles of yohimbine and idazoxan at
comparable doses would not only provide evidence that the two drugs are acting via similar
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mechanisms but also support the hypothesis that alterations in acoustic startle responding of
prenatally stressed offspring are due to 2-adrenoceptor neurotransmission.
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Idazoxan-induced alterations of acoustic startle responding
The objective of this experiment was to determine the effects of the 2-adrenoceptor
antagonist, idazoxan, on control and prenatally stressed offspring using the acoustic startle test.
Idazoxan is a known anxiogenic in a number of behavioral tests, including the Geller-Seifter
conflict test, light-dark test, and elevated plus maze (Venault et al., 1993; Cole et al., 1995;
Redfern and Williams 1995). Based on previous experiments using yohimbine, the hypothesis
for this experiment was that idazoxan would cause a significant increase in the acoustic startle
responding in both control and prenatally stressed offspring. It was also hypothesized that
idazoxan, like yohimbine, would produce a significant decrease in acoustic startle responding for
prenatally stressed offspring compared to controls.
In preliminary studies, idazoxan produced peak effects 20-65 minutes post-injection in
the acoustic startle test (Figure 17). As shown in Figure 18, idazoxan had a bi-phasic effect on
acoustic startle responding. At lower doses, idazoxan significantly increased acoustic startle
responding in both control and prenatally stressed animals. But at higher doses, idazoxan
significantly decreased acoustic startle responding in below vehicle (baseline) levels in control
(20 mg/kg) and prenatally stressed offspring (16 and 20 mg/kg). Additionally, prenatally stressed
offspring acoustic startle responding was significantly lower than control at the 8 mg/kg dose.
These findings were in agreement with our hypothesis that idazoxan would be anxiogenic
in control and prenatally stressed offspring. These findings were also in agreement with the
results from the acoustic startle experiment using yohimbine, where there was a significant
difference between control and prenatally stressed offspring. Once again, these findings suggest
alterations in stress responsive systems in prenatally stressed offspring. Idazoxan significantly
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decreased acoustic startle below baseline for both groups of animals at high doses. The decrease
could be due to an anxiolytic or non-specific effect of the drug. The latter is more likely as the
20 mg/kg dose produced bleeding from the noses of some of the animals. This also raises the
question as to whether yohimbine would have produced similar results at higher doses.
Idazoxan, despite its relatively high affinity for 2-adrenoceptors, also exhibits affinity for
5-HT1a receptors (Winter and Rabin 1992). Another possible mechanism of action for idazoxan
exists as well. Within the past decade, there has been growing evidence for the existence of a
receptor named the imidazoline-preferring receptor, which resembles the 2-adrenoceptor. It is
virtually insensitive to catecholamines but does selectively bind imidazolines and oxazolines,
including idazoxan (an imidazoline preferring receptor antagonist) and rilmenidine (an
imidazoline preferring receptor agonist) (Lehmann et al., 1989). Research has revealed a primary
function of the imidazoline-preferring receptor is regulation of blood pressure, as imidazolines,
but not catecholamines, injected into the nucleus reticularis were found to cause hypotension
(Bousquet et al., 1984). However, the role of the imidazoline-preferring receptor has not been
completely characterized. Therefore it also possible that the low acoustic startle responses in
both control and prenatally stressed offspring at higher doses of idazoxan (Figure 18) could
reflect imidazoline-preferring receptor effects.
Both yohimbine and idazoxan have similar affinities for 2-adrenoceptors (Winter and
Rabin 1992), and both drugs appear to have similar effects at lower doses. However, as
demonstrated in Figures 16 and 18, there are also differences in the behavioral profiles the two
drugs, especially at higher doses, which could be explained by a number of possibilities. To date,
there are four 2-adrenoceptor subtypes: a, b, c, and d, which is an analog of “a” (Lehmann et al.,
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1989; Redfern and Williams 1995). Of these, two subtypes are found in rat brain: a/d and c,
which have differential distributions (Redfern and Williams 1995). It is possible that yohimbine
and idazoxan could be acting via different 2-adrenoceptor subtypes, but at the doses used in this
study, such a finding would be very unlikely. However, behavioral differences between animals
treated with yohimbine versus those treated with idazoxan could be explained by the contention
that yohimbine and idazoxan are acting via different neurotransmitter systems. To more clearly
determine the mechanisms involved in producing the different behavioral profiles of yohimbine
and idazoxan and to further address potential differences in 2-adrenergic neurotransmission
between control and prenatally stressed offspring, the 2-adrenoceptor antagonist, RS 79948 was
tested in control and prenatally stressed offspring using the acoustic startle test. RS 79948 is a
highly selective 2-adrenoceptor antagonist with a very high affinity ratio for 2-adrenoceptors
versus other adrenoceptor subtypes and other receptors (Hume et al., 1996; Milligan et al.,
1997). Findings similar to those of yohimbine and idazoxan at comparable doses ranges would
provide strong evidence that all three compounds are eliciting their effects via 2-adrenoceptor
blockade. Additionally, differences in acoustic startle responding seen between control and
prenatally stressed offspring following RS 79948 would support the hypothesis that differences
are due to alterations in noradrenergic neurotransmission. However, a lack of similarity in the
findings between yohimbine and idazoxan and RS 79948 would suggest that the differences in
acoustic startle responding between control and prenatally stressed offspring are not due to
differences in 2-adrenoceptor blockade.
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RS 79948-induced alterations of acoustic startle responding
The objective of this experiment was to determine the effects of the highly selective 2adrenoceptor antagonist (Hume et al., 1996; Milligan et al., 1997), RS 79948, on control and
prenatally stressed offspring using the acoustic startle test. RS 79948 readily enters the CNS
(Hume et al., 1996) and binds rapidly and reversibly with equal affinity to all subtypes of 2adrenoceptors (Milligan et al., 1997). It has an 2/1-adrenoceptor selectivity ratio of greater
than 10,000 and has even greater selectivity for 2-adrenoceptors versus serotonergic (5-HT1a, 5HT2), -adrenergic, dopaminergic, muscarinic and dihydropyridine receptors (Milligan et al.,
1997). No experiments using this compound in vivo have been published, but based on previous
experiments using yohimbine and idazoxan, the hypothesis for this experiment was that RS
79948 would cause a significant increase in the acoustic startle responding in both control and
prenatally stressed offspring. It was also hypothesized that RS 79948 would produce a
significant difference between control and prenatally stressed offspring.
In preliminary studies, RS 79948 was found to produced peak effects 20-65 minutes postinjection in the acoustic startle test (Figure 19). As demonstrated in Figure 20, RS 79948
significantly increased acoustic startle responding in control and prenatally stressed offspring.
However, there were no significant differences between control and prenatally stressed offspring.
These findings were in agreement with our hypothesis that RS 79948 would be
anxiogenic in control and prenatally stressed offspring. However, the results from this study
were in disagreement with our hypothesis that RS 79948 would produce significant differences
between control and prenatally stressed offspring acoustic startle responding.
Based on the results of this study, the increased acoustic startle responding elicited by
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both yohimbine and idazoxan at lower doses of the drugs are mediated by 2-adrenoceptor
blockade. It is possible that the differences in the behavioral profiles of yohimbine, idazoxan,
and RS 79948 in control and prenatally stressed offspring are due to the differential effects of
each drug at the different 2-adrenoceptor subtypes. However, since RS 79948 has very
comparable affinities at all three of the 2-adrenoceptor subtypes found in rat brain (Hume et al.,
1996), any differences specific to a given subtype should have been revealed. These findings
suggests that the differential effects on acoustic startle responding produced by yohimbine and
idazoxan in prenatally stressed offspring are via interactions at other neurotransmitter receptors.
Both the noradrenergic and serotonergic systems have been shown to be altered by
prenatal stress, which might explain the differences in fearful behavior on the part of the
prenatally stressed offspring. Regarding the noradrenergic system, prenatal stress has been
shown to increase NE turnover (Takahashi et al., 1992b) and to produce region dependent
changes in the concentration of NE in basal conditions and in response to stress (Moyer et al.,
1978; Takahashi et al., 1992b; Reznikov and Nosenko 1996). Peters (1984) also found that
offspring of mothers exposed to crowding and saline injection during pregnancy had brain
region- and age-dependent changes in 1-, 2-, and -adrenoceptors levels. Lastly, in a recent
study by Weinstock et al. (1998), prenatal stress produced significant increases in plasma NE and
dihydroxyphenylglycol (DHPG) immediately following footshock, suggesting an increased
sensitivity of the sympathetic nervous system.
The case for the effects of prenatal stress on serotonergic systems is equally strong.
Significant changes in both 5-HT and metabolite levels (e.g. 5-hydroxyindolacetic acid, 5-HIAA)
have been shown in offspring stressed prenatally with handling and saline injection, which also
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produced a significant increase in the metabolic rate of 5-HT (Hayashi et al., 1998). Using a
similar prenatal stressing protocol, Peters (1986b) showed brain region- and age-dependent
changes in [3H]5-HT and [3H]spiperone binding, which were not due to changes in affinity. In a
separate study, Peters (1986a) showed that prenatally stressed offspring had an increased
behavioral sensitivity to serotonergic agonists as demonstrated by a significantly increased
occurrence of the 5-HT syndrome (wet-dog shakes). Some or all of the changes could serve as
compensatory mechanisms for other neurotransmitter systems involved in the stress response that
may be dysfunctional. It is quite possible that there is a decrease in the activity of the
noradrenergic or serotonergic neurotransmitter systems to offset the apparent up regulation of the
CRFergic system in prenatally stressed offspring.

Conclusions concerning the acoustic startle test
Generally speaking, the acoustic startle test seems to be a good measure of fearful
behavior. It was able to produce reliable and stable responses from both control and prenatally
stressed offspring during the establishment of baseline acoustic startle responding and in
response to vehicle injection during testing (Figures 15, 17, and 19). The acoustic startle test was
also able to measure fearful behavior in response to anxiogenic agents (Figures 16, 18, and 20).
Despite the fact these data were obtained using a three-day repeated measures design, confidence
in these results could be maintained as animals repetitively exposed to the acoustic startle test
over a three-day period did not habituate to the test (Figures 11 and 12).
The acoustic startle reflex itself has also been used to assess cognitive aspects of fearful
behavior in the fear-potentiated startle test and to determine changes in the sensitivity of
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pathways associated with reflexive responding via the prepulse-inhibition testing paradigm. The
primary disadvantage of the acoustic startle test is the difficultly in determining whether changes
in acoustic startle responding are due to changes in the reflex or due to changes in cognitive
levels of fearful behavior. Fortunately, this dilemma could be resolved with further testing using
both of the afore mentioned testing procedures. Finally, the acoustic startle response is one of the
most basic reflexes, which serves to alert the animal to potential threats and sources of danger.
Alterations of such a response, such as those seen in the present study with prenatally stressed
offspring, may have implications regarding the survival of the animal. It is possible that
impaired responding may lessen the chances of the animal’s survival when faced with a threat.
Such a finding would be in keeping the idea that prenatally stressed offspring have an increased
vulnerability to stress and an inability to adapt when presented with anxiogenic stimuli.

Effects of prenatal stress on blood pressure and heart rate responses to yohimbine and
idazoxan
One possible explanation for differences in acoustic startle responding between control
and prenatally stressed offspring after administration of yohimbine and idazoxan is that these
drugs are acting via the noradrenergic system, which has been shown to be altered by prenatal
stress (Moyer et al., 1978; Takahashi et al., 1992b; Reznikov and Nosenko 1996). The
sympathetic nervous system is one of the key components of the stress response. It controls such
autonomic parameters as blood pressure and heart rate and is primarily mediated by
noradrenergic system (Appenzeller, 1990). Therefore, it would stand to reason that differences in
noradrenergic neurotransmission due to prenatal stress should produce differences in blood
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pressure and heart rate as well. As a result, the objective of this experimental series was to
determine the effects of yohimbine (5 mg/kg) and idazoxan (8 mg/kg) on systolic blood pressure
and heart rate in control and prenatally stressed offspring using a tail cuff blood pressure and
heart rate monitoring system. Both yohimbine and idazoxan have been shown to increase blood
pressure (Harland and Brown 1988; Suemaru et al., 1989; Sved et al., 1992). Therefore, the
hypothesis for this particular set of experiments was that blood pressure and heart rate would be
increased in response to yohimbine and idazoxan for both control and prenatally stressed
offspring. Additionally, prenatally stressed animals are more sensitive to the anxiogenic effects
of aversive stimuli (e.g. restraint and footshock)(Fride et al., 1986; Wakshlak and Weinstock
1990; Takahashi et al.,1992a; Ward et al., 1994; Ward et al., 1995; Poltyrev et al., 1996; Vallée
et al., 1997).. Recent studies have shown increased heart rate and blood pressure of prenatally
malnourished rats under basal conditions and in response to aversive stimuli (Tonkiss et al.,
1998) and an increased sensitivity of the sympathoadrenal system of prenatally stressed offspring
exposed to footshock (Weinstock et al., 1998). Therefore, it was also hypothesized that
prenatally stressed animals would have significantly higher blood pressure and heart rate
compared to controls both under basal conditions and in response to drug.
There was no significant difference in basal systolic blood pressure between control and
prenatally stressed offspring (Figure 21). However, prenatally stressed animals did have a
significantly higher basal heart rate (Figure 24). There was no effect of yohimbine’s or
idazoxan’s vehicle on systolic blood pressure or heart rate for either control or prenatally stressed
animals (Figures 22, 23, 25 and 26). Yohimbine did not alter basal systolic blood pressure
(Figure 22) but did significantly increase heart rate (Figure 25). Idazoxan significantly increased
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both blood pressure and heart rate (Figures 23 and 26). Finally, there were no significant
differences between control or prenatally stressed offspring following the administration of either
drug at the doses that produced differential responses in the acoustic startle test (Figures 22, 23,
25 and 26).
The results from these studies were in agreement with the hypothesis that the heart rate of
prenatally stressed offspring would be significantly higher than controls. However, there was no
significant difference in basal blood pressure between control and prenatally stressed offspring,
contradicting our initial hypothesis. Tonkiss et al. (1998) showed that prenatal malnutrition
produced small but significant increases in blood pressure using radiotelemetry. Differences
between our findings and those of Tonkiss may be due differences in measurement techniques or
model of prenatal treatment. Radiotelemetric measurements are more accurate with less
variablility than tail cuff measurements of blood pressure. Therefore it is quite possible that
prenatal stress produced increased blood pressure in our animals, but it was not detected because
of our measurement technique. The increased blood pressure and heart rate in response to
idazoxan and the increased heart rate in response to yohimbine were all in agreement with our
initial hypothesis regarding the effects of the drugs. It is not certain whether these drugs act via
direct effects on the autonomic nervous system or indirectly via anxiogenesis and subsequent
activation of the sympathetic nervous system. However, it is clear that the lack of effects of
yohimbine on blood pressure reinforces the notion that yohimbine and idazoxan are acting via
different mechanism. Such findings can possibly be explained by differences in the relative
affinities of each drug. Idazoxan, which has a higher affinity for 2-adrenoceptors compared to
the other adrenoceptor subtypes, blocks 2-adrenoceptors, which, in turn, blocks the auto-
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inhibitory mechanism and results in an increased activity of noradrenergic neurons contained
within the sympathetic nervous system. This increase activity of the sympathetic nervous system
leads to increased heart rate via 1-adrenoceptor stimulation and vasoconstriction via 1adrenoceptor activation, resulting in both an increase in heart rate and blood pressure.
Yohimbine has a similar mechanism to that of idazoxan. However, since its relative affinity for
2-adrenoceptors versus 1-adrenoceptors is much lower, yohimbine is able to block 1adrenoceptors, negating the increased sympathetic activity at 1-adrenoceptors and resulting in no
change in blood pressure. The absence of differences between control and prenatally stressed
offspring suggests that the differences in acoustic startle responding seen between control and
prenatally stressed offspring following treatment with 5 mg/kg of yohimbine or 8 mg/kg
idazoxan are not due to differences in sympathetic activity.
Blood pressure and heart rate measurements using the tail cuff monitoring system seemed
to be fairly accurate. The test was quick and simple, and the testing apparatus was able to
produce consistent and reliable responses from both control and prenatally stressed offspring
during the establishment of baseline blood pressure and heart rates and in response to both
vehicle and drug (Figures 21-26). Unfortunately, there was a certain degree of variability in the
daily basal values of the test subjects and between individual testing stations, making it necessary
to express all vehicle and drug data in terms of each animal’s daily basal values. An additional
weakness of this particular method is that it is limited to making static measurements. This
prohibits the monitoring of moment to moment responding of the animals and prevents the direct
determination of peak drug effect and duration of action. Another problem is that generating full
dose response curves would be costly and animal-intensive. Such issues could easily be
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circumvented by using in-dwelling catheters. For our purposes, the time periods of interest for
yohimbine and idazoxan were previously determined using the results of the acoustic startle
tests. The rationale behind looking only at the 5 mg/kg dose of yohimbine and the 8 mg/kg dose
of idazoxan was to specifically address the differences in acoustic startle responding between
control and prenatally stressed animals at those doses. Clearly, further experimentation using
yohimbine and idazoxan at a wider range of doses is necessary in order to more fully examine the
effects of these drugs on the cardiovascular system.

Results from the defensive withdrawal test
The defensive withdrawal test is a behavioral testing paradigm designed to measure
changes in fearful behavior (Takahashi et al., 1989; Yang et al., 1990; Yang and Dunn 1990; De
Fonseca et al., 1996). The paradigm is an ethologically based “conflict” test that takes advantage
of two instinctive emotions exhibited by rats, fear and curiosity. In theory, the conflict produced
is the result of a rat’s natural tendency to explore a new environment (i.e. a well lit, large open
field) in the absence of perceived threat and to retreat or “withdrawal” to a safe environment (i.e.
the defensive withdrawal chamber) when fearful. Consequently, the emotional state of the
animal can be determined by analyzing the resultant behaviors exhibited. Anxious behavior can
be ascertained by determining the average amount of time spent visiting the chamber, with
increasing amounts of time spent in the chamber reflecting an increased fearfulness.
Additionally, this assay can be used to examine other behavioral parameters whose changes are
thought to be indicative of fearful behavior. One such behavior is the amount of time it takes the
animals to initially exit from the defensive withdrawal chamber, termed latency. Increasing
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latencies before exiting reflect an increased fearfulness. Two other behaviors that are
traditionally measured in open field tests to assess fearful behavior can also be measured using
the defensive withdrawal test. These include rearing and ambulation. Rearing behavior is
thought to be indicative of exploration and low-fear-level risk assessment (Dunn and Berridge
1990a; Yang et al., 1990; Yang and Dunn 1990; Blanchard et al., 1998). Therefore, decreased
exploration or risk assessment in the form of decreased rearing, reflects an increased fearfulness.
Changes in ambulatory behavior in some form of open field apparatus have traditionally been
thought to be indicative of changes in “emotionality” and fearful behavior (Chapman and Stern
1979; Weinstock et al., 1988). Unfortunately, there is no clear relationship between motor
activity and fear. Motor activity in the open field in the form of line crossing rates is considered
to be the compilation of several different behaviors (e.g. exploration, fearful behavior, and
locomotion), which can not be easily discriminated. However, this parameter serves as a useful
tool in determining the effects of agents or conditions on motor activity and provides insight to
the other changes in behavior produced, giving a more complete behavioral profile of the agents
tested.

Anxiogenic agents in the defensive withdrawal test
The acoustic startle response can be modified both indirectly at higher cognitive centers
of the brain and directly at the level of the acoustic startle reflex pathway (i.e. brainstem and
spinal cord) (Davis 1984). Consequently, it is very difficult to clearly determine whether
increases in acoustic startle responding are the result of increased fearfulness or simply the result
of drug-induced alterations of noradrenergic or serotonergic neurotransmission the level of the
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brainstem and spinal cord. In an attempt to support the findings that yohimbine, idazoxan, and
RS 79948 are anxiogenic agents in the acoustic startle test, these drugs were tested using the
defensive withdrawal test at doses that increased acoustic startle. Caffeine (File et al., 1988;
Bhattacharya et al., 1997), FG7142 (Cole et al., 1995), DMCM (Cole et al., 1995), and restraint
stress (Berridge and Dunn 1989a; Berridge and Dunn 1989b; Casada and Dafny 1991; Ward et
al., 1995; Smagin et al., 1996) are all known anxiogenic agents and were tested in the defensive
withdrawal test as positive controls. The hypothesis for this particular set of experiments was
that each of the afore mentioned agents would produce fearful behavior in the defensive
withdrawal test in the form of increased average time per visit, increased latency, decreased
rearing rates or decreased line crossing rates.
Caffeine was able to generate anxious behavior at the 20 mg/kg dose reflected by a
significant increase in latency (Figure 27) and significant decrease in rearing (Table 3 and Figure
28). The partial inverse BZ receptor agonist FG7142 produced a significant decrease in line
crossing rates at the 15 mg/kg dose (Figure 29). The full inverse BZ receptor agonist DMCM
generated anxious behavior at 0.5 mg/kg by eliciting significant decreases in rearing rate and line
crossing rate and significant increases in ATPV (Table 3; Figures 27, 28 and 29). Idazoxan was
anxiogenic as demonstrated by the significant increase in the initial latency to exit at the 0.8
mg/kg dose (Figure 28), the increase in ATPV at the 0.08 mg/kg dose (Table 3; Figure 27), and
the significant decreases in line crossing rates at both 0.08 and 0.8 mg/kg (Table 3, Figure 30).
Yohimbine produced fear behavior as demonstrated by decreased rearing rates at both 1.25 and 5
mg/kg doses (Table 3, Figure 29) and increasing defensive withdrawal at 1.25 mg/kg (Table 3,
Figure 27). Furthermore, yohimbine significantly decreased line crossing rates (Table 3, Figure
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30). The 2-adrenergic antagonist, RS 79948, significantly decreased line crossing rates only,
suggesting a mild anxiogenic effect of the drug (Figure 30). Finally, restraint was anxiogenic in
the defensive withdrawal test as demonstrated by the significant increases in latency following
120 minutes restraint (Figure 28) and the significant increase in ATPV following 60 minutes
restraint (Figure 27).
The findings of these experiments are in agreement with the hypothesis that anxiogenic
agents including yohimbine, idazoxan, and RS 79948 and restraint would elicit discernable
changes in fearful behavior in rats. The results from this experiment support the findings of the
acoustic startle test, where yohimbine (Figures 15 and 16), idazoxan (Figures 17 and 18), and RS
79948 (Figures 19 and 20) were anxiogenic. Additionally yohimbine, idazoxan, and RS 79948
had different behavioral profiles in the defensive withdrawal test (Table 3 and Figures 27-30),
reinforcing the earlier contention that these drugs are acting by different mechanisms.
The defensive withdrawal test was validated previously by experiments conducted in our
lab using centrally administered CRF and two hours restraint (Ward et al., 1994). We showed
that 1 µg CRF administered i.c.v. produced anxiogenic behavior in normal rats as demonstrated
by significantly increased average time per visit to the chamber and decreased rears per minute in
the open field. The results were similar to previously reported findings that have shown CRF to
be anxiogenic in the defensive withdrawal test, an effect that was prevented by pretreatment with
the CRF antagonist, -helical CRF(9-41), and the anxiolytics, chlordiazepoxide and propranolol
(Takahashi et al., 1989; Yang et al., 1990; Yang and Dunn 1990; De Fonseca et al., 1996). In a
subsequent experiment, two hours restraint significantly increased latency and average time per
visit and significantly decreased rearing rates. These effects were blocked following the
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administration of full and partial CRF antagonists, D-phe-CRF(12-41) (15 µg) and -helical CRF(941)

(60 µg), respectively (Ward et al., 1995). These findings supported the rationale behind using

the defensive withdrawal test to assess fearful behavior produced by different anxiogenic drugs.
Several drugs have been studied using the defensive withdrawal test (Takahashi et al.,
1989; Yang et al., 1992; Becker and Hennessy 1993; Gorman and Dunn 1993), focusing
specifically on the noradrenergic and CRFergic neurotransmitter systems. However, no work had
been done looking at the effects of compounds known to be anxiogenic in humans, including
caffeine (Chou et al., 1985; Loke et al., 1985; File et al., 1988; Bhattacharya et al., 1997),
FG7142 (Ableitner and Herz 1987; Lewin et al., 1989), DMCM (Stephens et al., 1986; Ableitner
and Herz 1987). Our results demonstrated that none of the anxiogenic agents tested were able to
modify all of the behavioral parameters measured (Figures 29 and 30; Table 3). However, each
agent had its own specific profile, suggesting their behavioral effects are likely to be stimulus and
pathway specific.
Historically, decreased rearing rates in an open field environment have been associated
with increased fearfulness (Dunn and Berridge 1990a; Yang et al., 1990; Yang and Dunn 1990).
Our data are consistent with this view. These data are also consistent with the risk assessment
model of rat behavior as rearing was significantly decreased in response to predatory stress (e.g.
cat-exposure) with subsequent increases in the risk assessment pattern of behavior (i.e.
orientation to the stimulus, visual scanning, assuming a flat back posture, freezing, etc.)
(Blanchard et al., 1998). Blanchard’s findings suggest rearing occurs in animals that are only
slightly fearful. However, such interpretations must be made with caution as rearing is strongly
influenced by environmental factors, such as the characteristics of the test situation, and other
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behaviors (e.g. sniffing). For example, it is possible that air flow from above the testing
apparatus would result in an increased rearing as the animals would try to sniff the air source.
Conversely, a decrease in rearing could be observed if airflow is coming from the bottom of the
apparatus (Caroline Blanchard, personal communication).
Open field ambulation (i.e. line crossing rates) as a measure of fearful behavior has been
a point of much debate and is extensively reviewed by Weinstock et al. (1988). In general,
decreased ambulation in some form of open field apparatus has traditionally been thought to
indicate increased “emotionality” and fearful behavior (Thompson 1957; Joffe 1969; Weinstock
et al., 1992; Poltyrev et al., 1996; Vallee et al., 1997; Mohapel and McIntyre 1998). The
findings presented here clearly point to an association between decreased line crossing rates and
increased fearful behavior (Figure 30). However, the lack of effects on line crossing rates in
response to caffeine and restraint bring such a conclusion into question. Aside from its
anxiogenic properties, caffeine serves as a stimulant (Misra et al., 1986; Lehnert et al., 1998;
Fenu and Morelli 1998). In open field tests, it has been shown to increase locomotor activity
(Finn and Holtzman 86 A.D.; Misra et al., 1986; File et al., 1988; Pohorecky et al., 1989; Fenu
and Morelli 1998). A possible explanation is that caffeine’s stimulant properties may be offset
by its anxiogenic properties, resulting in no overall effect or even an inhibitory effect on line
crossing rates. Such findings would be in agreement with a study from Bhattacharya et al.
(1997). In that study, the anxiogenic effects of caffeine were assessed using the open-field,
elevated plus-maze, social interaction and novelty-suppressed feeding latency tests at doses
similar to those used in the present study (i.e. 10, 25 and 50 mg/kg, i.p.). Caffeine decreased the
number of entries and time spent on the open arms of the elevated-plus maze, reduced social
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interaction in paired rats and increased the feeding latency in an unfamiliar environment in 48-h
food-deprived rats. Most importantly, caffeine also reduced ambulation and rearing in the openfield test. The lack of effect of restraint on line crossing rates is disconcerting. It is quite
possible that each of the anxiogenic agents presented in this study are acting on different
neurotransmitter systems, resulting in different behavioral profiles of each treatment. However,
restraint is a very potent anxiogenic treatment that acts on a number of stress responsive
neurotransmitter systems (as reviewed by Glavin et al., 1994) and has been shown to alter open
field behavior. In 1989, Berridge and Dunn demonstrated that restraint decreases exploration of
novel objects in open field tests in both rats and mice, while, Smagin and colleagues (1996)
showed that restraint produced fearful behavior in rats tested in the defensive withdrawal test,
increasing both the initial latency to exit from the defensive withdrawal chamber and the average
time per visit to the chamber, further suggesting the association of fear and stress. A possible
explanation of our findings is that estimates of ambulation in the open field may encompass
functionally unrelated activities such as exploration and flight induced by fear as suggested by
Archer and Blackman (1971). Additionally, motor activity can be situationally dependent with
the variable changing as experimental parameters change. For example, in the active avoidance
behavioral model, an animal has to complete the task of finding a “safe” area of the testing
apparatus to avoid being shocked. This task might lead to an increased motor activity. But if the
animal has already found the safe area, the resultant motor activity would be significantly less.
Therefore, based on these findings, it is quite possible other influences, aside from fear, could be
altering line crossing behavior, including drug-induced physiological changes (i.e. blood
pressure), motivational changes, or even sedation.
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The effects of sedation in the defensive withdrawal test
The purpose of this experiment was to demonstrate that other influences, aside from fear,
can impact line crossing rates. The objective of this experiment was to determine the effects of
diazepam-induced sedation on animals tested in the defensive withdrawal test by measuring
changes in motor activity. Diazepam is a known anxiolytic agent with sedative properties
(Hughes 1993; Stout and Weiss 1994; Reddy and Kulkarni 1997). It acts via modulation of the
BZ subunit of the -aminobutyric acid (GABA) receptor complex (Tyrer and Lader 1974;
Kellogg and Pleger 1989; Benistant et al., 1990; Carboni et al., 1996). Doses of diazepam (1 and
2 mg/kg, i.p.) were chosen based on previous studies conducted in our lab (data not shown). In
those experiments, it was expected that diazepam would elicit behaviors in the defensive
withdrawal associated with decreased fearfulness (i.e. a decreased initial latency, decreased
ATPV, increased rearing, and increased line crossing). However, diazepam had no effect on
latency or average time per visit to chamber. It did significantly decrease rearing and line
crossing rates, which are responses typically associated with fearful behavior. The underlying
cause of such results came into question as diazepam, in addition to its anxiolytic effects, has an
associated sedative effect (Sanger et al., 1995). It is possible that diazepam was unable to
produce any discernable anxiolytic effects in the defensive withdrawal test because of the drug’s
sedative effects at the doses chosen. Therefore based on these findings, the hypothesis for this
particular experiment was that diazepam would dose dependently decrease motor activity in the
defensive withdrawal test measured as changes in line crossing rates over time. Habituation to
the testing environment occurred during the testing period as shown by an approximate 50%
decrease in line crossing rates for vehicle treated animals and approximately 70% and 90%
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decreases in animals treated with 1 mg/kg and 2 mg/kg diazepam by the end of the testing period
(Figure 31). One mg/kg diazepam produced and rapid and significant 52% decrease in line
crossing rates within 7.5 minutes (Figure 31). The 2 mg/kg dose of diazepam also produced a
rapid and significant 81% decrease in line crossing rates within 5 minutes (Figure 31).
These findings are in agreement with the hypothesis that diazepam would lead to a
significant and dose-dependent decrease in the line crossing rates over the ten minute testing
period, suggesting that influences aside from fear can alter line crossing rates in the defensive
withdrawal test. The fact that there was a significant effect of habituation over time in vehicle
treated animals was not surprising. One component of the “conflict” presented in this behavioral
model is novelty, which serves as a motivational force for the animals. Habituation and the
resultant behavioral changes would be expected as the animal becomes more familiar with the
testing environment. These effects also preclude animals from being repetitively tested in the
defensive withdrawal test.
It is quite possible that other influences, including changes in blood pressure may alter
changes in open field activity, which could explain the findings for decreased line crossing rates.
In fact these findings may actually serve as possible explanation for the decreased rearing rates
found in response to many of the compounds tested here. In the blood pressure studies (Figures
21-23), yohimbine had no significant effect at 5 mg/kg (Figure 22). However, idazoxan
significantly increased blood pressure at 8 mg/kg (Figure 23), which could possibly account for
its effects at lower doses tested in the defensive withdrawal test.

Conclusions concerning the defensive withdrawal test
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The defensive withdrawal test seems to be a fairly reliable measure of fearful behavior,
despite the fact that no single behavioral parameter or combination of parameters were
consistently modified by all of the anxiogenic agents. The ability to measure several behavioral
parameters makes the test quite useful in that it is able to provide a more complete behavioral
profile of the compounds or treatments tested. This is a clear advantage in dealing with
anxiogenic compounds that act on different neurotransmitter systems and may be stimulus or
parameter specific.
Unfortunately, there are several problems with the defensive withdrawal testing
paradigm. It is assumed that only a dichotomy between fear and curiosity exits in this test. It is
very difficult to relegate all explanations of behavior in this test in terms of one or the other of
these instinctive emotions. Another fundamental problem with this test is that fear is considered
the pervasive motivational force that dictates behavior in this test and that all changes in behavior
are relative to the level of fear in the test subject. This may very well be the case, but assuming
that fear and curiosity are the only two behaviors exhibited in the defensive withdrawal test, it is
quite possible that changes in behavior could be dictated exclusively by the motivational forces
associated with curiosity. What more, the test is observation-oriented as opposed to task-driven
in keeping with its “ethological” philosophy. As a result, the animals dictate the behaviors
exhibited, making it impossible to discern what instincts are the underlying forces producing
changes in behavior. This is unlike a vast majority of other conflict models, where animals are
trained to perform a given task. Their ability to maintain that task in certain motivational states
and under conflict situations can then be studied (e.g. Geller-Seifter conflict task, Vogel punished
responding task) (Britton et al., 1985; Agmo et al., 1991).
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An additional point of interest is the variability in the basal behaviors exhibited in the
defensive withdrawal test (Table 3). The lack of consistency may actually reflect excessive
sensitivity to changes in the experimental environment (e.g. handling, variation in the time of
testing between animals, slight alterations in lighting, etc), differences in the groups of animals
tested, or even seasonal effects on behavior. Fortunately, this problem can be circumvented by
normalizing the behavior as percentage of vehicle or basal responding (Figures 27-30) in groups
tested concurrently.
In summary, these data have shown that the defensive withdrawal test is an extremely
complex assay that can measure several behavioral parameters in the assessment fear. The test
seems to be extremely sensitive to environmental conditions. However, based on the results
presented here, this test would be extremely useful in addressing the question of differences in
basal and challenged behavior due to prenatal stress.

Background and conclusions on the noradrenergic system
Based on the studies using the acoustic startle and defensive withdrawal tests, yohimbine,
idazoxan, and RS 79948 have very similar behavioral profiles. In the acoustic startle test, at low
doses each drug was anxiogenic in both control and prenatally stressed animals, producing
significant increases in startle responding (Figures 16, 18, and 20). Additionally, all three
compounds had biphasic effects as acoustic startle responding returned to basal levels or was
significantly reduced at higher doses of drug. Typically biphasic effects are not seen in
behavioral studies due to limited numbers of doses or limited dose ranges being tested.
However, varying doses over a several hundred-fold range produced significant differences in the

177

effects yohimbine, idazoxan, and RS 79948-197. Both yohimbine and idazoxan significantly
decreased acoustic startle responding in prenatally stressed rats compared to control at 5 and 8
mg/kg, respectively. No such differences were seen with RS 79948-197, which is a more
selective 2 -adrenoceptor antagonist with equal affinity for all three receptor subtypes (e.g. 2a/d,
2b, and 2c). These findings suggest that at lower doses yohimbine, idazoxan, and RS 79948197 are all acting via 2-adrenoceptor blockade, but at higher doses, yohimbine and idazoxan are
acting on other neurotransmitter systems. The possibility that higher doses of RS 79948-197
could elicit differences between control and prenatally stressed offspring can not be excluded.
However, such findings would bring RS-79948-197’s receptor selectivity into question despite
the fact that RS-79948 has a 10,000-fold 2/1-adrenoceptor selectivity ratio (Milligan et al.,
1997). The experiment presented in Figure 20 shows a 1000-fold dose range with increased
acoustic startle responding in both groups at the lowest dose. This implies that there may be
effects at much lower doses of the drug and that the 10 mg/kg dose may be near or exceed the
range at which the drug would maintain a fairly high selectivity for 2-adrenoceptors.
In the defensive withdrawal test, yohimbine, idazoxan, and RS 79948-197 increased the
average time per visit to the defensive withdrawal chamber (Table 3; Figure 27) and decreased
open field ambulation (Table 3; Figure 30). The similarities between the three compounds
suggest that these behaviors are at least partially mediated via 2-adrenoceptor antagonism.
Additionally, both yohimbine and RS 79948 were able to significantly decrease rearing rates
(Table 3; Figure 29). Idazoxan’s inability to decrease rearing rates are possibly due to
interactions at different receptors (e.g. imidazoline receptors or 5-HT1a receptors), which are
counteracting the 2-adrenoceptor antagonism. It is also possible that idazoxan simply has a
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higher affinity for a different system, such as the case with the imidazoline receptor, and that
there is not enough drug to available to have a significant interaction at 2-adrenoceptors to
produce a behavioral response. Regardless of the mechanism underlying the behavioral
differences between idazoxan and the other two compounds, it is clear that there is a separation
in the behavioral profiles of the three drugs, which is also seen in the latency to exit the defensive
withdrawal chamber (Table 3, Figure 28). Both idazoxan and yohimbine were able to increase
the latency before the initial exit from the chamber, where RS 79948 was ineffective. These
findings build on the results from the acoustic startle test as there are a number of similarities in
the behavioral profiles of yohimbine, idazoxan, and RS 79948. However, there are clear
differences as well.

General conclusions
In summary, there is a continually growing body of evidence linking long term physical
and psychological maladies in offspring and exposure of mothers to stressful and/or fearprovoking stimuli during critical developmental stages of gestation. A working model of
prenatal stress has been developed in our lab, using pregnant rats stressed during the last week of
gestation. The experimental evidence demonstrates the resultant prenatal stress syndrome
induced in the offspring generates characteristically exaggerated behavioral and physiological
responses to aversive stimuli. The data strongly suggest the importance of CRF, NE, and 5-HT
to the behavioral expression of fear and to the neurochemical and hormonal responses to stressful
stimuli. Clearly, this question of altered behavioral and physiological functioning of stress
response systems need further investigation, as dysregulation of such systems leads to an
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increased susceptibility to stressful stimuli and/or the precipitation of a broad range of
psychiatric, neuroendocrine, and inflammatory disorders.
Prenatal stress is a model of the impact of early life experiences, especially traumatic
ones, on brain development. Its effects are permanent, resulting in animals that are constitutively
“different.” Prenatally stressed offspring are in a state of chronic stress. They are also more
fearful and, at times, helpless when presented with stressful conditions. We really don’t know if
prenatally stressed rats are anxious, depressed or both because these are characteristics of many
types of psychiatric disorders, but such a model is clearly useful for the study of psychiatric
illnesses. For example, studying the effects of the mechanism of action of antidepressants or
anxiolytics is hampered by the real possibility that drugs act differently in animals and people in
different states. Many antidepressants have little or no effect in “normal” test subjects but have
profound effects in “depressed” ones. Additionally, most models of psychiatric illness
(especially depression and anxiety) involve relatively acute manipulations and have a very short
effective period, limiting their functionality. Such limitations could easily be circumvented,
given the permanent nature of the prenatal stress animal model.
Finally, it must be kept in mind that findings from this study should be interpreted
cautiously. Different species and strains of rodents originally taken from the wild have been
selectively bred to produce animals that are genetically similar to reduce between subject
variability and to greatly reduce undesirable traits such as aggressiveness. This undoubtedly
should bring the validity of studies involving these engineered animals under suspicion. It has
been observed that wild rats are more aggressive and fearful in response to anxiogenic stimuli
compared to control lab rats (personal communication Dr. D.C. Blanchard). Such an experiment
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raises the point that comparisons between “experimental” groups and “control” groups are
contextually dependent. Also, a lack of similarity in the findings between wild-type rats and lab
bred rats further begs the question if lab bred animals serve as true and appropriate controls.
What more, how valid are the results from studies involving animals selectively bred for a given
trait or genetically mutated strains of animals originating from colony bred animals? It may be
the case that changes seen in prenatally stressed animals are adaptive, resulting in animals that
are behaviorally and physiologically “different” from lab bred control animals but are more
similar to wild-type rats and are better suited for survival in the face of aversive stimuli.
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FUTURE STUDIES
Our data have shown that stressing pregnant rats with daily saline injection from
gestational day 14 to gestational day 21 produces offspring with behavioral deficits that persist
into adulthood, suggesting their permanence. With regard to global function, these animals
appear to be “normal” in basal behavioral states as demonstrated in the acoustic startle test,
which measures reflexive responses to fearful stimuli. Moreover, differences between prenatally
stressed and control (normal) offspring were observed only after the administration of anxiogenic
drugs. Doses of yohimbine (5 mg/kg; Figure 16) and idazoxan (8 mg/kg; Figure 18) that
produced increased acoustic startle in control animals were ineffective at increasing acoustic
startle responses in prenatally stressed animals.
Despite their reputation as selective 2-adrenoceptor antagonists, yohimbine and
idazoxan, have affinity for several other receptors (Lehmann et al., 1989; Michel et al., 1989;
Winter and Rabin 1992). Therefore, the possibility exists that these drugs confer their
anxiogenic effects via different neurotransmitter systems. As a result, the effects of RS 79948197, a highly selective 2-adrenoceptor antagonist (Hume et al., 1996; Milligan et al., 1997) were
assessed in order to definitively determine whether focus should remain on the 2-adrenoceptor
or investigations should switch to another neurotransmitter system. Results indicated that RS
79948 significantly increased acoustic startle responding in both control and prenatally stressed
offspring (Figure 20), suggesting that yohimbine’s and idazoxan’s effects on acoustic startle
responding are mediated by 2-adrenoceptor blockade. However, there were no significant
differences between control and prenatally stressed offspring at any dose of RS 79948 (Figure
20), suggesting that the differences in acoustic startle responding between control and prenatally
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stressed animals in response to yohimbine (5 mg/kg) and idazoxan (8 mg/kg) are not due to
differences in 2-adrenoceptor blockade. Based on these findings, we should look to another
neurotransmitter system as the underlying cause of differences between control and prenatally
stressed offspring in the acoustic startle test. A logical next choice is serotonergic system with
focus on the 5-HT1a receptor subtype.
Both yohimbine and idazoxan have comparable affinities for 5-HT1a receptors (Lehmann
et al., 1989; Winter and Rabin 1992) and serve as partial agonists at that receptor site (Cole et al.,
1995; Redfern and Williams 1995). A considerable amount of scientific evidence suggests that
5-HT inhibits acoustic startle responding (Davis 1984). Therefore blockade of 5-HT1a receptors
may contribute to the anxiogenic effects of yohimbine and idazoxan. The serotonergic system
has been shown to be altered by prenatal stress (Peters 1982; Peters 1989), which could also
serve as an explanation for the different responses elicited by yohimbine and idazoxan in control
and prenatally stressed offspring. Therefore a subsequent experiment will involve testing the
anxiogenic effects of an antagonist selective for the 5-HT1a receptor on acoustic startle
responding in prenatally stressed and control offspring. N-[4-(2-methoxyphenyl)-1-piperazinyl]N-(2-pyridinyl)cyclo-hexanecarboximide (WAY 100635) is a selective 5-HT1a receptor
antagonist with a dissociation constant of 0.10 nM (Gozlan et al., 1995; Forster et al., 1995;
Trillat et al., 1998; Corradetti et al., 1998). In rats, WAY 100635 has been shown to block the
anxiolytic effects of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the elevated plusmaze (Collinson and Dawson 1997) and to produce fearful behavior in an open field test (Beckett
and Marsden 1997). Therefore, we predict that WAY 100635 will be anxiogenic in control and
prenatally stressed offspring, resulting in significantly higher average acoustic startle responding
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for both. Furthermore, there will be detectable differences between control and prenatally
stressed offspring responding. If the antagonist produces a behavioral profile similar to those of
idazoxan and yohimbine (Figures 16 & 18), the results would imply that the differential effects
on acoustic startle responding in prenatally stressed offspring are mediated via alterations in the
serotonergic system.
The results from the defensive withdrawal test are another point of interest. Idazoxan,
yohimbine, and RS 79948 were anxiogenic in normal animals as demonstrated by significant
increases in average time per visit and latency or significant decreases in either line crossing or
rearing rates (Figures 27-30; Table 3). An important question stemming from these studies is
whether prenatally stressed offspring would behave differently in the defensive withdrawal test
after treatment with yohimbine, idazoxan, or RS 79948. Therefore, a subsequent experiment
assessing these drugs will be conducted using prenatally stressed offspring. The hypothesis is
that prenatally stressed offspring will be less responsive to higher doses of yohimbine and
idazoxan in comparison with controls. Finding differences in the behavioral profiles of
yohimbine, idazoxan, and RS 79948 similar to the findings in the acoustic startle test would
strengthen the conclusion that the effects in acoustic startle are related to fear and the mechanism
of action of these drugs differ.
Both yohimbine and idazoxan have been shown to increase blood pressure (Harland and
Brown 1988; Suemaru et al., 1989; Sved et al., 1992). One possible explanation for differences
in acoustic startle responding between control and prenatally stressed offspring after
administration of yohimbine and idazoxan is that blood pressure could be differentially affected
by prenatal stress. In blood pressure experiments using tail cuff, idazoxan (8 mg/kg; Figure 23)
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significantly increased blood pressure in both control and prenatally stressed offspring, whereas
yohimbine did not (5 mg/kg; Figure 22). Additionally there were no significant differences
between control and prenatally stressed offspring in response to either drug. These data suggest
that the difference seen in acoustic startle responding between control and prenatally stressed
offspring following the administration of 5 mg/kg yohimbine or 8 mg/kg idazoxan is not due to
differences in blood pressure. However, such results must be interpreted carefully as there are
inherent limitations associated with the tail cuff blood pressure measurement system. For
example, with tail cuff, blood pressure and heart rate can not be measured in a continuous
manner, which prevents determination of the time of peak effect and duration of action. It is also
more difficult, time consuming, and costly to generate cumulative dose-response curves for the
drugs in question. Fortunately, such limitations are circumvented using an in-dwelling catheter
technique of blood pressure measurement. Therefore, the objective of a subsequent study will be
to assess changes in blood pressure in prenatally stressed and control animals in response to a
range of doses of yohimbine and idazoxan using in-dwelling catheters. Based on the findings
thus far, the hypothesis for this particular series is that idazoxan will increase basal blood
pressure, while yohimbine will not. Additionally, there will be no differences in blood pressure
between control and prenatally stress offspring. Such results would corroborate our current
findings using tail cuff.
One of the objectives of this project was to determine differences in fearful behavior
between control and prenatally stressed offspring in response to anxiogenic stimuli. Therefore,
to further pursue this objective, differences in fearful behavior between control and prenatally
stressed offspring will be assessed in the acoustic startle test using the fear-potentiated startle
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paradigm. As first described by Brown, the amplitude of the acoustic startle reflex is augmented
by presenting the eliciting auditory startle stimulus in the presence of a cue (e.g. a light) that has
previously been paired with shock (Brown et al., 1951). The resultant conditioned response is a
state of fear, which is defined by freezing, autonomic changes, and fear potentiated startle
(McAllister and McAllister 1971; LeDoux et al., 1988). The “fear-potentiated startle effect” has
been replicated in a number of experimental series using different conditioned stimuli as well as
different startle-eliciting stimuli (Davis 1986). Therefore, the hypothesis for this experimental
series is that the fear potentiated startle paradigm will elicit fearful behavior in both control and
prenatally stressed offspring as demonstrated by a significant increases in Acoustic startle
responding over baseline when presented with a conditioned stimulus. Additionally, prenatally
stressed offspring will have significantly higher fear-potentiated acoustic startle than control
offspring.
To date no one has assessed fear-potentiated startle in prenatally stressed offspring. The
rationale behind the hypothesis that prenatally stressed offspring will be hyper-responsive to fearpotentiated startle is based our findings demonstrating prenatal stress-induced increases in CRF
content in the amygdala (Figure 6; Tables 1 & 2). Both CRF and the amygdala are important in
fear potentiated startle. Electrical stimulation of the amygdala (Rosen et al., 1991) and i.c.v.
CRF increased fear-potentiated startle as measured by the acoustic startle reflex (Swerdlow et al.,
1986; Liang et al., 1992a), while i.c.v. administration of -helical CRF and lesions of the CeA of
the amygdala block CRF’s enhancement of the acoustic startle reflex (Liang et al., 1992b).
Hence, with increased CRF content in prenatally stressed offspring we should see increased fearpotentiated startle.
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